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ABSTRACT 
Unravelling the Role of Glycosylation in Clostridium difficile Infection 
Izabela Marszalowska, B. Sc. (Hons)  
 
Alterations to the normal composition of our gut microbiota can result in disturbance 
of gut homeostasis. Opportunistic pathogens such as Clostridium difficile can profit 
from this environment, leading to colonisation of the gut.  
 
Clostridium difficile infection (CDI) is the most common healthcare associated 
disease in Ireland and with the incidence of occurrence on the rise. CDI represents a 
major health and economic burden to society. The primary pathogenesis of C. 
difficile has been attributed to its toxins; however the mechanisms that promote the 
initial colonisation and adherence of the pathogen still remain unclear. Glycosylation 
is an important factor affecting host-pathogen interactions in the gastrointestinal (GI) 
tract. We have, however discovered that the Surface Layer Proteins (SLPs) of C. 
difficile are not glycosylated and therefore do not contribute to host-pathogen 
interactions in this context. Subsequently, we examined the glycosylation profile on 
the surface of the colonic epithelium. To mimic the immunocompromised state of 
CDI patients, we used an in vivo model of antibiotic treatment to induce a 
susceptibility state in mice. Antibiotic treatment, and presumably the disturbance in 
microbiota composition, induced a protective state. This was evidenced by the glycan 
profile on the surface of the epithelium which was rich in fucose, a sugar known to 
promote the recovery of commensals, and depleted of sialic acid, an essential sugar 
used by C. difficile as an energy source. This protective state was further confirmed 
by the increased expression of anti-inflammatory cytokines IL-10 and TGFβ, and the 
increase in mucin and tight junction protein expression. We also observed decreased 
IL-22 expression, an essential cytokine for maintaining the integrity of the 
epithelium. For these reasons we propose that susceptibility to CDI is a result of 
compromised expression of IL-22 and the immunosuppressive environment induced 
by IL-10 and TGFβ that may delay the initial immune response to the pathogen. 
These findings are further supported by our observations of C. difficile infection in 
vivo where the increased sialic acid correlated with increased pathogen load and 
decreased IL-22 expression correlated with the excessive damage to the epithelial 
barrier. 
 
In this project we have identified novel mechanisms with an important role in CDI. 
These mechanisms may provide attractive targets for therapeutic intervention. 
Specifically, modulation of the fucose and sialic acid balance in the gut of 
immunocompromised patients may aid in commensal recovery and prevent C. 
difficile from thriving. Furthermore, enhancing IL-22 signaling may reinforce the 
integrity of the mucosal barrier in susceptibility state and infection. 
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CHAPTER 1 INTRODUCTION 
1. 1 CO-EVOLUTION OF HOST IMMUNE SYSTEM AND MICROBES 
The human immune system and microbes co-evolved in parallel in a mutualistic 
relationship (Ley et al. 2008). The mammalian gastrointestinal (GI) tract provides a 
unique niche for microbes. The human colon is by far the largest microbial 
community in the human body, harbouring more than 100 trillion microbial cells 
(Guarner 2015). These microbes became human symbionts by complementing the 
host’s digestive and anabolic pathways that the mammalian genome lack (Zaneveld 
et al. 2008). However, harmful pathogens were also present at very early stages of 
human evolution. Helicobacter pylori, a common gastric pathogen was shown to be 
associated with Homo sapiens host since before humans started the migration from 
Africa (Linz et al. 2007). This indicates that the human immune system had to 
evolve at a very early stage to provide protection against invading pathogens 
(Ohnmacht et al. 2011). 
1. 1. 1 Definition of Commensal Microbiota 
Microbes that reside in the human body can be referred to in the literature as 
microflora, microbiota or the more recently coined term microbiome. By definition, 
microbiota is understood as the ecological community of commensal, symbiotic, and 
pathogenic microorganisms that share our body space (Lederberg 2001). Recently 
coined “microbiome” is defined as the microbiota and its collective genomes 
(Bäckhed et al. 2005).  
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1. 1. 2 GI Tract as an Example of Dynamic Host-Microbial Interactions 
1. 1. 2. 1 General Structure 
The GI tract is the largest surface of the body that is exposed to the outer world 
(Pelaseyed et al. 2014). It is organised into the oral cavity, stomach, small and large 
intestine (colon). The intestines are divided in the duodenum, jejunum, ileum, 
caecum and colon (Pott & Hornef 2012). Distinct structural and functional 
differences are found along the intestines. This include variations in luminal water, 
ion and nutrient concentration, pH, microbiota composition and density, thickness 
and composition of mucus and spectrum of antimicrobial peptides (Robbe et al. 
2003; McGuckin et al. 2011). Variations in the mucus thickness and composition 
have implications in host-microbiota and host-pathogen interactions, and this topic is 
further explored in this thesis.  
The primary function of the GI tract is to digest food and provide the body with 
nutrients, but also, it is a residence site for many bacteria, both commensal and 
pathogenic. As the GI tract is constantly exposed to bacterial antigens, it has 
developed several mechanisms that protect it from bacterial invasion and 
overstimulation by commensals.  
The first line of defence is composed of a chemical barrier, which results in the 
destruction of potentially harmful species by chemical lysis. These barriers are 
composed of highly concentrated hydrochloric acid in the stomach that can hydrolyse 
chemical bonds, digestive proteases that are capable of cleaving all types of peptide 
bonds and bile salts that are able to dissolve cell membranes (Pelaseyed et al. 2014). 
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1. 1. 2. 2 Intestinal Epithelial Cells as a Barrier 
In the GI tract, a single layer of intestinal epithelial cells provides a physical barrier 
between the lumen colonised by bacteria and the subepithelial tissue that harbours 
various cells of immune system. The intestinal epithelial layer also actively 
participates in communication between both environments and the coordination 
between all these components is essential to maintain intestinal homeostasis.  
The epithelial cells that cover the GI tract are structurally and functionally polarised. 
An apical surface faces the intestinal lumen and a basolateral surface faces the 
underlying basement membrane and the lamina propria (Abreu 2010). This polarised 
structure is established through distribution of membrane proteins to the either apical 
or basolateral surface, and it is also supported by the presence of tight junction 
proteins. Additionally, the apical surface is covered by mucus. This organisation of 
the intestinal epithelial barrier is generally thought to be impermeable to commensal 
bacteria (Peterson & Artis 2014).  
The individual cells of the intestinal epithelial layer fulfil different tasks depending 
on their location along the GI tract. Enterocytes are the most abundant cells in the 
small intestine and they are interspersed by goblet cells, which produce heavily 
glycosylated mucins (Johansson & Hansson 2013). The Paneth cells and enterocytes 
actively sense microbiota and secrete antimicrobial peptides in response, including 
defensins, angiogenin 4, secretory phospholipase A2, lipopolysaccharide-binding 
protein, collectins, histatins, REGIIIα and REGIIIγ (Lindén et al. 2008; McGuckin et 
al. 2011). Fresh mucus is secreted by goblet cells and mixed with antimicrobial 
peptides secreted from the Paneth cells and enterocytes. This generates an 
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antimicrobial gradient in the mucus that facilitates the separation of microbiota from 
the epithelial cell surfaces (Pelaseyed et al. 2014).  
The mucosal surface area is significantly increased by the formation of villi and 
crypts. Villi are small intestinal protrusions and are indispensable for nutrient 
absorption. Crypts are gland-like invaginations known to generate a protected stem 
cell niche (Kim et al. 2014).  
Adjacent epithelial cells are held together through interactions between tight junction 
proteins (Ivanov 2012). Tight junction proteins in the intestinal epithelium prevent 
the free movement of luminal bacteria, toxins and antigens to the subepithelial layer 
(Suzuki 2012). Instead, tight junction proteins allow for selective permeability in the 
intercellular space between the adjacent cells (Ulluwishewa et al. 2011).  
All the components of this system co-operate in harmony to maintain the integrity of 
this barrier. When one of the components is compromised, it has a detrimental effect 
on the homeostasis of the GI environment. The structure of the colonic epithelial 
layer is outlined on Figure 1. 1.  
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Figure 1. 1 The structure of the human colon (large intestine). Cross section of the 
human colonic epithelium reveals basic structures of the epithelium. Colonic epithelium 
lacks villi (present in the small intestine), the invaginations of the surface epithelium form 
intestinal crypts, which contain goblet cells and their secretions. A. Intestinal lumen; B. 
Lamina propria; C. Muscularis mucosae; D. Blood vessel; E. Surface epithelium; F. Goblet 
cell; G. Stem cell; H. Crypt of Lieberkühn; I. Tunica submucosa. Image sourced form: 
http://www.bmb.leeds.ac.uk/teaching/icu3/mdcases/ws3/. 
 
1. 1. 2. 3 Intestinal Epithelial Cells and Their Role in Inducing the Immune 
System  
Intestinal epithelial cells were thought to play a passive role in the separation of 
bacterial lumen and subepithelial layers saturated with immune cells. However, 
intestinal epithelial cells express pattern-recognition receptors (PPRs) to detect 
microbial ligands, indicating that these cells actively participate in the surveillance  
of the mucosal immune system (Kabat et al. 2014). The PPRs expressed in intestinal 
CHAPTER 1                                                                                                                    INTRODUCTION 
 
6 
epithelial cells include NOD-like receptors (NLRs), RIG-I like receptors (RLRs) and 
Toll-like receptors (TLRs). Nucleotide-binding oligomerisation domain 1 (NOD1) 
and (NOD2) receptors are intracellular receptors that recognise bacterial 
peptidoglycans, while retinoic acid-inducible gene (RIG) receptors recognise viral 
RNA, and the subsequent downstream signalling of these receptors involves 
engaging cell death and autophagy pathways (Saxena & Yeretssian 2014). 
Of particular interest to this thesis are Toll-like receptors (TLRs), which play an 
important role in recognising pathogens and commensals but also viruses via 
pathogen-associated molecular patterns (PAMPs) and eliciting a subsequent immune 
response (Imler & Hoffmann 2001). There are 10 members of the TLR family in 
humans and 13 in mice (O’Neill et al. 2013). TLR2/TLR1 and TLR2/TLR6 
heterodimers recognise lipopeptides of the bacterial cell wall (Round et al. 2011). 
TLR4 is known for recognising lipopolysaccharide, a component of the outer 
membrane of Gram negative bacteria (Takeuchi et al. 1999). TLR5 recognises 
flagellin, a protein component of flagella (Vijay-Kumar et al. 2008). TLR9 
recognises the hypomethylated CpG DNA, which is specific to bacteria (Hemmi et 
al. 2000). TLR11 identifies uropathogenic bacteria (Zhang et al. 2004). Viruses are 
also detected via TLRs, as TLR3 participates in recognition of RNA from double- 
and single-stranded viruses (Alexopoulou et al. 2001). The intestinal epithelium of 
the GI tract has been shown to express all of the above TLRs, which highlights the 
abundance of the antigen load that the epithelium encounters (Abreu 2010).  
TLR binding to its specific ligand initiates a cascade of proinflammatory cytokines 
and chemokines, and subsequent recruitment of effector immune cells to the site of 
infection (Min & Rhee 2015). Specifically, the activation of most of TLRs results in 
the induction of cell signalling through Myeloid differentiation primary response 88 
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protein (MyD88), a universal adapter protein. This in turn activates a signalling 
cascade within the cell that leads to activation of Nuclear Factor kappa B 
transcription factor (NF-κB). Consequently, NF-κB induces transcription of 
proinflammatory mediators such as cytokines and chemokines, which orchestrate the 
subsequent immune cell recruitment and immune response (Kawai & Akira 2010).  
A healthy GI tract is colonised with commensal microbiota, therefore it is essential 
for the TLRs of the intestinal epithelial barrier to adapt to this antigen-rich 
environment, to prevent eliciting an immune response to commensal antigens. This is 
achieved by the spatial arrangement of the TLRs. For instance, TLR2, TLR4 and 
TLR5 have been shown to be expressed on the basolateral surface of the epithelium, 
while TLR3 and TLR9 are restricted to the intracellular space (Abreu 2010). 
Therefore TLRs become activated by their ligands only when the epithelial barrier 
has been breached.  
Activation of TLRs by commensals under steady state conditions is also crucial for 
maintaining the integrity of the barrier. It has been shown that recognition of 
commensal antigens by TLRs is essential for the stimulation of factors that protect 
the epithelium. This is evident from studies of MyD88 deficiency in mice. Inability 
of commensals to activate protective pathways through MyD88 in these mice results 
in increased mortality rate due to intestinal epithelium injury (Rakoff-Nahoum et al. 
2004). Furthermore, the TLR signalling has been shown to be important in 
maintaining a healthy epithelial barrier by inducing epithelial cell proliferation, IgA 
production, maintenance of tight junction proteins and secretion of antimicrobial 
peptides (Abreu 2010). Therefore, the TLRs in intestinal epithelial barrier have at 
least two distinct functions, protection from pathogens and maintenance of tissue 
homeostasis.  
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1. 1. 2. 4 Breach of Intestinal Epithelial Barrier Results in Recruitment of 
Innate Immune Response 
Despite the highly organised protection system within the intestinal epithelial barrier, 
the immune system is essential when the physical and chemical barriers have been 
breached. To facilitate these functions, the immune system of the GI tract is 
composed of a wide network of interactions between innate and adaptive immune 
cells, and the cytokines and chemokines facilitate the cell communication (Kayama 
et al. 2013). 
Breach of the intestinal epithelial barrier results in immediate activation of an 
immune response. As previously mentioned, intestinal epithelial cells are able to 
sense bacterial antigens via their TLRs. Activation of TLRs results in the secretion of 
proinflammatory cytokines and chemokines which orchestrate the subsequent 
immune response and cell recruitment. Specifically, innate immune cells, such as 
dendritic cells and macrophages are recruited from the lamina propria to clear the 
invading pathogens (Garrett et al. 2010). These cells act as innate effector cells by 
actively phagocytosing bacteria (Cerovic et al. 2014). Additionally, dendritic cells 
also sample the environment of the intestinal lumen by extending their dendritic 
processes (Hooper & Macpherson 2010). Intestinal macrophages contribute to 
tolerance at the epithelial barrier by secreting anti-inflammatory IL-10 cytokine 
(Cerovic et al. 2014).  
Chemokine release is essential for the recruitment of neutrophils to the site of the 
infection (Fournier & Parkos 2012). Neutrophils have chemokine receptors on their 
surface that detect molecules such as IL-8 (CXCL8), Macrophage inflammatory 
protein 2 (MIP-2) or complement molecule C5a (Maloy & Powrie 2011; Ohtsuka et 
al. 2001). Neutrophils present in the blood detect the gradient of chemokines and 
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traverse the vascular endothelium to reach the intestinal lamina propria within 
minutes (Fournier & Parkos 2012). Their main role of the neutrophils at the site of 
the infection is to phagocytose the bacteria, however the neutrophils can orchestrate 
further immune responses by secreting chemokines for further recruitment of 
immune cells, anti-inflammatory IL-10 to contain the inflammation, and IL-22, 
which is essential for restoring the epithelial barrier (Zindl et al. 2013).  
The sequential innate response to a breached epithelial barrier is quite complex but it 
is contained in order to control the recovery of gut homeostasis. When this balance is 
somehow compromised, it can lead to conditions such as Inflammatory Bowel 
Disease (IBD). While the etiology of IBD is clearly multifactorial, intestinal injury 
observed in IBD is largely attributed to the massive recruitment of neutrophils of an 
unknown origin (Maloy & Powrie 2011). However, the depletion of neutrophils in 
chemically-induced colitis resulted in exacerbated collapse of the epithelial structure 
(Kühl et al. 2007). This suggests that a balanced innate response is essential for the 
clearance of the pathogen, but also for maintaining homeostasis in the gut.  
1. 1. 2. 5 Induction of Adaptive Immune Response 
The activation of the innate immune cells has further implications for initiating the 
adaptive immune response. Activated macrophages and dendritic cells act as antigen-
presenting cells (APC) to T cells (Garrett et al. 2010). T cells are classified into two 
groups; CD4
+
 and CD8
+
. CD4
+
 T cells play a significant role in the GI tract, residing 
mostly in mesenteric lymph nodes and Peyer’s patches (Hooper & Macpherson 
2010). When APCs present PAMPS from pathogenic antigen via their PPRs to naïve 
T cells they develop into effector T cells (Helper T cell, Th cell). Certain pathogenic 
antigens have associated Th subsets; Th1 (intracellular bacteria and viruses), Th2 
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(helminths) and Th17 (bacteria and fungi) while naïve T cells presented with 
commensal antigen develop into Regulatory T cell (Tregs) (Nutsch & Hsieh 2012). 
The maturation of T cells is also influenced by the nature of the cytokines released 
by APCs. For example, secretion of IL-12 cytokine and IFNγ by APCs induces the 
maturation of Th1 cells, while IL-6, IL-23 and TGFβ have been shown to drive Th17 
development (Maloy & Kullberg 2008). Transforming growth factor β (TGFβ) is an 
important mediator of Tregs maturation (Ouyang et al. 2011; Peterson & Artis 2014). 
Each subset of T cells plays a particular role in the immune response in the GI tract; 
however the balance between Th cells and Treg cells is also essential for the 
maintenance of gut homeostasis.  
Th17 cells in the GI tract play an important role in both infection and homeostasis 
(Maloy & Kullberg 2008). They exert these actions via the secretion of IL-17 and IL-
22 (Ivanov et al. 2009). IL-17 has an essential role in enhancing tight junction 
protein formation and secretion of antimicrobial peptides, which is of particular 
importance when the epithelial layer is compromised (Liang et al. 2006). 
Additionally, IL-17 can regulate the expression of another cytokine, IL-22 
(Sonnenberg et al. 2010). IL-22 is a member of the IL-10 family of cytokines and 
plays a critical role in inflammation, immune surveillance and recovery of the 
epithelial barrier (Sonnenberg et al. 2011). This is evident by the wide spectrum of 
pathways affected by IL-22 signalling. It induces proliferation and anti-apoptotic 
pathways in the epithelium, which are important during disruption of the epithelial 
barrier (Mühl 2013). IL-22 strengthens the recovering epithelium by inducing the 
expression of antimicrobial peptides (Zheng et al. 2008) and mucus (Sonnenberg et 
al. 2010; Zenewicz et al. 2007; Radaeva et al. 2004), and it also shapes the sugar 
profile available for the recovering commensals (Pham et al. 2014). IL-22-deficient 
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mice suffered from increased epithelial damage, increased systemic burden of 
bacteria and higher mortality (Sonnenberg et al. 2010).  
Treg cells have a mostly immunosuppressive function through the release of IL-10 
cytokines. The main role of IL-10 is to repress the expression of proinflammatory 
cytokines during recovery to prevent tissue damage (Mühl 2013). Mice deficient in 
IL-10 and TGFβ develop a spontaneous colitis in response to commensal bacteria 
(Kühn et al. 1993; Shull et al. 1992), which highlights the importance of the TGFβ-
Tregs-IL-10 axis in regulating commensal microorganisms and maintaining gut 
homeostasis (Ohkusa et al. 2009). However, the overexpression of IL-10, together 
with TGFβ, is thought to lead to chronic persistent infections with pathogens such as 
Mycobacterium tuberculosis (Ouyang et al. 2011).  
 
1. 1. 2. 6 Mucus Composition 
The GI mucus system is important for minimising the exposure of antigens to the 
immune system, but is also crucial for the protection from self-digestion (Johansson 
et al. 2011). The mucus layer is secreted by goblet cells and typically contains 
several major components such as mucins and their associated glycans, antimicrobial 
peptides and secretory peptides (Juge 2012). Mucins are the main scaffolding 
component of the mucus layer (Moran et al. 2011). They are heavily glycosylated 
proteins that are capable of assembling into a viscous gel-like layer on the surface of 
the epithelium. The glycosylation chains attached to mucins are highly hydrophilic 
and absorb a large volume of water, hence the gel-like appearance. The high water 
content (>98%) provides an additional physical barrier as the mucus acts as a 
diffusion barrier protecting the epithelial layer (Pelaseyed et al. 2014). Moreover, 
CHAPTER 1                                                                                                                    INTRODUCTION 
 
12 
due to the carbohydrates that are attached to mucins, the intestinal proteases cannot 
reach the peptide bonds, rendering the mucus layer and epithelial layer resistant to 
self-digestion (Pelaseyed et al. 2014). 
 
 
Figure 1. 2 Organisation of the mucus layers within the human GI tract. The mucus 
layer varies in thickness along the GI tract, but also its organisation in to layers. Sourced 
from Juge 2012. 
 
The mucus layer has varying thickness along the GI tract (Figure 1. 2). It extends 
from 200 µm outwards from the epithelium in the stomach to up to 700 µm outwards 
from the epithelium in the colon (Hooper & Macpherson 2010; Juge 2012). The 
structure within the mucus layer allows for the spatial limitation of bacteria, both 
commensals and pathogens, and prevents microbes from interacting with the 
epithelium. In the stomach, there are two layers of mucus and the rate of mucus 
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production is relatively higher than other parts of the GI tract, which allows for the 
protection of the stomach lining from the action of acid and self-digestion. The small 
intestine has only one layer of mucus that is non-attached and is easily removed to 
facilitate the peristaltic movement of the food. The colonic mucus consists of two 
layers. The outer layer of colonic mucus harbours microbiota and facilitates the 
commensal metabolism by providing nutrients from glycosylated mucins. The inner 
mucus layer is firmly attached to the epithelial layer and it is considered sterile, due 
to the high level of antimicrobial peptides (Hooper & Macpherson 2010).  
The properties of the mucus layer are largely influenced by the mucin proteins that 
are secreted in any given part of the GI tract. Up to 20 different mucin genes have 
been identified to date (Kim & Ho 2010). These genes are expressed in a tissue- and 
cell-specific manner and are classified into two types, secretory and membrane-
associated. The mucins known to be expressed in GI tract are summarised in Table 1. 
1. MUC2 is the most prevalent mucin secreted in the colon (Peterson & Artis 2014; 
Johansson & Hansson 2013; Bergstrom et al. 2010). Other mucin genes that have 
been shown to be expressed and secreted in colon of mice, such as MUC1 (Petersson 
et al. 2011), MUC3 (Mack et al. 2003), MUC4 (Hoebler et al. 2006), MUC5AC 
(Shaoul et al. 2004), MUC6 (Walsh et al. 2013), MUC13 (Sheng et al. 2013), 
MUC15 (J. Huang et al. 2009) and MUC20 (Moehle et al. 2006).  
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Table 1. 1 Expression of mucins throughout the GI tract. Adapted from Moran et al. 2011 and 
McGuckin et al. 2011. 
Mucin Distribution Type 
MUC1 Oral cavity, stomach, gallbladder, pancreas, duodenum, 
small intestine, colon 
Cell surface-associated 
MUC2 Small intestine, colon Secreted gel-forming 
MUC3 Small intestine, colon, gall bladder, duodenum Cell surface-associated 
MUC4 Oral cavity, stomach, small intestine, colon Cell surface-associated 
MUC5AC Stomach, small intestine, colon Secreted gel-forming 
MUC5B Salivary glands, gallbladder, stomach Secreted gel-forming 
MUC6 Stomach, gallbladder, pancreas, duodenum, colon Secreted gel-forming 
MUC7 Salivary glands Secreted non-gel-forming 
MUC12 Stomach, pancreas, small intestine, colon Cell surface-associated 
MUC13 Stomach, small intestine, colon Cell surface-associated 
MUC15 Small intestine, colon, foetal liver Cell surface-associated 
MUC16 Oral cavity, peritoneal mesothelium, stomach, small 
intestine, colon 
Cell surface-associated 
MUC17 Stomach, duodenum, small intestine, colon Cell surface-associated 
MUC19 Sublingual gland, submandibular gland Secreted gel-forming 
MUC20 Colon Cell surface-associated 
 
1. 1. 2. 7 Glycosylation of the GI tract 
In addition to its protective role, the mucus layer that lines the GI tract is rich in 
glycans. The diversity of the glycan moieties serves an ideal habitat for commensals 
and pathogens, by providing both binding sites and energy to sustain the growth 
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(Hooper & Gordon 2001). In colonic mucus, the glycans are attached to the 
backbone of the mucin proteins.  
In glycoproteins, the oligosaccharide chains are attached to either to the oxygen in 
the side chain of serine or threonine (termed O-linked glycosylation), or the amide 
nitrogen in the side chain of asparagine (termed the N-linked glycosylation), see 
Figure 1. 3. Mucins have large numbers of O-linked oligosaccharides, and the glycan 
chains account for about 80% of the total mucin mass. Furthermore, the attached 
glycans are highly hydrophilic, which determines the rheological and biological 
properties of the mucins and mucus (Juge 2012). N-linked glycosylation is relatively 
uncommon in GI tract mucins. O-linked glycans contain from 1 to 20 residues 
connected in a linear or branched manner. The glycan chain structure is not 
genetically determined, rather it is a product of the genes coding for the 
glycosylating enzymes (Freitas et al. 2002). O-linked glycosylation biosynthesis 
takes place exclusively in the Golgi complex, whereas N-linked glycosylation begins 
in the endoplasmic reticulum and continues in the Golgi complex (Freitas & Chantal 
2000).  
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Figure 1. 3 Representation of O- and N-linked glycosylation found in GI tract. O-linked 
glycans are added to hydroxyl groups of mucin protein via serine (S) or threonine (T) amino 
acids, while N-linked glycans are attached to amide nitrogen of asparagine (N). The glycan 
chains can be linear or branched and are composed of one of four core structures and 
terminated with outlined glycans. Sourced from www.neb.com.  
 
The O-linked glycosylation is initiated by the addition of N-Acetylgalactosamine to 
the hydroxyl group of a serine or threonine of the mucin protein backbone. 
Following this, one of eight core structures of glycan chain is added. Core 1, core 2, 
core 3 and core 4 structures are most prevalent in the GI tract (Figure 1. 4). Next, the 
chains are elongated by the addition of new glycan units and capped with terminal 
glycans such as fucose, galactose, N-Acetylgalactosamine or sialic acid (also known 
as N-Acetylneuraminic acid) (Juge 2012; Varki 2009). While core structures of 
glycan chains are constant, the terminal glycan sequences are determined by the 
environment and the commensal microbiota.  
 
Mucins 
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Figure 1. 4 Diagrammatic representation of the core O-glycosylation structures present 
on mucins in the GI tract. The core glycans are then elongated by the addition of further 
glycan units, such as N-Acetylgalactosamine, N-Acetylglucosamine, Galactose, fucose or 
sialic acid, in branched or linear manner. Adapted from Moran et al. 2011and Juge 2012.  
 
The terminal glycans along the GI tract are region specific, and there is a reverse 
gradient of fucose and sialic acid along the GI tract. Fucose is most prevalent in the 
stomach, with low levels of sialic acid, while sialic acid is highly abundant in the 
colon where there are low levels of fucose. However, under disease conditions, this 
ratio becomes reversed, with high fucose and low sialic acid presented in the colon 
(Robbe et al. 2003).  
Aberrant mucin glycosylation leading to shorter carbohydrate chains, or altered 
composition is frequently associated with many pathological conditions. Altered O-
linked glycosylation of mucins has been associated with increased incidence of 
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Escherichia coli diseases as the altered glycosylation aids the pathogen adherence 
(Rhodes 2007). Also, patients with Ulcerative Colitis (UC) had altered glycosylation 
of MUC2 and this glycosylation profile was correlated with the severity of the 
intestinal inflammation (Larsson et al. 2011). Furthermore, altered glycosylation in 
UC increased risk of developing colon cancer (Saeland et al. 2012; Kawashima 
2012; Campbell et al. 2001). This highlights the importance of correct mucin 
glycosylation in the maintenance of gut homeostasis.  
There is a large body of evidence to suggest that commensal bacterial influence the 
glycosylation of the mucins (Freitas et al. 2002; Sommer et al. 2014; Xu et al. 2013). 
Disturbance of the microbiota, due to antibiotic use, and its subsequent effect on 
glycosylation and composition of the mucus remains unexplored despite its 
important role in homeostasis (Wlodarska et al. 2011; Hill et al. 2010). 
1. 1. 2. 8 Microbiology of the GI tract 
Human microbiota is essential for the postnatal maturation of mucosal and systemic 
immunity (Zeissig & Blumberg 2014). The inability to culture the majority of the GI 
microbiota compounded by the limited technology has inhibited research in this area. 
However, recent culture-independent approaches have advanced our understanding 
of the human microbiome (Tremaroli & Bäckhed 2012). These methods combine the 
molecular sequencing of nucleic acids with powerful bioinformatic tools capable of 
sorting the outcomes into taxonomic identification (Dave et al. 2012). A small 
subunit ribosomal RNA gene, 16S rRNA, has become the standard reference gene in 
prokaryote phylogenetic research, including the human microbiome project 
(Turnbaugh et al. 2007).  
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Use of these methods has led to discovery that only 9 out of 55 phyla of the Bacteria 
domain are detected in the human GI tract (Guarner 2015). The bacterial phyla that 
are present in the mammalian gut microbiota include Firmicutes, Bacteroidetes, 
Actinobacteria, Proteobacteria, Verrucomicrobia, Cyanobacteria, Fusobacteria, 
Spirochaetes and TM7 (Brown et al. 2013). Out of this, 90% of all taxa belong to just 
two phyla, Bacteroidetes and Firmicutes (Kim & Ho 2010).  
Bacterial composition varies along the intestinal tract, as each species of bacteria 
colonises a specific niche (Brown et al. 2013). This is also largely influenced by the 
nutrient availability and pH along the tract. The number of bacteria increases in distal 
colon direction. The stomach harbours very few microbes, whereas more than one 
kilogram of microbes reside in the human colon (Figure 1. 5) (Pelaseyed et al. 2014). 
Moreover, even within the large intestine, bacterial composition varies from cecum 
to rectum (Guarner 2015). 
Microbiota plays a number of crucial roles for the host, including assistance in 
digestion of certain nutrients (Sommer & Bäckhed 2013), protection from invading 
pathogens by colonisation resistance (Buffie & Pamer 2013), shaping the mucosal 
immune response (Thaiss et al. 2014) and mucus composition (Jakobsson et al. 
2015).  
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Figure 1. 5 The composition of the main bacterial phyla present in the GI tract. Most of 
the bacterial species found in the mammalian intestine are from the phyla Bacteroidetes or 
Firmicutes. Archaeal and eukaryotic microorganisms also can colonize the intestine in low 
abundance. Adapted from (Kamada et al. 2013; Brown et al. 2013). 
 
1. 1. 2. 9 Colonisation Resistance 
Beneficial commensal bacteria can prevent pathogens from colonising the gut by 
directly competing with them in a process known as colonisation resistance 
(Sassone-Corsi & Raffatellu 2015). Commensal bacteria can contribute to 
colonisation resistance in both direct and indirect manners such as adhesion 
exclusion, competition for carbon and micronutrient sources, secretion of 
antimicrobials such as bacteriocins and microcins and direct delivery of toxins upon 
contact with competitor (Sassone-Corsi & Raffatellu 2015). In indirect colonisation 
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resistance, the microbiota restricts the invading pathogens by enhancing the innate 
and adaptive immune response of the host, as well as the mucosal barrier 
composition (Buffie & Pamer 2013).  
The use of antibiotics is known to compromise the composition of the microbiome. 
Ubeda and Pamer reported that a single dose of clindamycin has the ability to 
diminish 90% of microbial taxa usually found in the human microbiome (Ubeda & 
Pamer 2013). This in turn has a several implications for the host-microbiota 
relationship. These include lack of competition for nutrients and space and secondary 
metabolites available in the GI tract, namely bile salts and short-chain fatty acids 
(SCFA). Sugars are important nutrients for bacteria, and the availability of sugars 
may influence the colonisation of various species. There is region-specific 
presentation of glycans along the gastrointestinal tract, which influence the species 
that colonise particular part of the gastrointestinal tract, especially in infancy (Robbe 
et al. 2003).  Additionally, commensals and the pathogens compete for the nutrients, 
and in healthy gut, commensals outcompete pathogens for nutrients in process 
known as colonisation resistance (Britton & Young 2014). Fucose, one of the 
glycans used as a nutrient, is important for the commensals, as commensals have 
readily available enzymes to digest the fucose. Pathogens are disadvantaged in the 
presence of fucose, as they either have to switch their metabolism to express 
appropriate enzymes, this include Salmonella, or do not possess enzyme that digest 
fucose, this include C. difficile (Ng et al. 2013). Additionally, glycans such as sialic 
acids have been shown to facilitate the infection with opportunistic pathogen such as 
C. difficile (Ng et al. 2013).       
Commensals play a role in converting primary bile salts into secondary bile salts, 
essential for lipid metabolism (Wlodarska et al. 2015). SCFA are a product of fiber 
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digestion by commensals and these SCFA are essential to ameliorate inflammatory 
conditions in the gut (Kelly et al. 2015). Therefore, the disturbance of commensals 
may additionally affect the host metabolism, but additionally this lack of balance 
may be used by opportunistic pathogens such C. difficile.   
While the role of the microbiota in the health of the GI tract has always been 
appreciated, it is only recently that greater efforts have been made to utilise the 
microbiota to restore homeostasis. This includes the use of prebiotics that are non-
digestible food ingredients that selectively promote the microbiota (Tremaroli & 
Bäckhed 2012). Other approaches involve the administration of probiotics, live 
microorganisms that confer a health benefit for the host (Kanai et al. 2015). Finally, 
the administration of faecal matter from a healthy donor to compromised patients has 
proven to be an effective method of restoring the colonisation resistance in 
compromised individuals (Rao et al. 2014; Pamer 2014).  
1. 1. 2. 10 Opportunistic Pathogens Employ Range of Mechanisms to Evade 
Host’s Protective Mechanisms 
Despite the variety of host defence mechanisms, the enteric pathogens have evolved 
methods to overcome these protective barriers. In some cases, pathogens take 
advantage of innate host responses to enter the body (Hornef et al. 2002). 
Furthermore, some of them act as opportunistic pathogens, as they co-exist with the 
commensal microbiota in the gut and only invade the gut when the host defence 
mechanisms are compromised (Linden et al. 2008; Pham et al. 2014; Kabat et al. 
2014). H. pylori attaches itself to mucins secreted in the stomach (Van De 
Bovenkamp et al. 2003), while Campylobacter jejuni load increases when the 
mucosal barrier is compromised (McAuley et al. 2007). Vibrio cholera has been 
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shown to produce a toxin that disrupts the epithelial integrity in the gut through the 
destruction of the tight junction proteins, aiding its colonisation post disruption of the 
barrier (Guichard et al. 2013).  
Pathogens can also actively evade immune recognition. Salmonella has been shown 
to modulate its surface features so it cannot be recognised by the innate immune 
system receptors such as TLRs (Guo et al. 1997). Listeria monocytogenes is able to 
survive within phagocytosing cells such as macrophage and even lyse these cells to 
escape back into the cytosol (Dramsi & Cossart 2002). Additionally, all of the 
aforementioned can also modulate their own metabolisms to resist antibiotic 
treatment. This mechanism includes bacterial surface pumps that remove 
unprocessed antibiotics, hydrolysis of the antibiotic or actively changing the target 
site of the antibiotic (Blair et al. 2014).   
This project is focused on another enteric pathogen, Clostridium difficile. We aim to 
elucidate the critical mechanisms that this bacterium utilises to evade the host 
immune system and clearance and to establish successful colonisation in the gut. 
1. 2 CLOSTRIDIUM DIFFICILE AS AN EXAMPLE OF ENTERIC PATHOGEN 
1. 2. 1 Impact   
C. difficile is a well-recognised causative agent of Clostridium difficile infection 
(CDI), the leading hospital-acquired infection in Ireland, United Kingdom and the 
United States (Barbut et al. 2007; Cheknis et al. 2009). C. difficile bacterium is 
resistant to commonly used broad-spectrum antibiotics like clindamycin, 
erythromycin, and fluoroquinolones (H. Huang et al. 2009; Redgrave et al. 2014). 
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Increased age (>65) is a well-accepted risk factor for the development of CDI. The 
majority of these patients are hospitalised and severely immunocompromised 
(Rodriguez et al. 2014; Shields et al. 2015). Recently, there has been increased 
prevalence of CDI in younger populations with no prior contact with hospital or 
antibiotic therapy, which is known as community-acquired infection (Lessa 2013).  
The clinical outcome for patients with CDI are diverse, ranging from asymptomatic 
colonisation to mild diarrhoea, to more severe cases of pseudomembranous colitis 
and toxic megacolon and even death (Karadsheh & Sule 2013). Another feature of 
CDI is the high relapse rate (up to 60% of patients) due to reinfection or reactivation 
of infection (Kim et al. 2014). Infection routinely requires isolation of affected 
patients, additional antibiotic therapy, and a prolonged hospital stay, which has 
implications for both patient turnover and health economics (Ghantoji et al. 2010; 
Hill 2014; Teena Chopra et al. 2015).  
1. 2. 2 Clostridium difficile Bacterium 
C. difficile is a Gram-positive, obligate spore-forming anaerobe rod-shaped 
bacterium (Stanley et al. 2013). It was initially described as a part of the microbiota 
of healthy neonates and named Bacillus difficilis due to difficulty in isolation and 
culture of the bacterium in the laboratory (Hall & O’Toole 1935). C. difficile was 
identified as a pathogen relatively recently. The first confirmed case of CDI was 
reported in 1977, when the introduction of clindamycin as the primary antibiotic of 
choice led to a rapid increase in the number of pseudomembranous colitis cases 
(Larson et al. 1978). In 1978, C. difficile was recognised as a causative agent of CDI 
by fulfilling the criteria of Koch postulates (George et al. 1978). Bartlett et al. 
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confirmed that the main pathogenicity of C. difficile was attributed to toxin 
production (Bartlett et al. 1978).  
1. 2. 3 Infection Route  
The infection route of C. difficile is complex and largely dependent on the 
immunocompromised state of the host (Figure 1. 6). C. difficile spores are ingested 
via the oral route, survive the acidic environment of the stomach and germinate into 
vegetative forms when they reach the anaerobic conditions of the colon (Paredes-
Sabja et al. 2014). C. difficile can only colonise the gut if the normal intestinal 
microbiota is disturbed or absent as happens following antibiotic therapy (Britton & 
Young 2012). As a result, the antibiotic-resistant C. difficile is not eliminated by the 
prescribed antibiotic treatment, and due to lack of competition, it proliferates to reach 
high densities in the intestinal lumen (Buffie & Pamer 2013). The lack of 
colonisation resistance from commensals has various implications, including the 
obvious lack of competition for energy sources, but also disturbed bile salt 
metabolism contributes to spore germination (Figure 1. 7) (Sorg 2014). Upon 
proliferation, C. difficile penetrates through the intestinal mucus and adheres to the 
epithelium. This process is recognised as colonisation and is known to be a critical 
step of infection (Denève et al. 2009). Successful adherence allows C. difficile to 
thrive and produce toxins, which induce epithelial damage and acute inflammation 
(Genth et al. 2008).  
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Figure 1. 6 Current understanding of C. difficile infection route. C. difficile takes 
advantage of the immunocompromised state of the host and lack of colonisation resistance 
from commensal microbiota. The pathogen proliferates then due to the abundance of 
nutrients and lack of inhibiting metabolites. This allows for toxin productions, that damages 
the epithelial layer. The influx of immune cells to the site of infection exacerbates the 
inflammation rather than clearing the pathogens. The resultant systemic organ failure can 
lead to death. Adapted from literature described in Section 1. 2. 3.  
 
1. 2. 4 Virulence Factors Contributing to CDI Pathogenicity 
1. 2. 4. 1 Toxins 
Biochemical and molecular studies have shown that the main clinical symptoms and 
signs of CDI, such as diarrhoea and inflammation of the colonic mucosa are largely 
explained by the actions of the TcdA and TcdB toxins produced by C. difficile (Rolfe 
& Finegold 1979). C. difficile produces three toxins, toxin A and toxin B, and binary 
toxin CDT (Rupnik 2005). All three toxins disrupt host actin filamentation via 
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different enzymatic activities. Toxin A and B achieve this by glucosylating and 
inactivating the Rho-GTPases, regulatory proteins of actin (Kuehne et al. 2010). 
Binary toxin CDT binds to intestinal cells and sabotages host actin polymerisation 
(Schwan et al. 2009). Overall, the toxins lead to depolymerisation of the actin 
filaments with loss of internal architecture of the cells, microtubule disorganisation 
and disruption of the tight-junctions that hold cells together. This results in 
accelerated breakdown of the epithelial membrane. Destruction of villus and brush 
border membranes is followed by mucosal loss, fluid accumulation and a pronounced 
inflammatory response, which results in increased bacterial adherence (Schwan et al. 
2014).  
The majority of the hypervirulent C. difficile strains co-produce both the TcdA and 
TcdB (toxinotype A
+
B
+
), whereas only a minority of C. difficile produces TcdB only 
(toxinotype A
-
B
+
) (Genth et al. 2008). As mentioned previously, toxins are described 
as the main virulence factors associated with CDI. In fact, delivery of the TcdA and 
TcdB toxins alone reproduced clinical symptoms of CDI in hamsters (Mullany & 
Roberts 2010). However, vaccines against toxins did not confer protection against 
CDI (Mullany & Roberts 2010). Furthermore, toxins are not produced until the late 
log and stationary phase of infection, when the population of C. difficile is well-
established (Hundsberger et al. 1997). This evidence suggests that other features of 
C. difficile may contribute towards its virulence.  
1. 2. 4. 2 Surface Layer Proteins 
The Surface layer (S-layer) of C. difficile is formed by the self-assembly of 
monomeric proteins into a regularly spaced, two-dimensional array (Fagan & 
Fairweather 2014). The S-layer of C. difficile is assembled from one protein, Surface 
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Layer Protein (SLP). SLPs are the most abundant proteins on the surface of C. 
difficile and are encoded by the slpA gene (Fagan et al. 2009). SlpA is translated into 
a single precursor protein, which is cleaved by Cwp84 protease into two subunits, 
High Molecular Weight (HMW) and Low Molecular Weight (LMW) (Bradshaw et 
al. 2014). The two subunits of SLP assemble on the surface of the bacterium into the 
paracrystalline lattice known as the S-layer (Fagan et al. 2009). The SLP gene cluster 
encodes a variety of other proteins such as Cwp66, Cwp84, which aid the processing 
of the precursor SLP protein. It is separated from the Pathogenicity Locus (PaLoc) 
region, which includes genes encoding toxins (Denève et al. 2009).  
The S-layer provides cell shape, cell adhesion and a protective coat (Schäffer et al. 
2001). S-layer proteins have been described in other bacteria as virulence factors 
such as Aermonas salmonicida and Campylobacter fetus (Thompson 2002; Noonan 
1997). SLPs of C. difficile have been shown to be essential for the adhesion to the 
epithelium (Calabi et al. 2002; Merrigan et al. 2013; Spigaglia et al. 2013). 
Furthermore, SLPs from C. difficile have been demonstrated to be potent immune 
stimulators of immune cells (Ausiello et al. 2006). In our previous studies we have 
demonstrated that SLPs are recognised by the immune system specifically via TLR4 
(Ryan et al. 2011) and they activated clearance mechanisms in macrophages, 
specifically, the phagocytosis by macrophages (Collins et al. 2014). Also, the 
immune response to SLPs is dependent on the ribotypes of the C. difficile (Bianco et 
al. 2011; Vohra & Poxton 2012). This suggests that SLPs may contribute to disease 
severity, however, this correlation has not yet been reported in the literature. 
Therefore, the exact role of SLPs in CDI is yet to be determined.  
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1. 2. 4. 3 Other Surface Features and Their Implication for Adhesion 
Adherence is a pivotal step during the colonisation process. Several surface-
associated proteins of C. difficile have been investigated for their possible role in 
adhesion and virulence. Flagella of C. difficile have been extensively researched for 
their role in adhesion and colonisation (Tasteyre et al. 2001). In general, the primary 
function of the flagella is to enable the motility of the bacterium. It also facilitates in 
the adherence to host cells, force-driven motility to nutrients and acts as an 
immunomodulator by triggering a proinflammatory reaction via TLR5 (Stevenson et 
al. 2015). Enteric pathogens such as C. jejuni, V. cholera and H. pylori employ 
flagella to facilitate their motility through the host GI tract. Contribution of flagella 
to the pathogenesis of C. difficile is complex, and it is not yet fully understood. 
While flagella genes are upregulated extremely early during in vivo infection with C. 
difficile (Janoir et al. 2013), it has been shown that flagella may not be essential for 
survival and colonisation (Janoir et al. 2013; Baban et al. 2013). However, it is 
thought the flagella may modulate the expression of TcdA and TcdB (Aubry et al. 
2012) and sporulation (Pettit et al. 2014) and for this reason its role in C. difficile 
pathogenicity cannot be overlooked.  
Several cell wall proteins of C. difficile, including Cwp84 and Cwp66, have also 
been investigated for their role in adherence (Fagan et al. 2011). Cwp84 is cysteine 
protease that is essential for processing of the immature SLPs and assembling them 
into the S-layer (Bradshaw et al. 2014). Cwp84 is also known to play a role in 
degrading the extracellular matrix of the host tissue, possibly aiding the docking of 
the bacterium on the epithelial surface (Janoir et al. 2007). Antibodies raised against 
Cwp66 were able to partially inhibit the adherence of C. difficile to cultured cells 
(Waligora et al. 2001). The gene cluster encoding for Cwp66 and Cwp84 was shown 
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to be under high evolutionary pressure, suggesting its role in evolution of the 
pathogen and immune evasion (Dingle et al. 2013). Pechine et al. determined that in 
patients sera, antibodies against Cwp66 and Cwp84 could be found until up to two 
weeks after the initial CDI diagnosis, suggesting their strong antigenic properties 
(Péchiné, Janoir, et al. 2005; Péchiné, Gleizes, et al. 2005). 
GroEL is a classical heat-shock protein, secreted by C. difficile upon heat challenge 
but also under other stresses including high osmolarity, low pH, nutrient starvation or 
the presence of subinhibitory concentrations of antibiotics (Mizrahi et al. 2014; Jain 
et al. 2011; Hennequin, Collignon, et al. 2001). The involvement of GroEL in C. 
difficile adhesion is controversial as it is a membrane-associated rather than a cell 
wall protein. However, Hennequin et al. demonstrated that antisera against GroEL 
was able to partially inhibit the C. difficile attachment to cells in culture (Hennequin, 
Porcheray, et al. 2001). Also, Pechine et al. showed that immunisation against 
GroEL may decrease the rate of C. difficile colonisation in the colon (Péchiné et al. 
2013). Fibronectin-binding protein (Fbp) is an adhesin that recognises the 
extracellular matrix fibronectin on the surface of the host tissues (Hennequin et al. 
2003). Hennequin et al. demonstrated that antibodies raised against this protein 
inhibited the adhesion of C. difficile to immobilised fibronectin (Hennequin et al. 
2003). Deletion of Fbp in C. difficile affected its adhesion to cultured intestinal 
epithelial cells, via unknown mechanisms (Barketi-Klai et al. 2011). The addition of 
fibronectin to the cell culture increased the adherence rate of C. difficile (Schwan et 
al. 2014). Moreover, the same authors were able to determine that infection with C. 
difficile induced changes in secretion of fibronectin, to form clusters on the surface 
of the epithelial layer, presumably to aid the adhesion (Schwan et al. 2014). Deneve 
et al. demonstrated that exposure of C. difficile to various antibiotics upregulated the 
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expression of genes suspected to be involved in the adherence such as Cwp66, 
Cwp84 and Fbp (Denève et al. 2008).  
1. 2. 4. 4 Spores 
Like other clostridia, C. difficile produces spores that are metabolically inert (Stanley 
et al. 2013). C. difficile spores are able to withstand harsh environmental conditions 
such as desiccation, chemicals and extreme temperatures (Rupnik et al. 2009). C. 
difficile is a strict anaerobe and therefore dormant spores play a key role in 
transmission of the pathogen (Paredes-Sabja et al. 2014). Spores frequently 
contaminate the environment around patients with CDI, with the potential to persist 
for months and even years (Burns & Minton 2011). Furthermore, C. difficile spores 
were recently shown to survive the temperatures and disinfectant treatments of 
typical hospital laundering cycles and to cross-contaminate bed linens during a wash 
cycle (Hellickson & Owens 2007). C. difficile strains have various sporulation 
capabilities, which adds this feature as another virulence factor (Burns & Minton 
2011). Enhanced germination of spores was connected with increased colonisation of 
the gut during infection with epidemic RT 027, which sporulates more readily than 
non-epidemic ribotypes (Akerlund et al. 2008). Furthermore, Carlson et al. recently 
determined that the germination of spores of various strains correlates with disease 
severity (Carlson et al. 2015). Germination of spores into vegetative cells in the GI 
tract occurs under the influence of primary bile salts and it is tied to commensal 
bacteria metabolism. Specifically, the action of commensal bacterial completes 
conversion of host-derived primary bile salts to secondary bile salts, which are 
essential for the lipid metabolism, see Figure 1. 7 (Sorg 2014). Spores of C. difficile 
germinate in presence of primary bile salts, however under normal conditions, 
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secondary bile salts inhibit the vegetative cells of C. difficile (Theriot & Young 
2014). When intestinal microbiota is disturbed, for example due to antibiotic 
treatment, the bile salts metabolism is compromised. In that instance, there is 
accumulation of primary bile salts, which result in excessive germination of C. 
difficile spores. Simultaneously, due to lack of inhibitory effect of secondary bile 
salts, the vegetative cells are actively proliferating in order to establish infection 
(Taur & Pamer 2014; Seekatz & Young 2014). 
 
Figure 1. 7 The role of commensal microbiota in bile salt metabolism. Commensal 
microbiota metabolises primary bile salts into secondary bile salts. While the primary bile 
salts facilitate C. difficile spore germination, secondary bile salts actively inhibit the 
vegetative cells of C. difficile. When microbiota is disturbed, there is an excess of primary 
bile salts (facilitating the germination of spores) and lack of secondary bile salts to abolish 
the vegetative cells. This results in C. difficile colonisation and toxin production that 
damages the epithelial barrier. Adapted from Taur & Pamer (2014) and Seekatz & Young 
(2014).  
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1. 2. 5 Mucosal Immune Response to C. difficile 
The mucosal immune response to C. difficile is quite complex, given that the host is 
already immunocompromised (Figure 1. 8). The early stages of infection are 
characterised by acute intestinal inflammation mediated by the innate immune 
response. This defence is mediated by antimicrobial peptides such as defensins, 
which dampen the toxins effect on the epithelium (Solomon 2013). Furthermore, the 
epithelial layer recognises the pathogen via TLRs, specifically, SLPs are recognised 
via TLR4 (Ryan et al. 2011) and TLR5 detects flagella (Jarchum et al. 2012). 
Proinflammatory signalling results in recruitment of innate immune cells, such as 
neutrophils via secretion chemokines such as of IL-8 and MIP-2 (Hasegawa et al. 
2011). Despite the involvement of these innate immune mechanisms, C. difficile 
toxins act rapidly to disrupt the epithelial layer. This results in the loss of tight 
junction proteins and collapse of the intestinal epithelial barrier (Solomon 2013). 
Once this barrier is breached, toxins come in contact with submucosal macrophages 
and dendritic cells. This triggers an aggravated cascade of proinflammatory 
cytokines such as IL-1β, IL-6, IL-8 and TNFα via NF-κB signalling (Madan & Petri 
Jr 2012). Furthermore, toxin A has been shown to block the secretion of mucins from 
goblets cells (Branka et al. 1997), resulting in a thinner mucus layer, which allows C. 
difficile and its toxins even closer to the intestinal epithelial barrier (Engevik et al. 
2014).  
The recruitment of neutrophils to the site of infection is a central part of C. difficile 
infection (Madan & Petri Jr 2012). While neutrophils are essential for the innate 
immune response and clearance of the pathogens via phagocytosis (Fournier & 
Parkos 2012), when the epithelial barrier is compromised, the influx of these cells 
results in exacerbated acute inflammation and further damage to the epithelium (Sun 
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& Hirota 2015). In our previous study we have shown that mice infected with C. 
difficile had increased the neutrophil infiltration into the colonic tissue, and this 
correlated with collapsed epithelial structure and acute inflammation (Lynch 2014, 
unpublished). The extensive acute inflammatory response appears to be a major 
factor contributing to injury in CDI, subsequently leading to organ failure and even 
death (Kelly & Kyne 2011).  
Among the cascade of secreted cytokines are those essential for inducing an adaptive 
immune response. In our previous research we have demonstrated that the type of 
adaptive response to C. difficile is largely influenced by the ribotype of C. difficile 
(Lynch 2014, unpublished). We determined that the persistence of infection with C. 
difficile RT 027 and lack of clearance mechanisms in mice were due to elevated 
levels of anti-inflammatory IL-10 which provides the environment for Treg 
development suggesting an immune evasion mechanism employed by the pathogen. 
Conversely, infection with C. difficile RT 001 resulted in activation of IL-17 
cytokine and promoting a Th17 environment. Th17 cells secrete IL-22 which is 
known to play role in epithelial layer recovery (Sadighi Akha et al. 2015). However, 
the exact role of Th17 cells and IL-22 in the clearance of C. difficile and restoration 
of the epithelial barrier remains unclear and warrants further investigation.    
Induction of adaptive immune response results in maturation of B cells and 
production of antibodies that aid the clearance of the pathogen. Antibodies detected 
in CDI patients’ sera include IgG, IgA and IgM, specific for toxins, SLPs, flagella 
and cell wall proteins. This indicates the complexity of the adaptive response against 
C. difficile (Drudy et al. 2004; Kelly & Kyne 2011). 
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Figure 1. 8 The interactions between C. difficile and the immune system. Vegetative 
cells of C. difficile induce a cascade of reactions upon recognition via innate immune 
response. While the pathogen produces the toxins that damage the tight junction proteins and 
the epithelium, the innate immune response recruits the neutrophils to the site of infection, 
while trying to mount the specific adaptive immune reaction. Neutrophils become 
detrimental to the epithelial damage, as the massive influx exacerbates the acute 
inflammation rather than phagocyting the pathogen. Infection resolution relies on how 
prompt the adaptive immune response, ie. the production of antibodies specific for the 
bacterial antigens. Furthermore, the exact role of IL-22 in recovery of the epithelial cells 
during infection is yet to be determined. Adapted from Sun & Hirota 2015 and the literature 
described in section 1. 2. 5. 
 
1. 2. 6 Ribotyping 
C. difficile has been identified as a pathogen relatively recently. The epidemiology of 
CDI has been very dynamic, with the emergence of new virulent strains and an 
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increase in the incidence of community-acquired CDI. Since the disease outcome is 
directly related to the strain of the C. difficile involved, there was a need for 
standardising the typing schemes and referencing, as several approaches to 
categorising C. difficile were in development (Manzo et al. 2014). This was to aid in 
tracking new outbreaks, the epidemiology of the pathogen and also to facilitate 
communication between research communities.  
Initial work focused on typing phenotypic features like toxin production (Wüst et al. 
1982) or isolation of plasmids (Clabots et al. 1988), and these approaches were based 
on clinical isolates which were cultured into pure colonies (Tortora et al. 2010). This 
method allowed for the identification of “type strains” and is a classic method of 
classifying bacteria. Genotyping gradually replaced the phenotypic procedures 
mentioned previously. Advances in molecular methods allowed for the classification 
of organisms based on having the same sequences in their housekeeping genes. 
Methods like pulse-field electrophoresis, restriction endonuclease analysis, and 
toxinotyping have since been used and have provided a greater insight into the 
classification of C. difficile (Mullany & Roberts 2010).  
PCR-ribotyping exploits the differences in the spacer regions between 16S and 23S 
of the ribosomal RNA. Both the number of operons and length of the spacer regions 
are different between the strains and these criteria are used for discrimination 
between the strains (Weisburg et al. 1991). In this case, the pattern generated by the 
DNA is visualised by gel electrophoresis and is referred to as ribotype (Brazier 
2001). PCR-ribotyping was first used to classify C. difficile in 1993 (Gurler 1993) 
and it is now the most widely accepted method with more than 100 distinguishable 
groups of C. difficile isolates identified to date (Martinson et al. 2015; Behroozian et 
al. 2013). In this project, C. difficile strains are referred to as ribotypes.  
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1. 2. 7 Current Therapies 
Treatment of CDI is far from straightforward, due to the fact that broad-spectrum 
antibiotics exacerbate the disease (Dawson et al. 2009). During the past few years, 
more severe and more resistant strains of C. difficile have emerged, which are able to 
overcome the standard treatment approach (H. Huang et al. 2009). Traditional 
therapies such as metronidazole and vancomycin (Vardakas et al. 2012) or 
corticosteroids (Wojciechowski et al. 2014) are still able to dampen the CDI 
symptoms. However, overuse of antibiotics such as fluoroquinolones has led to the 
emergence of resistance among the most prevalent strains of C. difficile (Redgrave et 
al. 2014). Thus, this has prompted the search for alternative treatment approaches. 
The Food and Drug Administration (FDA) has fast-tracked novel combination 
antibiotic treatments such as ramoplanin and actagardine (Mathur et al. 2013). 
Another new narrow-spectrum antibiotic with antimicrobial activity specific against 
C. difficile, but not the commensal microbiota, thuricin CD was recently reported 
(Rea et al. 2010). Furthermore, Ling et al. have reported the development of the 
antibiotic teixobactin, which was shown to be exceptionally active against C. difficile 
without any sign of antibiotic resistance emerging in the pathogen (Ling et al. 2015).  
While antibiotics promptly ameliorate the disease symptoms, most common and 
hypervirulent C. difficile strains demonstrate very high rates of antibiotic resistance 
(H. Huang et al. 2009) and therefore there is a need to develop alternative treatment 
therapies. Previously there were several attempts to develop vaccines, including 
vaccines against whole, or fragments, of toxin A and B (Foglia et al. 2012; 
Karczewski et al. 2014; Senoh et al. 2015), SLPs (O’Brien et al. 2005), fibronectin-
binding protein (Brun et al. 2008) and GroEL heat shock protein (Péchiné et al. 
2013). Tam Dang et al. reported the development of protease inhibitors that targeted 
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the assembly of the S-layer in C. difficile (Tam Dang et al. 2012). Another study 
proposed a treatment that utilises membrane perforation with the use of nisin and 
lysozyme (Chai et al. 2015). However the efficiency of these treatments is still under 
question. 
To date the most effective approach implemented in treating C. difficile has been 
Faecal Microbiota Transplant (FMT), with over 90% of patients with reoccurring 
CDI being successfully cured (Khoruts & Weingarden 2014). It consists of the 
transfer of a homogenised faecal suspension from a healthy donor to the GI tract of a 
diseased recipient (Di Bella et al. 2015). While it was known that this therapy is 
successful, its mechanism of action was poorly understood for many years (Aas et al. 
2003; Koenigsknecht & Young 2013). Recently it was reported that the delivery of 
healthy microbiome via FMT allows for the metabolism of the primary bile salts into 
secondary bile salts (Seekatz et al. 2014; Weingarden et al. 2014). In an 
immunocompromised state, the lack of commensal metabolism results in 
accumulation of primary bile salts and lack of secondary acids. This in turn has a 
great impact on C. difficile germination, as the primary bile salts facilitate the 
germination of spores, while lack of secondary bile salts allows for the proliferation 
of vegetative cells. Also, lack of commensal metabolism limits the digestion of fiber 
into short-chain fatty acids (SCFA), which are known for their inhibitory properties 
on vegetative cells of C. difficile (Britton & Young 2012). FMT restores the 
microbiota balance but also the commensal metabolism essential for the colonisation 
resistance.  
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1. 3 REASONING BEHIND THE STUDY AND AIMS  
The GI tract is a very tightly regulated system with all its components finely tuned to 
keep pathogens at bay. C. difficile is an opportunistic pathogen that exploits the 
situation when the host is immunocompromised. Recent research has shed more light 
on the factors contributing to infection, such as the role of microbiota. However, not 
many studies have explored the role of differences in SLP structure between different 
ribotypes as a potential virulence factor. The differences in SLPs could play a 
significant role in the adherence, recognition by the immune system and clearance 
mechanisms mounted in response to various ribotypes.  
Our hypothesis states that the SLPs of different ribotypes differentially interact with 
host mucosal epithelial barrier, and hence mount different responses. Post-
translational modifications, such as glycosylation, could contribute to SLPs being 
differentially recognised by the immune system. Furthermore, the susceptibility state 
may modify host’s responses to the pathogen and its initial recognition and induction 
of clearance pathway; however this area is largely unexplored in the pathogenicity of 
C. difficile. Finally, the glycans available on the surface of the epithelium are used by 
the pathogen for growth and we wanted to examine whether the glycans available in 
susceptibility state and during the infection with C. difficile promotes the pathogen 
growth.  
To address the above research questions, the aims of this thesis were: 
 To optimise the methods to grow a range of C. difficile and purify the SLPs 
from these ribotypes and compare the ex vivo response of colonic tissue to 
SLPs 
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 To examine glycosylation patterns of SLPs from these ribotypes, as 
glycosylation was proposed to potentially contribute to adherence and 
colonisation 
 
 To examine factors that could contribute to the susceptibility state in vivo in a 
murine model, namely glycosylation profile of the colonic epithelium, 
immune response and mucosal integrity state 
 
 To examine the glycosylation profile  of the colon during C. difficile infection 
in vivo and clearance mechanism of the pathogen 
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CHAPTER 2 MATERIALS AND METHODS  
2.1 MATERIALS 
 
Table 2. 1 Microbial Cell Culture 
Anoxomat Anaerobic Jar Mart Microbiology 
Brucella Agar with 5% Horse Blood BD 
Anaerobic Gas Generating Kit Thermo Fisher Scientific 
Anaerobe Indicator Test Sigma-Aldrich 
Dulbecco’s Modified Eagle’s Medium Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Cryovials Lennox 
Mr. Frosty Freezing Container Thermo Fisher Scientific 
Fastidious Anaerobic Broth Oxoid 
Brain Heart Infusion Broth Oxoid 
Hemin Sigma-Aldrich 
Vitamin K Sigma-Aldrich 
Sodium Thioglycolate Sigma-Aldrich 
10 µl Inoculation Loops Cruinn 
Presept Tablets VWR 
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Table 2. 2 S-layer Isolation and SLPs Purification 
50 ml Unskirted Centrifuge Tubes Sarstedt  
2 ml Screw Cap Centrifuge Tubes Sarstedt  
Trizma Base Sigma-Aldrich 
NaCl Sigma-Aldrich 
Urea Sigma-Aldrich 
cOmplete™ Protease Inhibitor Cocktail Roche 
Slide-A-Lyzer™ Dialysis Cassettes 10 K 
Molecular Weight Cut Off  
Pierce 
ÄKTAFPLC GE Healthcare 
MonoQ HR 10/10 Chromatography Column GE Healthcare 
10 ml Injection Loop GE Healthcare 
 
Table 2. 3 SDS PAGE 
30% Bis-acrylamide Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich 
Ammonium Persulfate (APS) Sigma-Aldrich 
N, N, N', N'-tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich 
PageRuler™ Plus Prestained Protein Ladder Fermentas 
Methanol Lennox 
Acetic Acid Sigma-Aldrich 
Glycine Sigma-Aldrich 
Brilliant Blue Sigma-Aldrich 
 
Table 2. 4 SLP Characterisation 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific 
Amicon® Ultra-4 Centrifugal Filter 10 K 
Molecular Weight Cut Off Devices 
Merck Millipore 
ToxinSensor™ Chromogenic LAL Endotoxin 
Assay Kit 
GeneScript 
VERSA Amax Microplate Reader Molecular Devices, CA, USA 
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Table 2. 5 SLP Glycosylation 
The Pierce™ Gycoprotein Staining Kit Thermo Fisher Scientific 
Asialofetuin Sigma-Aldrich 
Fetuin (Bovine) Sigma-Aldrich 
Glucose Oxidase Sigma-Aldrich 
Invertase (from Saccharomyces cervisiae) Sigma-Aldrich 
Thyroglobulin (Porcine) Sigma-Aldrich 
Transferrin Sigma-Aldrich 
PBS Biosciences 
Nunc 96-well Plate Sarstedt 
Carbo-Free™ Blocking Solution Vector Laboratories 
Biotinylated Lectins* Vector Laboratories 
CaCl2 Sigma-Aldrich 
MgCl2 Sigma-Aldrich 
MnCl2 Sigma-Aldrich 
Trizma Base Sigma-Aldrich 
Tween® 20 Sigma-Aldrich 
Streptavidin-conjugated Horseradish Peroxidase Sigma-Aldrich 
3,3’,5,5’-Tetramethylbenzidine (TMB) BD 
10% H2SO4 Sigma-Aldrich 
iBlot System Biosciences 
iBlot Nitrocellulose Blots Biosciences 
Bovine Serum Albumin Sigma-Aldrich 
Luminata Chemiluminescence Substrate Merck Millipore 
G-Box Fluorescence Gel Analysis System Syngene 
*Complete list of biotinylated lectins and their corresponding specificities are 
summarised in Table 2. 15. 
 
Table 2. 6 Animal Model  
C57BL/6J Female Mice (aged 9-15 weeks) Charles River 
Metronidazole Sigma-Aldrich 
Gentamicin Sigma-Aldrich 
Colistin Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
CHAPTER 2                                                                                          MATERIALS AND METHODS 
 
44 
Vancomycin Sigma-Aldrich 
Clindamycin Sigma-Aldrich 
1 ml Syringe BD 
27 G Needle BD 
PBS Biosciences 
Penicillin-Streptomycin (10,000 U/mL) Gibco 
RPMI Invitrogen 
LPS from E. coli Enzo Lifesciences 
6- and 24-well Tissue Culture Plates Nunc 
 
Table 2. 7 RNA Isolation and cDNA Synthesis Reagents 
NucleoSpin® RNA II Total Isolation Kit Macherey-Nagel 
DEPC-treated dH2O Invitrogen 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Molecular Grade Ethanol Sigma-Aldrich 
β-Mercaptanol Sigma-Aldrich 
RNaseZap® Sigma-Aldrich 
MJ Research PTC-200 Thermal Cycler GMI 
 
Table 2. 8 RNA and DNA Integrity by Gel Electrophoresis 
Agarose Thermo Fisher Scientific 
TAE Sigma-Aldrich 
RNA Sample Loading Buffer, without ethidium 
bromide 
Sigma-Aldrich 
Gene Ruler 100 bp Plus DNA ladder Thermo Fisher Scientific 
SYBR® Safe DNA Gel Stain Invitrogen 
6X DNA Loading Dye  Fermentas 
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Table 2. 9 RT qPCR Reagents 
FastStart Essential DNA Green Master Roche 
FastStart Essential dH2O Roche 
Lightcycler® 96-well Plates Roche 
Optical Adhesive Film Roche 
LightCycler® 96 Roche 
PrimeTime qPCR Primers IDT 
 
Table 2. 10 PrimeTime qPCR Primers (mixture of forward and reverse). All 
primers sourced from IDT. Complete sequences, corresponding protein products and 
exon locations are summarised in Table A2 (Appendix C). 
Mucins 
Muc1, Muc2, Muc3, Muc4, Muc5ac, Muc6 
Muc13, Muc15 and Muc20 
Inflammatory Cytokines 
Il1β, Il2, Il6, Il10, Il17a, Il22b, Ifng, Tnfa, 
Tgfb and Stat3 
IL-12 Family cytokines Il12a and Il23 
Chemokines Ccl2, Ccl3, Cxcl2 and Ccl5 
Toll-like Receptors Tlr2, Tlr4, Tlr5 and Tlr9 
Tight junction proteins Cdh1 and Ocln 
Glycosylation Enzymes Nans and Fut2 
Reference Genes B2m, Gusb, Ppia, Rps18 and Tbp 
 
Table 2. 11 Tissue Processing and Sectioning 
Optimum Cutting Temperature (OCT) 
Medium 
VWR 
Leica TP1020 Tissue Processor Leica 
Tissue Processing/Embedding Cassettes Sigma-Aldrich 
Formaline Sigma-Aldrich 
Ethanol Lennox 
Xylene Sigma-Aldrich 
Paraffin Sigma-Aldrich 
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Cryostat Leica 
SuperFrost® Plus Adhesion Slides VWR 
Microtome Leica 
 
Table 2. 12 Haematoxylin and Eosin Staining 
Harris Heamatoxylin Sigma-Aldrich 
Eosin Sigma-Aldrich 
Xylene Sigma-Aldrich 
Ethanol Lennox 
Sodium Biocarbonate Sigma-Aldrich 
HCl Sigma-Aldrich 
Histoclear Thermo Fisher Scientific 
DPX Mounting Medium Sigma-Aldrich 
 
Table 2. 13 Lectin Histochemistry 
FITC-conjugated lectins* Vector Laboratories 
Vectashield Hardset Mounting Medium with 
DAPI 
Vector Laboratories 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
CaCl2 Sigma-Aldrich 
MgCl2 Sigma-Aldrich 
Trizma Base Sigma-Aldrich 
Methyl α-D-mannopyranoside Sigma-Aldrich 
L-Fucose Sigma-Aldrich 
L-Fucose Sigma-Aldrich 
N-Acetyl-D-galactosamine Sigma-Aldrich 
N-Acetyl-D-glucosamine Sigma-Aldrich 
N-Acetyl-D-glucosamine Sigma-Aldrich 
N-Acetylneuraminic acid Sigma-Aldrich 
* Complete list of fluorescently-labelled lectins and their corresponding specificities 
are summarised in Table 2. 22. 
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2.2 METHODS 
 
2. 2. 1 Microbial Cell Culture 
All microbial cell culture was carried out using aseptic techniques in BIOMat
2 
class 
II Microbiological Safety Cabinet in Institute of Molecular Medicine (Trinity 
College, Dublin), based in St. James’s Hospital. All C. difficile ribotypes used in this 
project were a kind gift from Professor Thomas Rogers from Department of Clinical 
Microbiology, School of Medicine, Trinity College, Dublin. These ribotypes were 
sourced from patients with C. difficile infection.  
 
2. 2. 2 Overview of SLP Isolation from C. difficile.  
The steps involved in the isolation and purification of SLPs from C. difficile are 
summarised in Figure 2. 1. Each step in described in details in Sections 2. 2. 3 – 2. 2. 
7. 
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C. difficile 
culture 
Isolation  
of SLPs 
Purification  
SLPs Isolation Workflow 
Blood Agar incubation  
48 h/37°C 
Brain Heart Infusion Broth 
culture 18 h/37°C 
Overnight dialysis 
Incubation in 8 M Urea 
50 mM Tris:HCl pH 8.5  
1.5 h/37°C 
Washing cell debris 
Anion Exchange  
Chromatography (FPLC) 
SDS PAGE 
Concentration 
BCA Assay 
Endotoxin 
UV 
Cryoprotected stocks  
at -80°C 
Fastidious Anaerobic Broth 
culture 24 h/37°C 
Harvesting cells 
 at 1800 g 
Aliquoted stocks stored 
at -20°C 
Figure 2. 1 Overview of SLP isolation. The method is briefly described in section 2. 2. 
2, and in detail in Sections 2. 2. 3 – 2. 2. 7. 
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2. 2. 3 Bacterial Culture on Solid Medium 
An inoculum of a given ribotype was streaked of surface Brucella Agar with 5% 
Horse Blood with a sterile inoculating loop using standard streaking method (Figure 
2. 2). Plates were incubated upside down at 37°C for 48 h in anaerobic jar. An 
anaerobic Gas Generating Kit was used to generate anaerobic conditions in the jar. 
Furthermore, an Anaerobe Indicator Test was also inserted in the jar to monitor 
whether anaerobic conditions occurred in the sealed container. A colour change from 
pink to white indicated anaerobic conditions. 
 
Figure 2. 2 Principle of plate streaking. Fresh loop was used between A, B, C and D.  
 
2. 2. 4 Preparation of Microbial Spore Stocks 
To prepare fresh stock for each new isolate, a single colony was streaked onto the 
surface of blood agar as described in section 2. 2. 3.  
Two approaches for preserving stocks were developed. Initially, a solution of PBS 
with 15% glycerol was used for whole cell stock solution. In this case, colonies were 
incubated for 48 h and all colonies from one plate were swabbed from the surface of 
the agar and transferred into 2 ml of PBS/glycerol in a cryovial. Cell stocks were 
then immediately frozen at -80°C. A second approach involved preserving spores of 
A 
D 
C 
B 
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C. difficile. In this case agar plates were incubated for seven days under anaerobic 
conditions to generate spores. The cultures were harvested with disposable loops into 
1 ml of PBS in screw cap tubes. Tubes were then spun down at 5600 g and the 
supernatant was removed. The cell pellet was washed in 1 ml PBS, and heat-shocked 
at 56°C for 10 min to kill surviving vegetative cells. The spores were centrifuged and 
re-suspended in 1 ml DMEM with 15% glycerol. Cryovials were labelled, dated, and 
frozen overnight at -80°C using a Mr. Frosty freezing container. The next day 
cryovials were transferred to a box and returned to -80°C. The latter approach was 
preferred to prevent the culture forming mutations. 
2. 2. 5 Reviving of Microbial Spore Stocks 
The bacterial spore stock cryovial was kept on ice. Using a sterile loop, the surface 
of the stock was scraped and streaked onto the surface of blood agar plate. The stock 
cryovial was returned to -80°C, while the plates were incubated upside down at 37°C 
for 48 h in an anaerobic jar, as described in Section 2. 2. 3. One passage was 
sufficient to produce enough colonies to inoculate liquid broth culture.  
2. 2. 6 Liquid Broth Culture of C. difficile for Isolation of SLPs  
Fastidious Anaerobic Broth (FAB) and Brain Heart Infusion (BHI) broth were 
prepared according to manufacturer’s guidelines and autoclaved at 121°C and 15 
lb/in
2
 for 15 min. BHI broth was supplemented with 0.05% Sodium thioglycolate to 
ensure reducing conditions, and with vitamin K and hemin to support C. difficile 
growth (accordingly, 0.1 ml of 1% alcohol solution per litre of broth and 0.5 ml of 
1% solution per litre of broth).  
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FAB broth was inoculated with a single C. difficile colony from blood agar plates. 
Broth tubes were placed in a 5 L anaerobic jar and incubated anaerobically for 24 h. 
After 24 h incubation, there was visible growth of suspended C. difficile colonies. In 
the meantime, Brain Heart Infusion Broth was aliquoted into 50 ml tubes 
(approximately 48 ml) and incubated in an anaerobic jar for 1-24 h to remove 
oxygen. Using sterile transfer pipettes, approximately 1 ml of FAB inoculum was 
transferred into tubes with BHI broth. BHI broth was incubated for approximately 16 
h, under anaerobic conditions, until the turbid growth was observed. 
2. 2. 7 Isolation of SLPs 
2. 2. 7. 1 Removal of S-layer 
Bacterial cells were harvested by centrifugation at 3200 g for 20 min at 4°C. 
Supernatant was discarded into a container filled with Presept solution to inactivate 
any remaining bacterial cells or spores. Each pellet was washed twice in ice-cold 50 
mM Tris/HCl pH 7.4 by centrifuging at 3200 g for 20 min at 4°C. The pellets were 
then resuspended in 8 M urea/50 mM Tris/HCl pH 8.5, supplemented with protease 
inhibitor (5 tablets per 100 ml of 8 M urea/50 mM Tris/HCl pH 8.5) and incubated 
for 90 min at 37°C. Cells were then centrifuged at 12 500 g for 30 min at 4°C. 
Supernatant containing crude S-layer was carefully removed into fresh 50 ml tubes 
for storage at -20°C or dialysed immediately. 
2. 2. 7. 2 Dialysis of Crude S-layer Preparation. 
The crude protein extract underwent dialysis to remove urea from the solution. 
Dialysis cassettes (35 ml) with 10 K Molecular Weight Cut Off were rehydrated in 
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dialysis buffer (20 mM Tris/HCl pH 8.5) for 2 min. Dialysis buffer was compatible 
with running buffer for FPLC (described in Section 2. 2. 7. 3). 
The crude protein extract was added to the dialysis cassette and the excess air was 
removed in the cassette by pressing the membrane gently on both sides. The cassette 
was placed in 5 L of dialysis buffer (300 X volume of the crude SLP extract) and 
floated vertically. Buffer was placed on a stirring plate and moved to a 4°C room. 
The crude protein extract was dialysed for 2 h and the buffer was changed three 
times. The third change of buffer was left overnight at 4°C. The crude extract was 
dialysed in a total of 20 L of dialysis buffer. The next day the sample was retrieved 
and filtered through 0.2 µm filters to remove any solid impurities. The crude protein 
extract was aliquoted into 10 ml tubes and stored in -20°C before proceeding to 
purification. 
2. 2. 7. 3 Purification of SLPs using Fast Protein Liquid Chromatography 
(FPLC) 
The crude S-layer was purified using ÄKTAFPLC, which is a high-performance liquid 
chromatography for fast and easy purification of proteins. The assembled system 
allowed for ion exchange type of chromatography and was equipped with a MonoQ 
HR 10/10 chromatography column and a 10 ml injection loop (allows for 
introduction of large sample volumes into a pressurised fluid system). After 
assembling the instrument, the system was primed with running buffer (Buffer A; 20 
mM Tris/HCl pH 8.5) and elution buffer (Buffer B; 0.3 M NaCl/20 mM Tris/HCl pH 
8.5). The system was controlled by UNICORN™ Software (3.21v) which provided 
full control of purification process (Table 2. 14). 
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Crude S-layer fractions, comprised of isolated SLPs and other cell wall/cell surface-
associated proteins in 100% running buffer, were pumped into the column with the 
injection loop. Proteins bound to the column resin by a charge interaction. The flow 
rate of the mobile phase was kept constant, however the proportion of Buffer B to 
Buffer A was gradually increased from 0% to 100% (known as gradient). Proteins 
dissociated from the column upon increasing the gradient of elution buffer. The 
slope of the salt gradient was adjusted by changing the amount of total volume 
flowing through the column (measured in number of column volumes) and final salt 
concentration.  
The effluent containing the dissociated proteins passed through the flow cell. This 
allowed for detection of the NaCl concentration by conductivity (mS/cm) and protein 
concentration by absorption of UV light at 280 nm (mAU). As each protein was 
eluted and detected, it appeared as a peak on the chromatogram. The height and area 
of the peak was directly proportional to the concentration of the detected protein. 
The effluent fractions were set to 2 ml and were collected on a rotating rack 
(fractions numbered A1-A15, B1-B15, C1-C15 etc.) and approximately 45 fractions 
were collected in total per run. This allowed for satisfactory resolution between the 
eluted protein fractions. 
Depending on the slope of the NaCl gradient, several elution profiles were observed. 
The main peak observed on the chromatogram generated by the software 
corresponded to the eluted SLP fraction (eluted at approximately 40 min).  
To confirm the protein identity, 100 µl aliquots were kept frozen for SDS PAGE 
analysis. Before shutting down, the system was washed with Buffer B (0.3 M 
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NaCl/20 mM Tris/HCl pH 8.5) to remove any remaining proteins and Buffer A (20 
mM Tris/HCl pH 8.5) to calibrate the system. The system was stored in 20% ethanol.  
Table 2. 14 UNICORN™ Software (3.21v) Settings Applied to Purify SLPs 
using ÄKTAFPLC. CV: Column Volume; B: Eluting buffer (Buffer B). 
Parameter Setting 
UV Averaging Time  5.10 
Flow Rate 4.00 ml/min 
Starting Concentration Buffer B 0.00% B 
Equilibrate with 1 CV 
Flowthrough Fraction Size 0.00 ml 
Start Flowthrough at Next Tube 
Empty loop with 10 ml 
Wash Column with  5 CV 
Start Fractionation at 60% B 
Eluate Fraction Size 2.0 ml 
Start Eluate Fraction at First Tube 
Peak Fraction Size 0.00 ml 
Start Peak Fraction at Next Tube 
Peak Start Slope 100.00 mAU/min 
Peak End Slope 75.00 mAU/min 
Minimum Peak Width 0.31 min 
End Fraction at  100% B 
Target Concentration B 1 60% B 
Length of Gradient 1 20 CV 
Target Concentration B 2 100% B 
Length of Gradient 2 4 CV 
Target Concentration B 3 100% B 
Length of Gradient 3 2 CV 
Concentration of Eluent B 100% B 
Clean with  5 CV 
Reequilibrate with 2 CV 
CHAPTER 2                                                                                          MATERIALS AND METHODS 
 
55 
2. 2. 7. 4 SDS Polyacrylamide Gel Electrophoresis 
To confirm the identity of the detected protein peaks, proteins were separated by 
SDS denaturing polyacrylamide gel electrophoresis. Acrylamide gels (10% (w/v)) 
were cast between two glass plates and affixed to the electrophoresis unit using 
spring clamps. Samples were diluted with 5X Loading Buffer supplemented with 1 
M Dithiothreitol (DTT) and heated to 96°C for 5 min to denature any protein 
structures (See Appendix A). To run the samples on the gels, electrode running 
buffer was added to the upper and lower reservoirs. Prepared samples (10 µl) were 
loaded into wells and run at 30 mA per gel for approximately 45 min. Protein ladder 
containing pre-stained protein molecular weight markers was added to the first lane 
in each gel.  
2. 2. 7. 5 Identification of SLPs by Coomassie Staining 
When protein samples were separated completely, gels were removed from the casts, 
washed extensively with deionised water, and submerged in 10 ml of Coomassie 
Blue stain to identify any proteins present. The gels were then stained for 1 h with 
gentle agitation. After the incubation, the Coomassie stain was removed and the gels 
were washed briefly with dH2O. Destain solution was added and gels were left for 10 
min. Destain solution was then removed and the destaining was repeated four times. 
The gels were then left rocking in destain solution overnight at 4°C. The next day 
gels were examined for the presence of protein bands. Lanes with two bands 
(weights corresponding to both SLP subunits, High Molecular Weight at ~55 kDa 
and Low Molecular Weight at ~35 kDa) were selected. Corresponding crude protein 
fractions in 2 ml tubes were identified and defrosted.  
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2. 2. 7. 6 Concentration of Purified SLPs  
Samples were concentrated using centrifugal filters with 10 K Molecular Weight Cut 
Off to retain both subunits of SLP (HMW ~55 kDa and LMW ~35kDa). The filters 
were centrifuged at 4000 g for 15 min at 4°C. Concentrated protein samples were 
recovered from filter device. Furthermore, samples were subjected to UV radiation 
for 15 minutes to ensure sterility, aliquoted and stored at -20°C. 
2. 2. 7. 7 Measuring Protein Concentration with BCA assay 
Purified SLP concentration was measured using BCA Protein Assay Kit according to 
manufacturer’s guidelines. The assay uses the well-documented reduction of Cu+2 to 
Cu
+1
 by protein in a base, along with the colourimetric detection of Cu
+1
 using 
bicinchoninic acid (BCA). A purple colour is observed in the presence of protein, 
with darker colour signifying a higher concentration. 
Briefly, a standard curve was prepared from Bovine Serum Albumin (highest 
standard 2000 pg/ml, followed by 1500, 1000, 750, 500, 250, 125, 25 and 0 pg/ml) 
in 20 mM Tris:HCl pH 8.5 and plated in triplicate on a 96-well plate. Samples 
(diluted and neat) were also plated in triplicate. BCA solution was added to all wells 
and the plate was incubated at 37°C for 30 min. The plate was cooled to room 
temperature and the absorbance was read at 562 nm on a microplate reader. Standard 
curve and the protein concentrations were calculated using GraphPad Prism 5.01.  
2. 2. 7. 8 Endotoxin Test and UV Radiation 
Samples of concentrated SLP were tested for the presence of endotoxin. LAL assay 
kit was used as a quantitative in vitro end-point endotoxin test. It utilises a modified 
Limulus Amebocyte Lysate, which is an aqueous extract of blood cells 
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(amoebocytes) from the horseshoe crab, Limulus polyphemus. A synthetic colour 
producing substrate is used to detect endotoxin chromogenically. Reagents were 
prepared according to manufacturer’s instructions, and the test procedure was 
followed as per guidelines. Briefly, a measurable concentration ranges of 0.005 to 1 
Endotoxin Units/ml (EU/ml) were prepared. Standards and samples (100 μl) were 
placed in specific endotoxin-free vials in duplicate. A blank of LAL reagent water 
was also prepared. LAL (100 μl) was added to each vial and the samples were 
incubated at 37°C for 10 min. Chromogenic substrate solution (500 μl) was then 
added, the samples were gently mixed and incubated for 6 min. Stop solution (500 
μl) and colour stabiliser were added and samples were gently swirled to avoid 
generation of bubbles. Absorbance was read at 545 nm on a microplate reader.  
2. 2. 8 Confirmation of slpA Sequences 
The strains used in this study included R13537 (ribotype 001) and R12885 (ribotype 
014). The sequence of the slpA gene of these strains has been previously determined 
(accession numbers DQ060626 and DQ060638 respectively). To determine the slpA 
gene sequences of our clinical strains belonging to ribotypes 027 and 078, whole-
genome sequencing was performed. DNA was extracted from C. difficile using the 
Roche High-pure PCR template preparation kit (Roche, West Sussex, UK). Nextera 
XT library preparation reagents (Illumina, Eindhoven, The Netherlands) were used 
to generate multiplexed sequencing libraries of C. difficile genomic DNA, and 
resultant libraries were sequenced on an Illumina MiSeq®. Short-read data obtained 
has been deposited in the European Nucleotide Archive (ENA); project accession 
number PRJEB6566. Genome assemblies were performed using the Velvet short-
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read assembler and slpA gene sequences were retrieved for each isolate using 
BLAST (Altschul et al. 1990). 
2. 2. 9 Periodic Acid–Schiff Glycoprotein Staining 
The periodic acid-Schiff (PAS) method was used to detect glycosylated proteins that 
have sialic acid and other oxidisable carbohydrate groups. In this method, a gel or 
membrane containing separated proteins is treated with a periodate solution 
(Oxidising reagent), which oxidizes cis-diol sugar groups in glycoproteins. The 
resulting aldehyde groups are detected through the formation of Schiff-base bonds 
with a reagent that produces magenta bands. Crude and purified SLPs samples were 
separated by electrophoresis on a 12.5% (w/v) SDS denaturing polyacrylamide gel a 
as described before (Section 2. 2. 7. 4). Protein ladder containing molecular weight 
markers was added to the first lane in each gel. Soybean Trypsin Inhibitor was used 
as a negative control and Horseradish Peroxidase was used as positive control 
(included in the kit). A total of 10 µg of protein per sample was prepared, and loaded 
into wells and run at 30 mA per gel for approximately 45 min. When proteins were 
separated, gels were removed from casts and stained with Coomassie Brilliant Blue 
stain to confirm the protein identity. Schiff staining was performed according to the 
manufacturer guidelines. After completing the procedure, the glycols were stained, 
yielding magenta bands with a colourless background, while proteins with no 
glycosylation remained dark blue. 
2. 2. 10 Enzyme-Linked Lectin Assay (ELLA) 
An Enzyme-Linked Lectin Assay was used to probe the surface of the SLPs for the 
presence of various sugar moieties using a range of lectins (Figure 2. 3). SLPs were 
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diluted to a concentration of 5 µg/ml in PBS and 50 µl was added to 96-well plates. 
PBS was used as a negative control while a range of glycoproteins with known 
glycosylation patterns were used as positive controls. The plate was incubated 
overnight at 4°C. The plate was then aspirated and blocked for non-specific binding 
for 2 h at room temperature with Carbo-Free™ Blocking Solution. Plates were 
washed four times with TBST supplemented with 1 mM Ca
2+
/Mg
2+
/Mn
2+
. 
Biotinylated lectins (Table 2. 15) were diluted in TBST to a concentration of 5 µg/ml 
and 50 µl was added to corresponding wells and incubated for 1 h at room 
temperature. TBST was used as negative control for lectin specificity. Wells were 
aspirated and washed four times with TBST. Horseradish Peroxidase conjugated to 
streptavidin was diluted and 50 µl was added per well (1:10 000 dilution in TBST) 
and incubated for 1 h at room temperature. Wells were washed again four times in 
TBST and 90 µl of TMB was added, left for approximately 10 min and stopped with 
10% H2SO4. Absorbance was read at 450 nm using a microplate reader. The assay 
was run along with positive controls which are outlined in the Table 2. 16. 
 
Figure 2. 3 Schematic diagram of ELLA. SLPs were coated onto the surface of the 96-
well plate and were probed with biotinylated lectins. This interaction was quantified by 
addition of HRP-conjugated Anti-Biotin antibody and addition of substrate solution that 
change colour proportionally to the amount of lectin bound. Adapted from Thompson et al. 
(2011). 
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Table 2. 15 List of Biotinylated Lectins used in ELLA and Lectin Blotting. All lectins 
were sourced from Vector Laboratories and stored in -80°C. Recommended manufacturer 
concentrations were used. Table information was adapted from information provided on 
www.vectorlabs.com. 
Lectin 
Abbreviat
ion 
Source Glycan Specificity 
Aleuria aurantia AAL 
Aleuria aurantia  
mushrooms 
Fucose-(α-1,6)-N-
Acetylglucosamine 
Concanavalin A ConA 
Canavalia ensiformis  
(Jack Bean) seeds 
Core Mannose 
Dolichos biflorus DBA 
Dolicos biflorus 
 (Horse Gram) seeds 
α-N-Acetylgalactosamine 
Erythrina 
cristagalli 
ECL 
Erythrina cristagalli  
(Coral Tree) seeds 
Galactosyl-(β-1,4)-N-
Acetylglucosamine 
Galanthus nivalis GNL 
Galanthus nivalis  
(Snowdrop) bulbs 
(α-1,3)-Mannose 
Griffonia 
simplicifolia I 
GSL I 
Griffonia simplicifolia  
seeds 
α-N-Acetylgalactosamine 
and α-Galactose 
Griffonia 
simplicifolia II 
GSL II 
Griffonia simplicifolia 
 seeds 
α/β-N-Acetylglucosamine 
Jacalin Jacalin 
Artocarpus integrifolia 
(Jackfruit) seeds 
Galactosyl-(β-1,3)-N-
Acetylgalactosamine 
Lens culinaris LCA 
Lens culinaris  
(lentil) seeds 
α-Mannose 
Maackia 
amurensis II 
MAL II 
Maackia amurensis  
seeds 
Galactosyl-(α-2,6)/(α-2,3)-
Sialic Acid-(β-1,4)-N-
Acetylgalactosamine 
Narcissus 
pseudonarcissus 
NPL 
Narcissus 
pseudonarcissus 
(Daffodil) bulbs 
Terminal and High Mannose 
Peanut PNA Arachis hypogaea peanuts 
Galactosyl-(β-1,3)-N-
Acetylgalactosamine 
Soybean SBA 
Glycine max  
(soybean) seeds 
Terminal α/β-N-
Acetylgalactosamine 
Sambucus nigra SNA 
Sambucus nigra  
(Elderberry) bark 
Galactosyl-(α-2,6)/(α-2,3)-
Sialic Acid 
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Table 2. 16 Most abundant glycans found on glycoproteins used as positive controls 
used in ELLA. Adapted from Thompson et al. 2011, Larrgy 2011 and Kalisz et al. 1997. 
Asialofetuin Terminal Galactose and N-Acetylgalactosamine 
Fetuin (Bovine) Terminal and High Sialic Acid 
Glucose Oxidase N-Acetylglucosamine 
Invertase (from Saccharomyces cervisiae) High Mannose  
Thyroglobulin (Porcine) Sialic Acid 
Transferrin Terminal Sialic Acid, Fucose and Galactose 
2. 2. 11 Lectin Blotting 
Crude S-layer fractions and purified SLPs (10 µg of total protein) of C. difficile RT 
001, 002, 027 and 078, along with pre-stained molecular markers, were separated by 
SDS PAGE on 10% (w/v) acrylamide gels under denaturing conditions. Gels were 
washed in water to remove salts and were transferred onto a nitrocellulose membrane 
using the iBlot system, and stained with Ponceau S to confirm the transfer of 
proteins. Non-specific lectin binding sites were blocked for 1 h at room temperature 
using Carbo-Free™ Blocking Solution. Afterwards, membranes were washed four 
times in wash buffer (TBS with 0.01% Tween20® supplemented with 1 mM 
Ca
2+
/Mg
2+
/Mn
2+
). Samples were then incubated for 1 h at room temperature with 
1:2000 dilution of biotinylated lectin made up in lectin buffer (TBS with 0.01% 
Tween20® supplemented with 1% Bovine Serum Albumin and 1 mM 
Ca
2+
/Mg
2+
/Mn
2+
), followed by a wash step. Membranes were then incubated with 
1:250 dilution of streptavidin-conjugated horseradish peroxidase in lectin buffer for 
1 h at room temperature, followed by another wash step. Chemiluminescent substrate 
was then added to the membranes to detect HRP-lectin complexes. The intensity of 
the signals was detected by the G-Box fluorescence gel analysis system and exposed 
for a range of times (from 30 s to 120 s). 
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2. 2. 12 Animal Models 
2. 2. 12. 1 Housing 
Female C57BL/6J mice aged 9 to 15 weeks were used in this study. Mice were 
purchased from Charles River (UK) and were certified to be specific-pathogen free. 
Animals were housed in licenced facility in Bioresource Unit in Dublin City 
University and had ad libitum access to water and animal chow. Facility was 
monitored daily for temperature and humidity.  
2. 2. 12. 2 Project Approval and Ethics Statement  
All procedures were carried out in accordance with the Health Products Regulatory 
Authority and performed under project licence number AE19115_P001, project titled 
“Interaction between Surface Layer Proteins from Clostridium difficile and the gut 
epithelium”. All animal protocols received ethical approval from Dublin City 
University Research Ethics Committee.  
2. 2. 12. 3 In vivo susceptibility model 
Animals were assessed for the overall health on day 0 of the study to exclude any 
individuals that possibly experienced barbering (See Section 2. 2. 12. 4). Animals 
were divided into two groups, control and treatment. The control group received 
filtered water from day 0 to day 7, and this group was injected intraperitonially with 
body-temperature PBS on day 5. The treatment group received a cocktail of 
antibiotics in drinking water from day 0 to day 3 (and filtered water from day 4 to 
day 7), which was followed by an intraperitoneal injection of clindamycin on day 5. 
The antibiotics, their mode of action and relevant dosage are outlined in Table 2.17.  
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Animals were assessed daily for appearance, behaviour, water intake, weight and 
stool consistency. All scores were noted in Monitoring Score Sheet (Table 2. 18) and 
there was an individual sheet for each animal used in the study. The total score was 
used to determine Daily Disease Activity Index to assess animal welfare and any 
possible disease progress.  
As mentioned, water intake was monitored for welfare purpose. However, it was also 
correlated with the body weight of each animal (dosage per kg body weight) to 
Table 2. 17 Antibiotics used to induce susceptibility state in mice. Dosage and route of 
delivery was adapted from Chen et al. (2008). Information about primary specificity of the 
antibiotics and associated mode of action were sourced from Walsh (2003). 
Antibiotic 
Antibiotic 
Conc. 
Daily 
Dosage 
Delivery Specificity Mode of action 
Metronida- 
zole 
0.215  
mg/ml 
21.5 
mg/kg 
Oral in 
water 
Anaerobic 
bacteria 
Nucleic acid 
synthesis inhibitor 
(disrupting DNA 
structure) 
Gentamicin 
0.035  
mg/ml 
3.5 
mg/kg 
Oral in 
water 
Gram-ve 
bacteria 
Protein synthesis 
inhibitor (blocking 
30S subunit) 
Colistin 
850  
U/ml 
4.2 
mg/kg 
Oral in 
water 
Gram-ve 
bacilli 
Bactericidal action 
by solubilising the 
membrane 
Kanamycin 
0.4  
mg/ml 
40 
mg/kg 
Oral in 
water 
Gram-ve 
bacteria 
Protein synthesis 
inhibitor (blocking 
30S subunit) 
Vancomycin 
0.045  
mg/ml 
4.5 
mg/kg 
Oral in 
water 
Gram+ve 
bacteria 
Cell wall synthesis 
inhibitor (blocking 
peptidoglycan 
assembly) 
Clindamycin n/a 
10 
mg/ml 
IP 
injection 
Anaerobic 
bacteria 
Protein synthesis 
inhibitor (blocking 
50S subunit) 
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ensure that sufficient amount of the antibiotics was ingested to eradicate the 
microbiota. The general approach to susceptibility model is outlined in Figure 2. 5. 
Table 2. 18 Daily Disease Activity Index was determined based on the factors outlined 
below. Actions taken based on the total score for any given day: 0-2 normal; 4-6 monitor 
carefully, but notify Project Manager; 6-8 seek opinion from named animal care and welfare 
officer; consider termination; >9 terminate. Animal with >20% body weight loss should be 
euthanised regardless of the Total Score for any given day. The criteria were based on 
Wolfensohn & Lloyd (2012) and University of Colorado Denver/Anschutz Medical Campus 
(www.ucdenver.edu).  
Score 0 1 2 3 
Appearance Normal 
General lack of 
grooming, 
barbering 
Coat staring, 
ocular or nasal 
discharges 
Piloerection,  
hunched up 
Behaviour Normal Minor changes 
Abnormal: 
reduced mobility, 
inactive 
Unsolicited vocalisation, 
self-mutilation, restless or 
immobile 
Water 
intake 
Normal 
Limited <15% 
body weight 
Below 10% body 
weight 
No intake 
Weight Normal 
<5% weight 
loss 
5-15% weight loss >15% weight loss* 
Stool 
Consistency 
Normal 
Soft but still 
formed 
Very soft, no 
shape 
Diarrhoea (defined as 
mucus/faecal material 
adherent to anal fur) 
 
Animals were sacrificed humanely by cervical dislocation on day 7 and colons were 
removed. The colon was opened longitudinally and faecal matter was removed. The 
colon length and colon weight were recorded as an indication of colitis. The distal 
part of the colon was used for the subsequent experiments. Colonic tissue was 
preserved as follows, for RNA isolation, 0.5 cm of colon was stored in RNAlater at -
80°C, for lectin blotting 0.5 cm was snap-frozen in liquid nitrogen and stored at -
80°C, for ex vivo analysis 1 cm pieces of colon were washed in PBS and PBS with 
10 000 U/ml penicillin and 10 000 µg/ml streptomycin and incubated as per Section 
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2. 2. 12. 6. Finally, for tissue embedding, 1.5 cm of colon was rolled using Swiss 
Roll technique (Moolenbeek & Ruitenberg 1981) and inserted into plastic cassettes 
and stored in formaline.  
2. 2. 12. 4 Barbering 
In early stage of handling mice, we have noticed that female C57BL/6J mice were 
prone to barbering. Barbering is a behaviour-associated hair loss and includes 
trimming, nibbling, and plucking of fur and whiskers (Figure 2. 4 B). It may include 
barbering of cage mates (hetero-barbering) or oneself (self-barbering) and it is 
commonly observed in mice (Nicholson et al. 2009). It is particularly common in 
certain strains, such as C57BL/6J, suggesting a strong genetic component (Kalueff et 
al. 2006). The signs of barbering were used as an indicator of appearance and were 
accounted for in daily disease index. 
A 
 
B 
 
Figure 2. 4 Female C57BL/6J were used in this project. Animals were sourced from 
Charles River (UK) and were used between ages of 9 to 15 weeks. Animals were monitored 
daily for the appearance (A). Any case of barbering (B) was monitored carefully and animals 
experiencing hair loss were removed from this study. Sourced from www.criver.com (A) 
and from Kalueff et al. (2006) (B). 
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2. 2. 12. 5 In Vivo Clostridium difficile Infection Model 
C57BL/6J mice were subjected to antibiotic treatment as described in section 2. 2. 
12. 3. On day seven, animals were divided into two groups. First group was 
challenged with oral gavage of 10
3 
of C. difficile spores, RT 001. The control group 
was allowed to restore microbiota and was not challenged with any infectious agent. 
Animals were weighed daily and monitored for overt disease, including diarrhoea. 
Moribund animals with >15% loss in body weight were humanely killed. At day 
three and day seven post-infection, animals were sacrificed and cecum content was 
harvested to assess the CFU counts. Also, colon tissue was rolled using Swiss roll 
technique, preserved in OCT medium and snap-frozen in liquid nitrogen and 
subsequently stored at -80°C for further analysis. The general approach to infection 
model is outlined in Figure 2. 5. 
The in vivo infection model was carried out in collaboration with Pat Casey and 
Professor Colin Hill in the Alimentary Pharmabiotic Centre, University College 
Cork. Isolation of colonic samples was carried out by Dr Maja Kristek, Dr Mark 
Lynch and Dr Joseph deCourcey.  
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Day 0  
Antibiotic Cocktail 
Treatment Group: Antibiotics in water and IP injection of clindamycin 
Control Group: autoclaved water and IP injection of PBS 
Day 3  
Switch to water 
Day 5  
IP injection  
Day 7  
Animals were sacrificed 
All groups were pre-treated with antibiotic cocktail and IP 
injection of clindamycin 
Treatment: Oral gavage of C. difficile ribotype 001 
        Control: no infectious agent 
Day 0  
Antibiotic Cocktail 
Day 3  
Switch to water 
Day 5  
IP injection 
Day 7  
Animals were challenged 
with pathogen  
Day 3 Post-infection  
Animals were sacrificed 
Day 7 Post-infection  
Animals were sacrificed 
S
u
sc
ep
ti
b
il
it
y
 M
o
d
el
 
In
fe
ct
io
n
 M
o
d
el
 
Figure 2. 5 Outline of in vivo approach of two animal models investigated during this project. The first study, the susceptibility model, investigated the 
effect of disturbance in commensal microbiota on susceptibility to infection. Second study, the infection model, involved infecting susceptible animals with C. 
difficile RT 001. This model focused on host’s mucosal response to infection and mechanisms involved in clearing the pathogen and the recovery of the 
epithelial structure. 
CHAPTER 2                                                                                          MATERIALS AND METHODS 
 
68 
 
2. 2. 12. 6 Ex vivo Colon Culture 
Mice were sacrificed by cervical dislocation and the abdominal cavity was opened 
aseptically. The GI tract was removed and the cecum and colon were identified. The 
colon was cut out and faeces were removed. The colon was then opened 
longitudinally and the distal colon was cut into 1 cm pieces (colon explants). These 
colon explants were washed in sterile PBS for 1 min, followed by a wash in PBS 
with 10 000 U/ml penicillin and 10 000 µg/ml streptomycin. Explants were then 
transferred into individual wells in a 24-well plate and cultured in 1 ml of RPMI 
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. Explants were 
stimulated with 100 ng/ml of LPS, 20 µg/ml of SLP 001 or 20 µg/ml of SLP 027, 
respectively, and left for 6 h incubation at 37°C/ 5% CO2.  
After incubation, explants were stored stored in 300 µl of RNAlater at -80°C 
overnight and processed as per section 2. 2. 15. 
2. 2. 13 Mammalian Cell Culture 
All cell culturing techniques were carried out using aseptic technique in a class II 
laminar airflow unit (Holten 2010 - ThermoElectron Corporation, USA). Cell 
cultures were maintained in a 37°C incubator with 5% CO2 and 95% humidified air 
(Model 381 – ThermoElectron Corporation, USA). Cell cultures were and visualised 
with an inverted microscope (Olympus CKX31, Olympus Corporation, Toyko, 
Japan). 
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2. 2. 14 Basic Principles of Reverse Transcription quantitative Polymerase 
Chain Reaction (RT qPCR) 
Reverse Transcription quantitative Polymerase Chain Reaction (RT qPCR) is a 
molecular method based on the principles of PCR where a region of DNA is 
amplified using primers to surround a specific targeted portion of DNA and amplify 
it exponentially using a heat stable DNA polymerase. In RT qPCR the amount of 
DNA amplified is real time and allows for absolute (total copies) or relative 
quantification (normalisation to a gene of choice) of target DNA.  
RT qPCR has become the most precise and accurate method for analysing gene 
expression. RT qPCR has the advantage of measuring the starting copy number and 
detecting small differences in expression levels between samples because 
amplification and quantification occur simultaneously.  
The intercalating dyes are nonsequence-specific fluorescent dyes that exhibit a large 
increase in fluorescence emission when they intercalate into double-stranded DNA. 
Intercalating dye of choice for these experiments was SYBR® Green. During the RT 
qPCR, the primers amplify the target sequence and multiple molecules of the dye are 
inserted between the bases of the double-stranded product, causing fluorescence. The 
background fluorescence from SYBR® Green when in solution as a free dye and 
stimulated by light of appropriate wavelength is very low. In contrast, when double-
stranded DNA product is formed and SYBR® Green becomes incorporated into the 
minor grove of DNA helix, there is a proportional increase in fluorescence roughly 
2000x the initial fluorescent signal. 
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The main advantage of using intercalating dye is that they are not specific to a 
particular sequence, therefore are inexpensive and versatile to a range of molecular 
targets.  
 
 
 
Figure 2. 6 The Principle of 
Fluorescence Produced by 
Intercalating Dye. During the annealing 
step, the primers hybridise in sequence-
dependent manner to the complementary 
DNA strand. During the extension step, 
the intercalating dye (grey circles) 
incorporates to newly formed double-
stranded product. Fluorescence increases 
proportionally to the length of the 
amplicon. The process is repeated in each 
cycle with increasing total fluorescence. 
 
2. 2. 15 RNA Isolation 
All work involving nucleic acids was carried out in an RNase-free environment. This 
was ensured by the use of dedicated bench space, dedicated pipettes and sterile 
RNase-free consumables (pipette tips with filters, 1.5 ml and 0.2 ml microcentrifuge 
tubes). All surfaces and pipettes were wiped with RNase Zap solution.  
RNA was isolated from frozen tissue samples using NuceloSpin® RNA II Total 
Isolation Kit. Frozen tissue samples weighing 30 mg were homogenised in 350 µl of 
lysis buffer using a rotor-stator homogeniser. Next, 3.5 µl of β-mercaptanol was 
added and mixed thoroughly. The viscosity of the lysate was reduced by filtration 
through NuceloSpin® filters (violet ring) and centrifuged for 1 min at 11 000 g. The 
filter was then discarded and the RNA binding conditions were adjusted by adding 
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molecular grade ethanol to the filtrate. The preparation was applied onto a 
Nucelospin® column (blue ring), and centrifuged for 30 sec at 11 000 g. The 
membrane on the column was then desalted by washing with Membrane Desalting 
Buffer and centrifuged at 11 000 g for 1 min. Next, rDNase was added onto the 
membrane to digest any remaining DNA and incubated for 15 min at room 
temperature. The rDNase was then deactivated by adding 200 µl of RA2 buffer and 
any remaining impurities from the isolation were washed twice with RA3 buffer. 
Bound RNA was eluted by adding 60 µl DEPC-treated dH2O, preheated at 65°C, 
onto the membrane and centrifuged at 11 000 g for 1 min. The RNA was collected in 
sterile 1.5 ml RNase-free microcentrifuge tubes and kept at -80°C. 
2. 2. 16 RNA Quality Control 
It is important for any downstream experiments to ensure consistent quantity and 
quality of RNA between the samples. Poor approach to quality control can 
compromise the entire experiment and may have a large impact on the results. 
Furthermore, differences in quality between two samples can lead to 
misinterpretation of gene expression differences. The quality and quantity of isolated 
RNA was examined by UV spectrophotometry (Section 2. 2. 17. 1) and gel 
electrophoresis (Section 2. 2. 17. 2). 
2. 2. 17. 1 RNA Quantification by UV Spectrophotometry 
The RNA was quantified using the NanoDrop ND-1000 spectrophotometer. Also, 
the quality of the isolated nucleic acid was assessed by A260/A280 ratio and A260/A230 
ratio. The A260/A280 ratio is used to assess the purity of RNA, generally a ratio of ~2.0 
is accepted. If the ratio is appreciably lower in either case, it may indicate the 
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presence of protein or other contaminants that absorb strongly at 280 nm. The 
A260/A230 ratio is used as a secondary measure of nucleic acid purity and the ratio is 
usually in the range of 2.0-2.2. If the ratio is lower than the recommended range it 
may indicate the presence of contaminants which absorb at 230 nm, such as EDTA 
or carbohydrates. Interestingly, phenol (used in traditional RNA isolation protocols) 
can absorb at 270 nm and 230 nm and might affect the reading of both ratios. 
Briefly, 1.2 µl of RNase-free water was used to blank the instrument and 1.2 µl of 
sample was loaded to read the absorbance spectra from 230 nm to 600 nm. 
2. 2. 17. 2 RNA Integrity Analysis by Gel Electrophoresis 
To assess the integrity of the RNA, 1 µg of total RNA from each sample was used 
for visualisation. Briefly, 1% agarose gel was prepared in 100 ml of 1X TAE buffer. 
To visualise the RNA, 10 µl of SYBR Safe was added to cooled agarose solution and 
poured into gel rig and left to set in the dark. Samples were reduced by addition of 
buffer containing formamide and heated to 65°C for 10 min. Samples along with 100 
bp ladder were resolved on a gel at 150 V for ~30 min. The gel was then visualised 
using the G-Box Gel Imagine System. Intact total RNA has two clear bands, 
corresponding to 28S and 18S subunits. The ratio of intensity of 28S to 18S should 
be 2:1. 
2. 2. 17 Reverse Transcription of RNA to Complementary DNA (cDNA) 
Transcription is the synthesis of RNA from a DNA template, while reverse 
transcription is referred to as the process of synthesis of DNA from a RNA template. 
The conversion from RNA to DNA is essential as PCR uses only DNA-dependent 
polymerases. The complementary DNA (cDNA) to isolated RNA was synthesised 
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using High Capacity cDNA Reverse Transcription kit. During the reverse 
transcription, single-stranded mRNA is reversely transcribed into cDNA. The 
reaction mixture is composed of a normalised amount of total RNA, a MultiScribe™ 
Reverse Transcriptase enzyme, random primers, dNTPs and enzyme buffer (Table 
2.19).  
Table 2. 19 RNA and DNA integrity by gel electrophoresis 
Components Volume 
10x Reverse Transcriptase Buffer  2 µl 
10x Random Primers  2 µl 
25X dNTP (100 mM)  0.8 µl 
MultiScribe™ Reverse Transcriptase  1 µl 
Total RNA mixed with Nuclease Free H20  14.2 µl 
Total  20 µl 
 
The reaction was gently mixed, spun and placed in a Thermocycler and run 
according to settings recommended by the manufacturer, outlined in Table 2. 20. The 
reaction generates a cDNA suitable for use in quantitative PCR. 
 
Table 2. 20 Thermocycler settings for generation of cDNA 
Step Temperature Duration 
1 25°C 10 min 
2 37°C 120 min 
3 85°C 5 min 
4 4°C ∞ 
 
2. 2. 18 Primer Efficiency 
The efficiency of the qPCR reaction is an important factor in data analysis. 
Efficiency of qPCR can be influenced by many factors including target length, target 
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sequence, primer sequence, buffer conditions, impurities in the sample cycling 
conditions and enzyme used. The efficiency of a successful assay will be between 
90% and 110%. Amplification efficiency can be calculated by analysing the slope of 
the log-linear portion of the standard curve. When the template concentrations are 
plotted onto the X axis and Cq values are on the Y axis, the PCR efficiency equals 
10
(-1/slope)
 – 1. Theoretical maximum efficiency of 1.00 (100%) indicates doubling of 
a product with each cycle. However, the efficiencies derived from the plots are not 
exact values but estimates, therefore, it explains the efficiencies < or > 100%. 
Relative standard curves were set up to determine the efficiency of the primers in the 
assay performance and were used as quality control for the qPCR reaction. Relative 
standard curves were generated using s serial dilution of a neat sample down to 10
-4
. 
The log of dilutions was plotted against Cq values. The PCR efficiency is close to 
100% when the slope of the amplification curve is close to -3.32. The R
2
 value of the 
line was also taken into account and values of >0.95 were deemed acceptable. 
Efficiency of the qPCR reaction was carried out for every primer pair used in this 
study (as summarised in Table A2, Appendix C) and only primers that demonstrated 
efficiency between 90-110% were used.  
2. 2. 19 Normalisation 
In order to ensure the consistency during the qPCR, several normalising steps were 
introduced. This included normalising sample size by weighing it before tissue 
processing. All tissue samples used in this project (ie. in vivo and ex vivo) were cut to 
weigh approximately 30 mg, as this was the capacity of the RNA isolation kit. Also, 
only one type of isolation kit was applied to all samples. Furthermore, upon 
isolation, each sample was quantified using the NanoDrop and the amount of total 
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RNA was normalised to the sample with the lowest concentration (usually 1 µg/ml) 
to ensure that the same amount is used for each reverse transcription reaction. 
Finally, in order to carry out analysis, a PCR-dependent reference was applied in 
form of reference genes. This strategy targets the RNAs that are universally and 
constitutively expressed, and whose expression does not differ between the 
experimental and control groups. It is recommended to screen for multiple reference 
genes, as the most appropriate normalising genes to use will depend on the tissue 
source. The best practise it to include at least two or three normalisation genes to 
determine which expression levels fluctuate the least. The reference genes screened 
for the purpose of this project are outlined in Table 2. 21. 
Table 2. 21 Reference Genes Screened for Normalisation of RT qPCR 
Gene ID Description 
B2M Beta-2-microglobulin 
GUSB Glucuronidase, beta 
PPIA Peptidylpropyl isomerase A 
RPS18 Ribosomal protein S18 
TBP TATA box binding protein 
 
2. 2. 20 Data Analysis 
The approach used to analyse RT qPCR data involved relative quantification. To 
determine levels of expression, the differences (Δ) between threshold cycle (Cq) 
were measured. Relative quantification determines the changes in steady-state 
mRNA levels of a gene across multiple samples and expresses it relative to the levels 
of another mRNA. Relative quantification does not require a calibration curve or 
standards with known concentration. 
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2. 2. 21 DNA Product Analysis by Gel Electrophoresis 
To assess the specificity of the primers towards the DNA targets, the RT qPCR 
reactions were visualised on agarose gel. The RT qPCR product (20 µl) was mixed 
with DNA buffer in 6:1 ratio and resolved on 1% agarose gel in 1X TAE with SYBR 
Safe. Samples were run at 150 V for ~30 min along with 100 bp ladder. The gel was 
then visualised using the G-Box Gel Imagine System. One sharp band indicated the 
specificity of the primer towards the target. 
2. 2. 22 Processing and Paraffin-Embedding of Colon Tissue  
To embed the tissue, 1.5 cm of colon was rolled using Swiss Roll technique and 
stored in formaline at room temperature until processing (Moolenbeek & Ruitenberg 
1981). Leica TP1020 Tissue Processor was used to treat the samples. Samples were 
initially stored in formaline for at least 24 h, followed by steps outlined in the Table 
2. 22. The cassettes were then promptly removed and moved to the paraffin 
embedding station. Plastic moulds were used to position the tissue and tissue was 
overlaid with molten paraffin. When the paraffin solidified, the tissue blocks were 
stored at room temperature.  
Tissue blocks were cut into 6 µm section using microtome and mounted onto 
Histobond microscope slides (slides are pre-coated with adhesive coating for 
mounting tissue sections).  
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Table 2. 22 Stages of Tissue Processing for Paraffin-embedding. 
Stage Solution Duration 
1 Formaline At least 24 h 
2 70% Ethanol 1 h 
3 96% Ethanol 1 h 
4 100% Ethanol 1 h 
5 100% Ethanol 1 h 
6 Xylene 1 h 
7 Xylene 1 h 
8 Paraffin 1 h 
9 Paraffin ∞ 
 
2. 2. 23 Colonic Tissue Sectioning 
Two types of tissue preservation were used in this study, OCT (low temperature) and 
paraffin-embedding. These techniques required a separate approach in tissue 
sectioning and storage of slides.  
2. 2. 23. 1 OCT 
Samples were stored at -80°C and were sectioned using cryostat. Cryostat was 
calibrated to ~-20°C. A drop of OCT medium was used to secure frozen roll of colon 
tissue on the metal mount. The thickness was initially set to 10 µm to expose the 
tissue surface, after which the sections were cut to 6 µm. Finally, the tissue was cut 
at 6 µm and sections were mounted onto slides. The superfrost slides were wrapped 
individually in tin foil and stored at -20°C. 
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2. 2. 23. 2 Paraffin-embedding 
Unlike OCT-preserved tissue, paraffin-embedded blocks were stored at room 
temperature. Sections were cut using microtome. The thickness was initially set to 10 
µm to expose the tissue surface, after which the sections were cut at 6 µm. Sections 
were then transferred onto the surface of water bath set to 50°C, to soften the wax 
surrounding the tissue, before being mounted onto the histobond slides. The slides 
were then stored at room temperature in a slide box.  
2. 2. 24 Haematoxylin and Eosin Staining 
To visualise the structure of the colon, slides were stained with Haematoxylin and 
Eosin (H&E). To remove paraffin, slides were soaked in Xylene for 15 min at room 
temperature (this step was omitted for OCT-mounted tissue). Slides were then 
washed in PBS for 5 min, followed by staining with Haematoxylin for 8 min. Excess 
of dye was washed off for 5 min with tap water. Sections were then differentiated in 
1% acid/alcohol for 30 sec/3 dips. Tap water was used to wash sections for 1 min 
and before being placed in 0.1% sodium bicarbonate for 1 min. Slides were again 
washed under tap water for 5 min, followed by 10 dips in 95% Ethanol. Eosin was 
used to counter stain slides for 1 min (constant dipping). Sections were then 
dehydrated by dipping in 75% ethanol for 3 min, 95% ethanol for 3 min (two times), 
100% ethanol for 3 min and Histoclear for 3 min (two times). Finally, slides were 
then secured with a coverslip and DPX mounting medium and stored at room 
temperature until required.  
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2. 2. 25 Fluorescent Lectin Staining of Colonic Tissue Sections 
Tissue sections from the in vivo susceptibility and infection models were probed for 
the presence of various glycans with FITC-conjugated lectins (Table 2. 23). First, 
tissue sections were pre-treated as described in Section 2. 2. 24. Paraffin-embedded 
sections were soaked in Histoclear for 15 min to remove any paraffin, followed by 
rehydration steps, (2 min in 100% ethanol, 2 min in 70% ethanol, and 2 min in 
dH2O). OCT-embedded sections were left to thaw for 5 min and soaked in acetone 
for 1 min. From this step, both methods of preserving tissue followed the same 
protocol. Briefly, slides were washed in Tris buffer for 30 s, followed by a wash in 
Tris buffer with 1 mM Mg
2+
/Ca
2+
 for 30 s. FITC-conjugated lectin was diluted to 5 
µg/ml in lectin buffer (Tris buffer with 1 mM Mg
2+
/Ca
2+
 with 1% BSA). Slides were 
covered in lectin solution and kept at room temperature, in the dark for 20 min. 
Following this, slides were washed to remove any excess of lectin. This comprised 
of three washes in Tris buffer with 1 mM Mg
2+
/Ca
2+
 for 30 s (with vigorous 
agitation), followed by a soak in the same buffer for 4 min. Slides were then left to 
air-dry. To preserve the staining, slides were mounted by adding ~10 µl of 
Vectashield mounting media with DAPI (to visualise tissue structure) and covered 
with long cover slide. Slides were kept in the dark at 4°C and examined under 
fluorescent microscope within a week.  
2. 2. 25. 1 Incubation with Monosaccharides to Confirm the Lectin Specificity 
To confirm lectin binding specificity, lectins were pre-incubated with corresponding 
monosaccharide prior to tissue incubation. Slides were prepared as described in 
section 2. 2. 26. However, 0.5 M of monosaccharide was added to the FITC-
conjugated lectin in lectin buffer and incubated at room temperature for 30 min. Pre-
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incubated lectins were then added onto tissue sections as previously described in 
Section 2. 2. 25.  
2. 2. 26 Fluorescence Microscope Examination and Analysis 
Samples were visualised using the Olympus BX51 Fluorescent Microscope 
controlled by Cell^2 software. Images were analysed using the Image J software. 
Firstly, samples were blindly scored for the presence of the fluorescence signal. The 
part of the epithelium structure where the signal was obtained was noted (intestinal 
lumen, columnar surface epithelium, lamina propria, goblet cells, stem cells, crypt of 
Lieberkühn, muscularis mucosae or submucosa; Figure 2. 8). The intensity of such 
signal was also noted (+++ denoting extremely strong staining; ++ denoting strong 
staining; + some staining present; lack of signal was left blank). This analysis 
presented the distribution of glycosylation within the epithelial structure. 
Furthermore, the total intensity of the slide was scored. Briefly, the image was split 
into separate channels (DAPI and FITC) and FITC channel was used further. Total 
intensity of the image was measured and normalised to background fluorescence. For 
each condition, at least five images were taken. 
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Table 2. 23 FITC-conjugated lectins used to examine glycans on the surface of the colonic 
epithelium. Table comprises the primary specificity of lectin and monosaccharide sugars used 
to inhibit the interaction between lectin and tissue, as recommended by manufacturer. All 
information sourced from www. vectorlabs.com. 
Lectin 
Abbrev
iation 
Source Specificity 
Inhibiting 
sugar 
Concanavalin A ConA 
Canavalia 
ensiformis 
(Jack Bean) seeds 
Core Mannose 
Methyl α-D-
mannopyranosid
e 
Aleuria aurantia AAL 
Aleuria aurantia 
mushrooms 
Fucose-(α-1,6)-N-
Acetylglucosamine 
L-Fucose 
Ulex europaeus I UEA I 
Ulex europaeus 
(Furze Gorse) 
seeds 
α-Fucose L-Fucose 
Dolichos biflorus DBA 
Dolicos biflorus 
 (Horse Gram) 
seeds 
α-N-
Acetylgalactosamine 
N-Acetyl-D-
galactosamine 
Peanut PNA 
Arachis hypogaea 
peanuts 
Galactosyl-(β-1,3)-
N-
Acetylgalactosamine 
N-Acetyl-D-
galactosamine 
Succinylated 
Wheat Germ 
sWGA 
Triticum vulgaris 
(wheat germ) 
α/β-N-
Acetylglucosamine 
N-Acetyl-D-
glucosamine 
Griffonia 
simplicifolia II 
GSL II 
Griffonia 
simplicifolia 
 seeds 
α/β-N-
Acetylglucosamine 
N-Acetyl-D-
glucosamine 
Sambucus nigra SNA 
Sambucus nigra  
(Elderberry) bark 
Galactosyl- 
(α-2,6)/(α-2,3)-Sialic 
Acid 
N-
Acetylneuraminic 
acid 
Wheat Germ WGA 
Triticum vulgaris 
(wheat germ) 
Sialic Acid 
N-
Acetylneuraminic 
acid 
Maackia 
amurensis I 
MAL I 
Maackia amurensis 
seeds 
Galactosyl-(α-2,3)-
Sialic Acid  
N-
Acetylneuraminic 
acid 
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CHAPTER 3 CLOSTRIDIUM DIFFICILE GROWTH 
AND SURFACE LAYER PROTEINS ISOLATION 
3. 1 INTRODUCTION 
Surface Layer Proteins (SLPs) are the main components of the S-layer of C. difficile. 
There is high sequence variability of SLPs between different ribotypes (Mccoubrey 
& Poxton 2001; Calabi et al. 2001; Karjalainen et al. 2002). The differences in these 
surface antigens may contribute to immune evasion, resulting in some ribotypes 
causing more severe infection, while others are cleared efficiently by the immune 
system.  
The colonisation of C. difficile is the primary step in the pathogenesis process. This 
includes adhesion to the host mucosal surface in the colon. However, the pathogen 
surface is also the first set of antigens that the host immune system encounters 
(Calabi & Fairweather 2002). The recognition of these antigens is crucial for eliciting 
an immune response and subsequent clearance of the bacterium. Strong serum IgG 
response to SLPs from C. difficile in patients’ samples have indicated that SLPs are 
indeed recognised by the immune system (Eidhin et al. 2006) and therefore may be 
important in activating the immune response.  
The surface of the C. difficile is covered by S-layer, regularly ordered planar array of 
proteins, located on the outside of the cell wall (Sleytr & Beveridge 1999). Proteins 
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of the S-layer are the most abundant of cellular proteins, suggesting their importance 
for the bacterium (Sára & Sleytr 2000). Unlike other S-layer proteins, SLPs of C. 
difficile are composed of two subunits, namely Low Molecular Weight (LMW) and 
High Molecular Weight (HMW) subunits (Calabi et al. 2001). These two 
biologically distinct entities are product of one gene product, slpA. The precursor 
protein is then cleaved into two mature subunits by Cwp84 (Bradshaw et al. 2014).  
The LMW subunit appears to be the main immunogenic antigen with considerable 
sequence variability (Eidhin et al. 2006). The LWM subunit is positioned facing the 
outside environment and this likely affects its structure, as it is recognised by 
antibodies (Fagan et al. 2009). The sequence variability found in the LMW subunits 
of various ribotypes, was initially thought to reflect the pressure to evade the immune 
response. However, our group recently determined that the most virulent ribotypes 
with the most sequence variability in LMW subunit, are still recognised by the 
immune system and indeed elicit a more potent immune response (Lynch 2014, 
unpublished). This induces the inflammatory environment in the gut with neutrophil 
infiltration. This, altogether with toxin secretion, propagates colonic epithelium 
damage.   
The HMW subunit is the anchor of the SLPs within the cell wall. The HMW subunit 
is relatively conserved and it is suspected to mediate the adhesion of the bacterium to 
host GI tissues (Calabi et al. 2002). While the S-layer plays an important role in 
protection of bacterium from outside factors, the SLPs from C. difficile have 
specifically been shown to be involved in adherence (Fagan & Fairweather 2014; 
Merrigan et al. 2013). 
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Additionally, the SLPs from C. difficile have been shown to elicit an immune 
response from immune cells such as macrophages (Collins et al. 2014), dendritic 
cells (Ryan et al. 2011) and monocytes (Ausiello et al. 2006). However, these studies 
focused on the effect of a single ribotype of C. difficile on these immune cells only. 
Given the sequence differences between strains of C. difficile, we aimed to assess the 
effects of SLPs isolated from multiple strains of C. difficile and determine these 
effects in colonic mucosal environment rather than the immune cells alone.   
This chapter is comprised of two parts. First, the methods to isolate and purify the 
SLPs from C. difficile ribotypes 001, 002, 010, 014, 027, 046 and 078 needed to be 
developed and optimised as our group had only previously purified SLPs from C. 
difficile ribotype 001. These ribotypes were isolated from patients’ samples by our 
collaborators at St. James’s Hospital, in Sir Patrick Dunne Laboratory (Trinity 
College, Dublin).  
The second part of this chapter investigated the colonic mucosal response ex vivo to 
two SLPs ribotypes. Here we aimed to demonstrate if SLPs from two clinically 
distant ribotypes, RT 001 and RT 027 were able to elicit different immune and 
mucosal response in colonic environment. In order to assess this, we examined 
expression of key inflammatory factors such as cytokines, chemokines and Toll-like 
receptors (TLRs), but also expression of mucosal integrity proteins such as tight 
junction and mucins.   
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3. 2 RESULTS 
3. 2. 1 Clostridium difficile Growth  
3. 2. 1. 1 Growth of C. difficile on the Surface of Blood Agar was Optimised. 
The growth of C. difficile of ribotypes 001, 002, 010, 014, 027, 046 and 078 was 
observed only under strict anaerobic conditions, generated by use of the gas pack kit. 
Two setups of the anaerobic chamber were initially tested (first with the gas pack, 
which required the addition of 10 ml of water and a metal catalyst; second with the 
gas pack only). The second setup was found to be more reliable in generating 
anaerobic conditions. Removal of oxygen was monitored by the use of as anaerobe 
indicator test, which turned from pink to white in the absence of oxygen (under 
reducing conditions).  
Upon streaking bacterial spores on the surface of blood agar, no growth was 
observed after 24 h or 48 h when anaerobic conditions were not maintained, as 
observed in Figure 3. 1 F. In this case, spores of RT 078 were streaked onto the 
surface of blood agar and the plate was placed in an anaerobic jar. However, the jar 
was not sealed properly and anaerobic conditions were not maintained.  
Overall, spores from RT 001, RT 002, RT 010, RT 014, RT 017, RT 027, RT 046 
and RT 078 were used in this study, and all ribotypes recovered well in anaerobic 
conditions (Figure 3. 1 A-E). Growing the bacterial culture on the surface of the 
blood agar plate was the first step of the SLP isolation. Initially three passages of 
bacterial streaking of 48 h were performed before proceeding to liquid culture. 
However, this was shortened to only one passage to avoid introducing any mutation 
that could have occurred during the extended period of incubation. 
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3. 2. 1. 2 Differences in Colony Morphologies were Observed Between C. difficile 
Ribotypes 001, 002, 014, 017, 027 and 078.  
During the optimisation of C. difficile growth, we observed substantial differences in 
the colony morphology between different ribotypes. In order to compare the colony 
morphology between ribotypes, C. difficile RT 001, RT 002, RT 014, RT 017, RT 
027 and RT 078 were streaked onto the surface of blood agar and were incubated for 
48 h under previously described anaerobic conditions. The colony morphology is 
summarised in Table 3. 1 and described using the key in Figure 3. 2.  
Ribotypes RT 001, RT 002, RT 017 and RT 027 appeared to have an irregular shape 
with undulate margins, while ribotype 014 was observed to have colonies of circular 
shape with an entire margin. Furthermore, RT 002, RT 014, RT 017 and RT 027 
were observed to have flat elevation, rough texture and dull appearance, while RT 
001 had slightly raised elevation, smooth texture and a glistening appearance. 
Colonies were either large (RT 002 or RT 017) or moderate (RT 001, RT 014 and RT 
027) in size. All ribotypes had colonies of cream color and had opaque (RT 001 and 
RT 002) or translucent (RT 014, RT 017 and RT 027) optical properties. 
3. 2. 1. 3 Growth of C. difficile in Liquid Broth Culture was Optimised. 
To isolate SLPs, C. difficile was cultivated in liquid broth culture. The same 
anaerobic conditions as described in section 3. 2. 1 were applied (anaerobic jar and 
gas pack). The liquid broth culture required optimisation. Initially, a two-step culture 
was applied, in Fastidious Anaerobic Broth (FAB) to aid recovery of bacterial cells 
from solid medium to broth culture, followed by incubation in Brain Heart Infusion 
(BHI) to grow microbial cells in dense suspension. All ribotypes of C. difficile 
recovered well as suspended colonies after 24 h in FAB.  
CHAPTER 3                                                       C. DIFFICILE GROWTH AND SLPS ISOLATION 
 87   
To aid removal of oxygen from BHI culture, the broth was freshly autoclaved, 
sodium thioglycolate was added, and finally the broth was incubated under anaerobic 
conditions for a minimum of 1 h. The growth in BHI broth depended on the ribotype. 
It was observed that RT 001, RT 002, RT 010, RT 014, RT 027 and RT 078 required 
an incubation time of 18 h to present turbid growth of OD ~0.8 to 1. In the case of 
RT 078, an 18 h incubation time caused the culture to precipitate into sediment. 
Therefore, the incubation time for this ribotype was shortened to 8 h (summarised in 
Table 3.2).  
Furthermore, the total growth procedure (blood agar plate, FAB incubation and BHI 
incubation) was shortened by omitting the FAB culture. It was observed that all 
ribotypes recovered well upon inoculation from blood agar plate directly into BHI 
broth and it did not affect the growth rate, SLPs isolation, or final yield of SLPs of 
any ribotypes used in this study. 
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Figure 3. 1 Growth of RT 001, RT 002, RT 014, RT 017, RT 027 and RT 078 of C. 
difficile on the surface of blood agar plate. Bacterial spores were streaked on the surface 
of the blood agar and incubated in anaerobic conditions at 37°C for 48 h except for F, as this 
culture was maintained under aerobic conditions at 37°C for 48 h. Presented here are 
ribotype 001 (A), ribotype 002 (B), ribotype 014 (C), ribotype 017 (D), ribotype 027 and 
ribotype 078 (F). Differences in colony morphology are summarised in Table 3. 1. 
RT 001 
 
RT 002 
RT 014 
 
RT 017 
 
RT 027 
 
RT 078 
 
10 mm 
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Table 3. 1 Bacterial colony morphology of RT 001, RT 002, RT 014, RT 017, RT 027 
and RT 078. Variations in bacterial morphology had been observed macroscopically. 
The general shape, margin, size, texture, appearance, pigmentation and optical property 
were determined by looking down at the top of the colony. The nature of colony elevation 
was determined when viewed from the side as the plate was held at the eye level.  
Characteristics 001 002 014 017 027 078 
Shape Irregular Irregular Circular Irregular Irregular Irregular 
Margin Undulate Undulate Entire Undulate Undulate Undulate 
Elevation Raised Flat Flat Flat Flat Flat 
Size Moderate Large Moderate Large Moderate Moderate 
Texture Smooth Rough Rough Rough Rough Rough 
Appearance Glistening Dull Dull Dull Dull Dull 
Pigmentation Cream Cream Cream Cream Cream Cream 
Optical 
Property 
Opaque Opaque Opaque Translucent Translucent Translucent 
 
 
 
Figure 3. 2 Colony morphology key used to describe C. difficile ribotypes (adapted 
from Bauman 2012). 
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Table 3. 2 Time required for C. difficile BHI liquid culture incubation. All ribotypes 
required 18 h incubation to achieve OD of ~0.8 – 1, while RT 078 incubation was shortened 
to 8 h only, because of higher growth rate presented by this ribotype. 
C. difficile Ribotype Incubation Time 
001 18 h 
002 18 h 
010 18 h 
014 18 h 
027 18 h 
046 18 h 
078 8 h 
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3. 2. 2 Crude SLPs RT 001, RT 002, RT 010, RT 014, RT 027 and RT 078 Were 
Purified by FPLC and Proteins Were Identified by SDS PAGE. 
SLPs were isolated from the surface of C. difficile RT 001, RT 002, RT 010, RT 014, 
RT 027, RT 046 and RT 078 using an 8 M urea/20 mM Tris/HCl pH 8.5 method. 
Crude samples were dialysed to remove urea and were the subject of FPLC to isolate 
fractions containing SLPs. Proteins bound to the anion exchange chromatography 
column were washed off by an increasing NaCl gradient depending on the size and 
affinity of the column. To ensure maximum resolution of protein fractions in the 
crude sample and to prevent loss of the protein of interest, the slope of the NaCl 
gradient was optimised experimentally for each ribotype used in this study. 
To confirm the protein identity, fractions collected during FPLC were run on SDS 
PAGE (10% w/v) and stained with Coomassie Brilliant Blue. SLPs are composed of 
two subunits, High Molecular Weight (HMW; approximately 55 kDa) and Lower 
Molecular Weight (LMW; approximately 35 kDa) and fractions containing both 
protein subunits were identified by the appearance of those two bands. 
3. 2. 2. 1 Purification of RT 001.  
Purification of crude SLPs RT 001 with FPLC was optimised to maximise the yield. 
Initially fractionation was carried out with two intervals of NaCl gradient, ten 
column volumes from 0% to 50% NaCl gradient, followed by four column volumes 
from 50% to 100% (Figure 3. 3). This resulted in good resolution between peaks as 
confirmed by SDS PAGE analysis (Figure 3. 5 A-B). However, fractions B2-B8 
(corresponding to peak eluting at 37 min), contained only LMW subunit, while 
fractions containing both subunits eluted at 42 min (B10 – C5). To prevent subunit 
dissociation, the S-layer isolation procedure was changed. When whole microbial 
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cells were incubated with 8 M urea/20 mM Tris/HCl pH 8.5 in a shaking incubator, 
we suspected that LMW subunits dissociated on their own (as they are presented on 
the outermost on the surface). Therefore, the shaking incubator was avoided in 
favour of a steady incubator and dissociation of the LMW subunit was no longer 
observed in any isolation of SLPs from any ribotype. The same purification 
procedure (same NaCl gradient) was applied and SLPs eluted at 49 min (Figure 3. 4) 
and SDS PAGE analysis confirmed that those fractions contained both subunits (B8 
– B14, Figure 3. 5 C).  
 
CHAPTER 3                                                       C. DIFFICILE GROWTH AND SLPS ISOLATION 
 93   
 
 
 
Figure 3. 3 Optimising FPLC purification of SLPs RT 001. The gradient of buffer B was 
set between two intervals, five column volumes at 0-50% NaCl and four column volumes at 
50-100% NaCl. It resulted in steep gradient and low resolution between eluted peaks. First 
large peak had retention time of 26 min (not collected). Two peaks were eluted around 40 
min, one at 37 min, corresponded to LMW subunit and second peak at 42 min corresponding 
to SLPs (confirmed by SDS PAGE analysis, Figure 3. 5 A–B), dissociation of subunits was 
caused by different incubation conditions during SLPs isolation. UNICORN™ 3.21v 
Chromatogram legend: Blue line: protein concentration measured by UV light absorption at 
280 nm (mAU); Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 
100%; Red dotted line: NaCl concentration measured by conductivity (mS/cm); Red dashed 
line (A1-C12): collected fractions.  
SLP 
LMW 
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Figure 3. 4 FPLC purification of crude of SLPs RT 001. The gradient of buffer B was set 
between two intervals, twenty column volumes at 0-50% NaCl and four column volumes at 
50-100% NaCl. It resulted in good resolution between the peaks, SLPs fraction eluted at 49 
min. SDS PAGE analysis confirmed identity of SLPs and purity of the fraction collected 
(Figure 3. 5 C). UNICORN™ 3.21v Chromatogram legend: Blue line: protein concentration 
measured by UV light absorption at 280 nm (mAU); Green dashed line: concentration of 
NaCl gradient (Buffer B), from 0% to 100%; Red dotted line: NaCl concentration measured 
by conductivity (mS/cm); Red dashed line (A1-C11): collected fractions. 
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Figure 3. 5 SDS PAGE was used to confirm identity of SLPs RT 001. Isolated SLPs were 
purified using liquid chromatography. To confirm the identity of proteins isolated from the 
culture, fractions were run on 10% SDS polyacrylamide gels and stained with Coomassie 
Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) and Lower 
Molecular Weight (LMW; bottom) subunits of SLPs, any other bands observed are 
considered impurities of surface isolation. Fractions containing two bands were processed 
further. Three figures above represent different purification approaches. A and B: Fractions 
B2-B8 contained only LMW subunit that dissociated separately during S-layer isolation on 
shaking incubator, SLPs fractions are easily identified (B10 – C15) however impurities are 
also observed due to steep NaCl gradient. C: Under optimised conditions of isolation and 
purification, high purity fractions are easily identified (B8 – B14). 
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3. 2. 2. 2 Purification of RT 002. 
Purification of crude SLPs RT 002 with FPLC was experimentally optimised. 
Formerly, it was observed that initially detected proteins were just minor proteins 
and peptides. Therefore, 50% NaCl over ten column volumes was applied from the 
beginning of purification to wash off all the proteins that were not of interest and 
speed up the process. It was followed by steadily increasing the NaCl gradient from 
50% to 100% NaCl over four column volumes (Figure 3. 6). This resulted in 
extremely low resolution between fractions as only two peaks were detected during 
purification. The first peak eluted at 5 min and was very large (70 mAU), indicating 
a high concentration of protein content was lost in waste effluent. However, this 
peak was not collected to confirm the identity of proteins. The second peak eluted at 
37 min, however, the concentration was low as observed by FPLC (10 mAU) and 
confirmed by SDS PAGE, as very faint bands were observed (A8 – A10, Figure 3. 8 
A). 
During the optimised FPLC purification, 50% NaCl was applied over five column 
volumes, then changed to increase gradually to 60% NaCl over two column volumes 
and then to 100% over four column volumes (Figure 3. 7). As a result, good 
resolution between peaks was observed and the purity of SLP fractions was 
confirmed by SDS PAGE (A8 – B1, Figure 3. 8 B). 
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Figure 3. 6 Optimising FPLC purification of SLPs RT 002. The gradient of buffer B was 
set between two intervals, ten column volumes at 50% NaCl and four column volumes at 50-
100% NaCl. It resulted in a large peak eluting at 5 min, while second peak had retention 
time of 37 min and very low protein concentration. Also, very small numbers of fractions 
were set to be collected (A1-B1). This chromatogram corresponds to SDS PAGE analysis 
(Figure 3. 8 A). UNICORN™ 3.21v Chromatogram legend: Blue line: protein concentration 
measured by UV light absorption at 280 nm (mAU); Green dashed line: concentration of 
NaCl gradient (Buffer B), from 0% to 100%; Red dotted line: NaCl concentration measured 
by conductivity (mS/cm); Red dashed line (A1 – B1): collected fractions. 
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Figure 3. 7 FPLC purification of crude of SLPs RT 002. The gradient of buffer B was set 
between three intervals, five column volumes at 50% NaCl, two column volumes at 50-60% 
and four column volumes at 60-100% NaCl. It resulted in large peak eluting at 5 min. With 
this elution profile SLPs has retention time of 27 min. Identity of the protein was confirmed 
by SDS PAGE analysis (Figure 3. 8 B). UNICORN™ 3.21v Chromatogram legend: Blue 
line: protein concentration measured by UV light absorption at 280 nm (mAU); Green 
dashed line: concentration of NaCl gradient (Buffer B), from 0% to 100%; Red dotted line: 
NaCl concentration measured by conductivity (mS/cm); Red dashed line (A1 – C3): 
collected fractions. 
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Figure 3. 8 SDS PAGE was used to confirm identity of SLPs RT 002. Isolated SLPs 
were purified using liquid chromatography. To confirm the identity of proteins isolated 
from the culture, fractions were run on 10% SDS polyacrylamide gels and stained with 
Coomassie Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) 
and Lower Molecular Weight (LMW; bottom) subunits of SLPs, any other bands 
observed are considered impurities of surface extraction. Fractions containing two bands 
were processed further. Two figures above represent different purification approaches. A: 
Low concentration of protein was observed (B5 – B7); B: Under optimised conditions of 
isolation and purification, high purity fractions are easily identified (A8 – B1). 
 
 
 A6   A8 A10 A12  A14  B1  
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3. 2. 2. 3 Purification of RT 010. 
The purification of crude SLPs RT 010 with FPLC was experimentally optimised. 
Formerly, it was determined that initially detected proteins are just minor proteins 
and peptides. Therefore, 50% NaCl over ten column volumes was applied from the 
beginning of the purification to wash off all the proteins that were not of interest. It 
was followed by steadily increasing the gradient from 50% to 100% NaCl over four 
column volumes (Figure 3. 9). This resulted in extremely low resolution between 
fractions as only two peaks were detected during purification. The first peak eluted at 
5 min and was very large (200 mAU), indicating a high concentration of protein 
content was lost in the waste effluent. However, this peak was not collected to 
confirm the identity of proteins. The second peak eluted at 60 min, however the 
concentration was low as observed by FPLC (25 mAU) and confirmed by SDS 
PAGE, with very faint bands being observed (A13 – A15, Figure 3. 11 A). 
Furthermore, the software was set to collect only small number of fractions, which 
resulted in some of the SLPs peak to be eluted in waste effluent (Figure 3. 9, 
fractions eluting >60 min were not collected). 
During optimised FPLC purification, the NaCl gradient was applied in two intervals, 
first from 0% to 50% over twenty column volumes and from 50% to 100% over four 
column volumes (Figure 3. 10). This resulted in high resolution between peaks and 
the purity of SLP fractions was confirmed by SDS PAGE analysis (A13 – B4, Figure 
3. 11 B). 
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Figure 3. 9 Optimising FPLC purification of SLPs RT 010. The gradient of buffer B was 
set between two intervals, twenty column volumes at 50% NaCl and four column volumes at 
50-100% NaCl. It resulted in large peak eluting at 5 min, while second peak had retention 
time of 60 min. Also, a very small number of fractions were set to be collected (A1-A12), 
resulting in some of the effluent being lost in waste. This chromatogram corresponds to SDS 
PAGE analysis (Figure 3. 11 A). UNICORN™ 3.21v Chromatogram legend: Blue line: 
protein concentration measured by UV light absorption at 280 nm (mAU); Green dashed 
line: concentration of NaCl gradient (Buffer B), from 0% to 100%; Red dotted line: NaCl 
concentration measured by conductivity (mS/cm); Red dashed line (A1 – A12): collected 
fractions.  
SLP 
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Figure 3. 10 FPLC purification of crude of SLPs RT 010. The gradient of buffer B was 
set between two intervals, twenty column volumes at 0-50% NaCl and four column volumes 
at 50-100% NaCl. It resulted in a large peak eluting at 30 min, which was not collected. 
With this elution profile SLPs has retention time of 43 min. Identity of the protein was 
confirmed by SDS PAGE analysis (Figure 3. 11 B). UNICORN™ 3.21v Chromatogram 
legend: Blue line: protein concentration measured by UV light absorption at 280 nm (mAU); 
Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 100%; Red dotted 
line: NaCl concentration measured by conductivity (mS/cm); Red dashed line (A1 – D4): 
collected fractions. 
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Figure 3. 11 SDS PAGE was used to confirm identity of SLPs RT 010. Isolated SLPs 
were purified using liquid chromatography. To confirm the identity of proteins isolated from 
the culture, fractions were run on 10% SDS polyacrylamide gels and stained with Coomassie 
Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) and Lower 
Molecular Weight (LMW; bottom) subunits of SLPs, any other bands observed are 
considered impurities of surface extraction. Fractions containing two bands were processed 
further. Two figures above represent different purification approaches. A: Very low 
concentration of SLPs was observed (A13 – A15); B: Under optimised conditions of 
isolation and purification, high purity fractions are easily identified (A13 – B4).  
A1    A3   A5   A7   A9  A11 A13  A15  A9 A11   A13 A15   B2   B4  B6   B8  B10 
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3. 2. 2. 4 Purification of RT 014. 
The purification of crude SLP RT 014 with FPLC was experimentally optimised. 
Initially fractionation was carried out with two intervals of NaCl gradient, ten 
column volumes from 0% to 50% NaCl gradient, followed by four column volumes 
from 50% to 100% (Figure 3. 12). This was sufficient to produce high resolution 
between peaks and SLPs eluted at 57 min. However, due to prolonged storage of the 
crude SLPs, concentration yielded was very low (20 mAU). High purity of fractions 
and low protein concentration was confirmed by SDS PAGE analysis (A5 – A9, 
Figure 3. 14 A).  
During optimised FPLC purification, 50% NaCl was applied but only over five 
column volumes, then changed to increase gradually to 60% NaCl over two column 
volumes and then to 100% over four column volumes (Figure 3. 13). This produced 
sufficient resolution between peaks and resulted in high purity fractions with 27 min 
retention time for SLPs (70 mAU). Purity and high concentration was confirmed by 
SDS PAGE analysis (A9 – A13, Figure 3. 14 B). 
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Figure 3. 12 Optimising FPLC purification of SLPs RT 014. The gradient of buffer B 
was set between two intervals, twenty column volumes at 0-50% NaCl and four column 
volumes at 50-100% NaCl. It resulted in multiple peaks eluting, SLPs had a retention time of 
57 min. Overall protein concentration was very low due to prolonged storage. This 
chromatogram corresponds to SDS PAGE analysis (Figure 3. 14 A). UNICORN™ 3.21v 
Chromatogram legend: Blue line: protein concentration measured by UV light absorption at 
280 nm (mAU); Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 
100%; Red dotted line: NaCl concentration measured by conductivity (mS/cm); Red dashed 
line (A1 – A14): collected fractions.  
SLP 
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Figure 3. 13 FPLC purification of crude of SLPs RT 014. The gradient of buffer B was 
set with three intervals, five column volumes at 50% NaCl, two column volumes at 50-60% 
and four column volumes at 60-100% NaCl. It resulted in large peak eluting at 5 min, not 
collected. With this elution profile SLPs has retention time of 27 min. Identity of the protein 
was confirmed by SDS PAGE analysis (Figure 3. 14 A). UNICORN™ 3.21v Chromatogram 
legend: Blue line: protein concentration measured by UV light absorption at 280 nm (mAU); 
Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 100%; Red dotted 
line: NaCl concentration measured by conductivity (mS/cm); Red dashed line (A1 – C3): 
collected fractions. 
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Figure 3. 14 SDS PAGE was used to confirm identity of SLPs RT 014. Isolated SLPs 
were purified using liquid chromatography. To confirm the identity of proteins isolated from 
the culture, fractions were run on 10% SDS polyacrylamide gels and stained with Coomassie 
Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) and Lower 
Molecular Weight (LMW; bottom) subunits of SLPs, any other bands observed are 
considered impurities of surface extraction. Fractions containing two bands were processed 
further. Four figures above represent different purification approaches. A: Low 
concentration of protein was observed (A10-A14). B: Under optimised conditions of 
isolation and purification, high purity fractions are easily identified (A9 – A13). 
A7   A9  A11  A13  A15  B2  B4   B6   B8 
 A1    A3   A5   A7 A9   A11  A13 
 
CHAPTER 3                                                       C. DIFFICILE GROWTH AND SLPS ISOLATION 
 108   
3. 2. 2. 5 Purification of RT 027. 
The purification of crude SLPs RT 027 with FPLC was experimentally optimised. 
Initially fractionation was carried out with two intervals of NaCl gradient, twenty 
column volumes from 0% to 50% NaCl, followed by four column volumes from 
50% to 100% (Figure 3. 15). High resolution between fractions was achieved, 
however SDS PAGE analysis showed that SLP dissociated from the surface in two 
fractions, first peak eluting at 37 min and corresponding to LMW subunit (A11 – 
A13, Figure 3. 17 A) and second peak eluting at 39 min with whole SLP (A15 – 
B15, Figure 3. 17 A-B). When whole microbial cells were incubated with 8 M 
urea/20 mM Tris/HCl pH 8.5 in a shaking incubator, we suspect that LMW subunits 
dissociated on their own (as they are presented on the outermost on the surface). 
Therefore, the shaking incubator was avoided in favour of a steady incubator and 
dissociation of the LMW subunit was no longer observed in any isolation of SLPs 
from any ribotype. When the isolation procedure was changed, the same purification 
procedure was applied (same NaCl gradient), SLPs eluted at 40 min (Figure 3. 16) 
and SDS PAGE analysis confirmed that those fractions contained both subunits (A9 
– A15, Figure 3. 17 C).  
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Figure 3. 15 Optimising FPLC purification of SLPs RT 027. The gradient of buffer B 
was set between two intervals, ten column volumes at 0-50% NaCl and four column 
volumes at 50-100% NaCl. It resulted in high resolution between the peaks. Large peak with 
retention time of 29 min was not collected. Two peaks were eluted around 40 min, one at 37 
min, corresponded to LMW subunit and second peak at 39 min corresponding to SLPs 
(confirmed by SDS PAGE analysis, Figure 3. 17 A – B), dissociation of subunits was 
possibly caused by different incubation conditions during SLPs isolation. UNICORN™ 
3.21v Chromatogram legend: Blue line: protein concentration measured by UV light 
absorption at 280 nm (mAU); Green dashed line: concentration of NaCl gradient (Buffer B), 
from 0% to 100%; Red dotted line: NaCl concentration measured by conductivity (mS/cm); 
Red dashed line (A1 – A12): collected fractions.  
LMW 
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Figure 3. 16 FPLC purification of crude of SLPs RT 027. The gradient of buffer B was 
set between two intervals, twenty column volumes at 0-50% NaCl and four column volumes 
at 50-100% NaCl. It resulted in large peak eluting at 30 min, not collected. With this elution 
profile SLPs has retention time of 40 min. Identity of the protein was confirmed by SDS 
PAGE analysis (Figure 3.17 C). UNICORN™ 3.21v Chromatogram legend: Blue line: 
protein concentration measured by UV light absorption at 280 nm (mAU); Green dashed 
line: concentration of NaCl gradient (Buffer B), from 0% to 100%; Red dotted line: NaCl 
concentration measured by conductivity (mS/cm); Red dashed line (A1 – D4): collected 
fractions. 
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Figure 3. 17 SDS PAGE was used to confirm identity of SLPs RT 027. Isolated SLPs 
were purified using liquid chromatography. To confirm the identity of proteins isolated from 
the culture, fractions were run on 10% SDS polyacrylamide gels and stained with Coomassie 
Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) and Lower 
Molecular Weight (LMW; bottom) subunits of SLPs, any other bands observed are 
considered impurities of surface extraction. Fractions containing two bands were processed 
further. Three figures above represent different purification approaches. A and B: Fractions 
A11 – A13 contained only LMW that dissociated separately during S-layer isolation on 
shaking incubator, but high purity fractions of SLPs can also be observed (A15 – B1; B3 – 
B15); C: Under optimised conditions of isolation and purification, high purity fractions are 
easily identified (A7 – A15). 
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3. 2. 2. 6 Purification of RT 046. 
The purification of crude SLP RT 046 with FPLC was experimentally optimised. 
Initially fractionation was carried out with two intervals of NaCl gradient, ten 
column volumes from 0% to 50% NaCl, followed by four column volumes from 
50% to 100% (Figure 3. 18). This resulted in a steep gradient of NaCl, which would 
be insufficient to separate fractions of proteins. However, due to prolonged storage, 
protein concentration was extremely low (all detected peaks <10mAU). Fractions 
containing SLPs were identified with SDS PAGE analysis however very faint bands 
confirmed very low protein concentration (A13 – B1, Figure 3. 20 A and B).  
During optimised FPLC purification, 50% NaCl was applied but only over five 
column volumes, then changed to increase gradually to 60% NaCl over two column 
volumes and then to 100% over four column volumes (Figure 3. 19). This resulted in 
good resolution between peaks and retention time for SLP at 28 min. High protein 
concentration was detected (50 mAU) and was confirmed by SDS PAGE analysis 
(A15 – B11, Figure 3. 20 C and D).  
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Figure 3. 18 Optimising FPLC purification of SLPs RT 046. The gradient of buffer B 
was set between two intervals, ten column volumes at 0-50% NaCl and four column 
volumes at 50-100% NaCl. It resulted in very low concentration of proteins, possibly due to 
prolonged storage at -20°C. This chromatogram corresponds to SDS PAGE analysis (Figure 
3. 20 A – B). UNICORN™ 3.21v Chromatogram legend: Blue line: protein concentration 
measured by UV light absorption at 280 nm (mAU); Green dashed line: concentration of 
NaCl gradient (Buffer B), from 0% to 100%; Red dotted line: NaCl concentration measured 
by conductivity (mS/cm); Red dashed line (A1 – D15): collected fractions. 
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Figure 3. 19 FPLC purification of crude of SLPs RT 046. Gradient of buffer B was set 
between three intervals, five column volumes at 50% NaCl, five column volumes at 50-60% 
and four column volumes at 60-100% NaCl. It resulted in large peak eluting at 5 min, not 
collected. With this elution profile SLPs has retention time of 28 min. Identity of the protein 
was confirmed by SDS PAGE analysis (Figure 3. 20 C – D) UNICORN™ 3.21v 
Chromatogram legend: Blue line: protein concentration measured by UV light absorption at 
280 nm (mAU); Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 
100%; Red dotted line: NaCl concentration measured by conductivity (mS/cm); Red dashed 
line (A1 – C4): collected fractions. 
 
SLP 
CHAPTER 3                                                       C. DIFFICILE GROWTH AND SLPS ISOLATION 
 115   
kDa 
250 
150 
100 
 
70 
55 
 
 
 
35 
 
25 
 
 
10 
kDa 
250 
150 
100 
70 
 
55 
 
 
35 
 
 
25 
 
10 
kDa 
250 
150 
100 
 
70 
55 
 
 
 
35 
 
25 
 
10 
kDa 
250 
150 
100 
 
70 
55 
 
 
35 
 
25 
 
10 
 
A 
 
B 
 
C 
 
D 
 
 
Figure 3. 20 SDS PAGE was used to confirm identity of SLPs RT 046. Isolated SLPs 
were purified using liquid chromatography. To confirm the identity of proteins isolated from 
the culture, fractions were run on 10% SDS polyacrylamide gels and stained with Coomassie 
Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) and Lower 
Molecular Weight (LMW; bottom) subunits of SLPs, any other bands observed are 
considered impurities of surface extraction. Fractions containing two bands were processed 
further. Four figures above represent different purification approaches. A and B: Low 
concentration of SLPs was observed (A15-B1; B9); C and D: Under optimised conditions of 
isolation and purification, high purity fractions are easily identified (A15 – B7). 
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3. 2. 2. 7 Purification of RT 078. 
The purification of crude SLP ribotype 078 with FPLC was experimentally 
optimised. A unique FPLC profile was observed when purifying crude preparation of 
RT 078 isolated from precipitated bacterial sediment. Two main peaks were 
observed, first at 30 min, the second peak eluted at 56 min (Figure 3. 21). Because 
this profile was not consistent with any other profile observed before, those samples 
were abandoned and not used for further analysis. Purification of crude preparation 
of RT 078 from optimised broth culture (BHI incubation for 8 h) is presented on 
Figure 3. 22. However, steep gradient from 0 to 100% NaCl over only ten column 
volumes caused low resolution between peaks. SDS PAGE analysis confirmed 
presence of impurities in fractions on interests (B1 – C3, Figure 3. 24 A – B).   
During optimised FPLC purification, the NaCl gradient was applied in two intervals, 
first from 0% to 50% over twenty column volumes and from 50% to 100% over four 
column volumes (Figure 3. 23). This resulted in high resolution between peaks, SLP 
eluted at 49 min. The purity of SLP fractions was confirmed by SDS PAGE analysis 
(B12 – C5, Figure 3. 24 D). 
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Figure 3. 21 Optimising FPLC purification of SLPs RT 078. The gradient of buffer B 
was set between two intervals, ten column volumes at 0-50% NaCl and four column 
volumes at 50-100% NaCl. Broth culture growth resulted in precipitated bacterial sediment, 
due to bacterial aggregation or death of bacterial culture. Characteristic FPLC profile was 
observed, two main peaks eluting, first with retention time of 30 min and second peak with 
retention time of 56 min. These SLPs were not used in this study and were disposed. 
UNICORN™ 3.21v Chromatogram legend: Blue line: protein concentration measured by 
UV light absorption at 280 nm (mAU); Green dashed line: concentration of NaCl gradient 
(Buffer B), from 0% to 100%; Red dotted line: NaCl concentration measured by 
conductivity (mS/cm); Red dashed line (A1 – B8): collected fractions.  
SLP 
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Figure 3. 22 Optimising FPLC purification of SLPs RT 078. The gradient of buffer B 
was set to one interval, ten column volumes at 0-100% NaCl. It resulted in multiple the 
peaks observed, however the resolution between fractions was not satisfactory and multiple 
bands were observed on SDS PAGE analysis (Figure 3. 24 A – B) UNICORN™ 3.21v 
Chromatogram legend: Blue line: protein concentration measured by UV light absorption at 
280 nm (mAU); Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 
100%; Red dotted line: NaCl concentration measured by conductivity (mS/cm); Red dashed 
line (A1 – C8): collected fractions.  
SLP 
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Figure 3. 23 FPLC purification of crude of SLPs RT 078. The gradient of buffer B was 
set between in one interval, ten column volumes at 0-100% NaCl. It resulted in multiple the 
peaks eluting, SLPs fraction eluted at 49 min. SDS PAGE analysis confirmed identity of 
SLPs and purity of the fraction collected (Figure 3. 24 D). UNICORN™ 3.21v 
Chromatogram legend: Blue line: protein concentration measured by UV light absorption at 
280 nm (mAU); Green dashed line: concentration of NaCl gradient (Buffer B), from 0% to 
100%; Red dotted line: NaCl concentration measured by conductivity (mS/cm); Red dashed 
line (A1 – C8): collected fractions. 
 
SLP 
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Figure 3. 24 SDS PAGE was used to confirm identity of SLPs RT 078. Isolated SLPs 
were purified using liquid chromatography. To confirm the identity of proteins isolated from 
the culture, fractions were run on 10% SDS polyacrylamide gels and stained with Coomassie 
Brilliant Blue. Two bands represent Higher Molecular Weight (HMW; top) and Lower 
Molecular Weight (LMW; bottom) subunits of SLPs, any other bands observed are 
considered impurities of surface extraction. Fractions containing two bands were processed 
further. Three figures above represent different purification approaches. A and B: High 
concentration of SLPs however impurities observed due to steep NaCl gradient applied 
during the purification (B1 – C3); C: Under optimised conditions of isolation and 
purification, high purity fractions are easily identified (B14 – C3). 
B12  B14 C1 C3  C5   C7   
A1   A3     A5  A7  A9  A11  A13  A15  B1 B3  B5   B7  B9  B11  B13  B15  C1  C3 
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3. 2. 2. 8 FPLC Purification Profile of SLPs Was Optimised.  
Two methods of SLP purification were optimised experimentally; this included the 
adjustment of the NaCl gradient and volume of buffer B. This is summarised in 
Table 3. 2. The first method allowed for SLP fractions to elute at 27 min, while the 
second method allowed for SLPs to be eluted at 40 min. Both methods proved to be 
sufficient to purify SLPs from a crude sample and provided good resolution between 
eluting peaks. Also, it was noticed that both methods could be applied to all 
ribotypes used in this study. The second method was chosen for any future 
purification of all ribotypes to decrease any inconsistencies in the procedure. 
 
Table 3. 3 Optimised SLPs purification methods. Two methods to purify SLPs with FPLC 
were identified. Both methods were identified as reliable to produce satisfactory yield and 
good resolution between fractions. Method 2 was choses for any future purifications of all 
ribotypes to omit any inconsistencies in the procedure.  
Purification 
Method 
NaCl Gradient (% Buffer B) and Column volumes 
(CV) applied SLP Retention  
(min) Interval I Interval II Interval III 
Method 1 
50% 50 – 60% 60 – 100% 
27 min 5 CV 2 CV 4 CV 
Method 2 
0 – 50% 50 – 100% - 
40 min 20 CV 4 CV - 
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3. 2. 3 SLPs From RT 001 and RT 027 Induced Different Responses from 
Colonic Tissue Ex Vivo. 
To examine the mucosal immune response to SLPs of various ribotypes, colon 
explants were cultured ex vivo and stimulated with purified SLPs RT 001 and RT 
027. Parameters measured included gene expression of inflammation and mucosal 
integrity markers. Colon was sourced from female C57BL/6J mice and cultured in 
the presence of LPS or SLPs from RT 001 and RT 027  
3. 2. 3. 1 SLPs RT 001 and RT 027 Induced Changes in Expression of 
Inflammatory Markers Ex Vivo. 
After 6 h incubation, total RNA was harvested from the tissue. RT qPCR was then 
carried out to examine the expression of genes involved in maintaining the colonic 
immune response, such as cytokines (Figure 3. 25), chemokines (Figure 3. 26), and 
TLRs (Figure 3. 27). It was determined that in cases of all inflammatory cytokines 
(Figure 3.25), RT 001 and RT 027 stimulated the gene expression differently. This 
included increased expression of proinflammatory cytokines Il23, Il2, Il6 (p<0.05), 
and Il17a and anti-inflammatory cytokine Il10 when stimulated with SLPs RT 027. 
The stimulation with RT 001 did not change expression of Il23 and Il6, it also 
decreased expression Il10 and Il17a. Only expression of Il2 was induced by SLPs of 
both ribotypes. Expression of cytokines Tnfa (p<0.05) and Tgfb (p<0.01) was 
decreased significantly by stimulation in case of both RT 001 and RT 027. 
Responses to the LPS stimulation resulted in decrease of cytokines, except for the 
Il2, Tnfa and  Tgfb, which were upregulated. In the case of chemokines (Figure 
3.26), RT 001 and RT 027 also presented different profile of expression. Ccl3 
(MIP1α) was induced 3-fold by stimulation with SLP RT 027 (p<0.05), while 
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stimulation with SLP RT 001, presented 1.5-fold change. The increase induced by 
SLP RT 027 proved to be significant relative to control (p<0.05) and to SLP RT 001 
(p<0.05). In the case of Cxcl2 (MIP2α), there was 3-fold increase in expression when 
stimulated with SLP RT 027, while there was 0.2-fold decrease when stimulated 
with SLP RT 001. The increase induced by SLP RT 027 also proved to be significant 
relative to control (p<0.05) and to SLP RT 001 (p<0.05). Expression of Ccl2 
(MCP1) was decreased by stimulation with both SLPs, however significance was not 
observed. Expression of Ccl5 (RANTES) was also decreased by both SLPs, 0.1-fold 
by SLP RT 001 and 0.75-fold by SLP RT 027. There was significance decrease of 
Ccl5 (RANTES) relative to control (p<0.05), LPS (p<0.05) and RT 001 (p<0.05). 
The stimulation with LPS resulted in decrease of expression of all chemokine genes 
under investigation. Overall, the stimulation with RT 001 resulted in decreased 
expression relative to RT 027 and this difference was significant in expression of 
chemokines genes Ccl3 (MIP1α), Cxcl2 (MIP2α) and Ccl5 (RANTES).  
TLRs also presented different profiles of expression when stimulated with SLPs of 
the two ribotypes. The expression of Tlr2, Tlr4, Tlr5 and Tlr9 was induced when 
stimulated with SLP RT 027 (15-fold, 1.5-fold, 6-fold and 3-fold, respectively). In 
contrast, stimulation with SLP RT 001 resulted in relatively lower induction of Tlr2 
and Tlr9 (1.5-fold in both cases) and decrease of expression of Tlr4 and Tlr5 (0.5-
fold in both cases). This included significant difference in decrease between RT 001 
and RT 027 in expression of Tlr2 (p<0.05). LPS stimulation resulted in increase of 
expression of Tlr2 and Tlr9, 2-fold and 3-fold respectively, and decrease of 
expression fo Trl5 (0.1-fold). There was a minor change in expression of Tlr4 when 
stimulated with LPS.  
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Figure 3. 25 SLPs from RT 001 and RT 027 induced inflammatory cytokines 
expression from colon ex vivo. Mice colon explants were stimulated for 6 h with 100 ng/ml 
of LPS or 20 µg/ml of SLPs RT 001 or RT 027, respectively. Tissue from each sample was 
homogenised and mRNA was extracted using Nucleospin RNA II kit and quantified. 
Normalised amounts of mRNA were converted into cDNA using a High Capacity cDNA 
Mastermix. The cDNA was mixed with primers for Il12a, Il23, Il1b, Il2, Il6, Il10, Il17, Tnfa 
and Tgfb and FAST SYBR Mastermix. Samples were assayed in triplicates and analysed on 
LightCycler®96. Groups were compared using relative quantitation. After normalising 
samples to geometric mean of two endogenous controls, Ppia and B2m, expression of 
control sample was normalised to 1, and expression in treatment group is shown relative to 
this value. Results are means ±SD of 3 biological replicates per group. One-way ANOVA, 
followed by Newman-Keuls Multiple Comparison test was carried out to search for 
statistical significance (*p<0.05, **p<0.01, ***p<0.001) (GraphPad Prism 5.01). 
* 
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Figure 3. 26 SLPs from RT 001 and RT 027 induced chemokines expression from colon 
ex vivo. Mice colon explants were stimulated for 6 h with 100 ng/ml of LPS or 20 µg/ml of 
SLPs RT 001 or RT 027, respectively. Tissue from each sample was homogenised and 
mRNA was extracted using Nucleospin RNA II kit and quantified. Normalised amounts of 
mRNA were converted into cDNA using a High Capacity cDNA Mastermix. The cDNA 
was mixed with primers for Ccl3 (MIP1α), Cxcl2 (MIP2α), Ccl2 (MCP1) and Ccl5 
(RANTES) and FAST SYBR Mastermix. Samples were assayed in triplicates and analysed 
on LightCycler®96. Groups were compared using relative quantitation. After normalising 
samples to geometric mean of two endogenous controls, Ppia and B2m, expression of 
control sample was normalised to 1, and expression in treatment group is shown relative to 
this value. Results are means ±SD of 3 biological replicates per group. One-way ANOVA, 
followed by Newman-Keuls Multiple Comparison test was carried out to search for 
statistical significance (*p<0.05, **p<0.01, ***p<0.001) (GraphPad Prism 5.01).  
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Figure 3. 27 SLPs from RT 001 and RT 027 induced TLRs expression from colon ex 
vivo. Mice colon explants were stimulated for 6 h with 100 ng/ml of LPS or 20 µg/ml of 
SLPs RT 001 or RT 027, respectively. Tissue from each sample was homogenised and 
mRNA was extracted using Nucleospin RNA II kit and quantified. Normalised amounts of 
mRNA were converted into cDNA using a High Capacity cDNA Mastermix. The cDNA 
was mixed with primers for Tlr2, Tlr4, Tlr5 and Tlr9 and FAST SYBR Mastermix. Samples 
were assayed in triplicates and analysed on LightCycler®96. Groups were compared using 
relative quantitation. After normalising samples to geometric mean of two endogenous 
controls, Ppia and B2m, expression of control sample was normalised to 1, and expression in 
treatment group is shown relative to this value. Results are means ±SD of 3 biological 
replicates per group. One-way ANOVA, followed by Newman-Keuls Multiple Comparison 
test was carried out to search for statistical significance (*p<0.05, **p<0.01, ***p<0.001) 
(GraphPad Prism 5.01). 
* 
* 
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3. 2. 3. 2 SLPs RT 001 and RT 027 Induced Changes in Expression of Mucosal 
Integrity Markers Ex Vivo. 
After 6 h incubation, total RNA was harvested from the tissue. RT qPCR was then 
carried out to examine the expression of genes involved in maintaining the colonic 
immune response, such as mucins (Figure 3. 28) and tight junction proteins (Figure 
3. 29). Mucin genes were expressed differently when stimulated with SLP RT 001 
and RT 027 (Figure 3. 28). Expression of Muc1, Muc3 and Muc4 was decreased by 
SLPs of both ribotypes, however in all cases the decrease induced by RT 001 was 
relatively lower than RT 027. Muc1 was decreased 0.5-fold and 0.25-fold, 
respectively (p<0.05), Muc3 was decreased 0.5-fold and 0.1-fold, respectively (non-
significant), and Muc4 was decreased 0.25-fold and 0.1-fold, respectively (non-
significant). SLPs RT 027 increased expression of Muc2, Muc5ac (p<0.05), Muc6, 
Muc13 (p<0.05) and Muc20 (p<0.05) relative to stimulation of these genes by SLPs 
RT 001. Expression of Muc15 was not detected in this tissue under these conditions. 
Stimulation with LPS resulted in increase of expression of Muc2, Muc5ac, Muc6, 
Muc13 and Muc20 (2-fold, 1.5-fold, 1.5-fold and 1.5 respectively). Decrease of 
expression was observed in the case of Muc3 and Muc4 (0.5-fold and 0.25-fold).  
The expression of tight junction proteins of epithelial cells was different following 
stimulation with SLPs RT 001 and RT 027 (Figure 3.29). Stimulation with SLP RT 
027 resulted in downregulation of expression of both e-cadherin Cdh1 and occludin 
Ocln, 0.1-fold and 0.25-fold, respectively. Stimulation with RT 001 downregulated 
the expression of Cdh10.5-fold, while it upregulated the expression of Ocln 2-fold. 
However these changes in the expression were not statistically significant. There was 
no change in expression in Cdh1 and Ocln when stimulated with LPS. 
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Figure 3. 28 SLPs from RT 001 and RT 027 induced mucin expression from colon ex 
vivo. Mice colon explants were stimulated for 6 h with 100 ng/ml of LPS or 20 µg/ml of 
SLPs RT 001 or RT 027, respectively. Tissue from each sample was homogenised and 
mRNA was extracted using Nucleospin RNA II kit and quantified. Normalised amounts of 
mRNA were converted into cDNA using a High Capacity cDNA Mastermix. The cDNA 
was mixed with primers for Muc1, Muc2, Muc3, Muc4, Muc5ac, Muc6, Muc13, Muc15 and 
Muc20 and FAST SYBR Mastermix. Samples were assayed in triplicates and analysed on 
LightCycler®96. Groups were compared using relative quantitation. After normalising 
samples to geometric mean of two endogenous controls, Ppia and B2m, expression of 
control sample was normalised to 1, and expression in treatment group is shown relative to 
this value. Results are means ±SD of 3 biological replicates per group. One-way ANOVA, 
followed by Newman-Keuls Multiple Comparison test was carried out to search for 
statistical significance (*p<0.05, **p<0.01, ***p<0.001) (GraphPad Prism 5.01). 
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Figure 3. 29 SLPs from RT 001 and RT 027 induced tight junction protein expression 
from colon ex vivo. Mice colon explants were stimulated for 6 h with 100 ng/ml of LPS or 
20 µg/ml of SLPs RT 001 or RT 027, respectively. Tissue from each sample was 
homogenised and mRNA was extracted using Nucleospin RNA II kit and quantified. 
Normalised amounts of mRNA were converted into cDNA using a High Capacity cDNA 
Mastermix. The cDNA was mixed with primers for e-cadherin, Cdh1, and occludin, Ocln, 
and FAST SYBR Mastermix. Samples were assayed in triplicates and analysed on 
LightCycler®96. Groups were compared using relative quantitation. After normalising 
samples to geometric mean of two endogenous controls, Ppia and B2m, expression of 
control sample was normalised to 1, and expression in treatment group is shown relative to 
this value. Results are means ±SD of 3 biological replicates per group. One-way ANOVA, 
followed by Newman-Keuls Multiple Comparison test was carried out to search for 
statistical significance (*p<0.05, **p<0.01, ***p<0.001) (GraphPad Prism 5.01). 
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3. 3 DISCUSSION 
The focus of this chapter was to optimise the growth of C. difficile and the 
subsequent isolation and purification of SLPs. Furthermore, the effect of SLPs RT 
001 and RT 027 on the mucosal immune response and mucosal integrity barrier was 
examined ex vivo.  
The Latin name C. difficile was supposed to indicate the difficulty of culturing this 
microbe in the laboratory. Optimisation of growth included the liquid microbial 
culture. Initially a two-step culture was applied. FAB incubation is supposed to aid 
the recovery of bacterial cells from solid into broth culture. This step was followed 
by incubation in BHI broth, which is an ideal medium for growth of anaerobic 
fastidious microorganisms. To shorten the procedure, bacterial colonies were 
inoculated directly into BHI broth, omitting the FAB incubation. The microbial 
culture in BHI is well-established in C. difficile research (Wright et al. 2005; 
Emerson et al. 2008; Carlson et al. 2013; Drudy et al. 2004; Ausiello et al. 2006; 
Dapa et al. 2013). Other liquid media were considered, such as Tryptone Yeast 
growth media (TYG; Engevik et al. 2014; Janoir et al. 2013), Columbia broth 
(Theriot & Young 2014) or Protease Peptone Yeast Extract (PPYE) broth (Cerquetti 
et al. 2000). However, these media are used for various purposes such as isolation 
from human sample and differentiation from other bacteria. For example, the PPYE 
approach used by Cerquetti et al. aimed to recover C. difficile from patients’ 
samples, as a selective type of media (Cerquetti et al. 2000). This was not necessary 
in this study, as the stocks of C. difficile were isolated and purified, and only 
required an enrichment medium.  
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The liquid culture of C. difficile in BHI broth was optimised to achieve 
recommended growth of OD 1.0. All ribotypes required 18 h to achieve turbid 
growth of OD 0.8-1, an incubation time which was comparable with other studies 
(Vohra & Poxton 2012). However, RT 078 presented the culture with sediment after 
this period of incubation, due to aggregation of microbial cells or the cell culture 
reaching the death phase and observed sediment was identified as cell debris. To 
support the growth of RT 078 and to enrich the medium, BHI broth was 
supplemented with vitamin K and hemin, nutritious supplements known to enhance 
the cultivation of anaerobes (MacFaddin 1985; Roe et al. 2002). Also, to adjust to 
the higher growth rate of RT 078, the culture of this ribotype was shortened to 8 h. 
This proved to be satisfactory to support the growth of RT 078.  
Various bacterial species differ in their susceptibility to disrupt their S-layers, 
therefore there are numerous methods described to isolate S-layers (Sleytr & 
Beveridge 1999). Methods applied to isolate the S-layer from C. difficile include a 
low pH glycine method (Calabi et al. 2001), a cation substitution method (LiCl) 
(Koval & Murray 1984) and a hydrogen-bond-breaking method (8 M urea; Cerquetti 
et al. 2000). Cerquetti et al. reported the latter method was sufficient to completely 
remove the hexagonally arranged SLPs from the surface of C. difficile (Cerquetti et 
al. 2000). Furthermore, Wright et al. compared all the methods used to isolate S-
layer from the surface of C. difficile and concluded that SLPs recovered in roughly 
equimolar amounts by both low pH glycine and 8 M urea treatments (Wright et al. 
2005). Therefore, the latter method was used to isolate S-layer from C. difficile in 
this project.  
Initially, isolation of the S-layer with 8 M urea was carried out with constant 
agitation during incubation, a technique used by other groups (Vohra & Poxton 
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2012). However, we observed that this caused the LMW to dissociate separately 
from the surface and appeared as separate bands eluted during FPLC. Therefore, the 
incubation was carried out without agitation, to prevent this from happening and this 
was no longer observed.  
The SLPs make up to 99% of the surface of C. difficile (Calabi & Fairweather 2002), 
however there are other proteins presented on the surface. To remove additional 
surface proteins and debris, crude S-layer extract was purified using FPLC anion 
exchange chromatography. The FPLC purification approach (target NaCl 
concentration and the length of the purification) was determined experimentally, and 
it resulted in the identification of one method to purify SLPs from S-layer extract.  
As mentioned beforehand, the surface of C. difficile is comprised of SLPs, therefore 
they are the predominant surface antigen and are recognised by the immune system. 
In this chapter, the colonic mucosal response ex vivo to two ribotypes, RT 001 and 
RT 027 was investigated. To our knowledge, such analysis has not been previously 
performed. These two ribotypes were chosen, as they present different clinical 
disease outcomes. RT 001 is associated with mild symptoms and prompt recovery, 
while infection with RT 027 is described as hypervirulent and causing a long-lasting 
infection (Archbald-Pannone et al. 2014). Both ribotypes also represent the most 
commonly isolated C. difficile ribotypes in Europe and Northern America (Barbut et 
al. 2007; Cheknis et al. 2009). 
Furthermore, our group previously described that SLPs elicit an immune response 
(Collins et al. 2014; Ryan et al. 2011) and undergo evolutionary selection in a 
ribotype dependant-manner (Lynch 2014, unpublished). The SLPs RT 001 induced 
cytokine secretion from dendritic cells via activation of TLR4 (Ryan et al. 2011). 
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Also, stimulation with the same ribotype of SLPs resulted in activation of 
macrophages, observed as increase in phagocytosis, which is important in clearance 
(Collins et al. 2014). Other studies have demonstrated that human monocytes 
stimulated with SLPs RT 012 secreted elevated levels of proinflammatory IL-6 and 
IL-1β (Ausiello et al. 2006).  
While these studies provided an important insight into how SLPs activate the 
immune system, they were based on interaction between one ribotype of SLPs with 
single type of immune cells. As already mentioned, C. difficile infection outcome 
varies between the ribotypes. Moreover, the sequence of SLPs is different between 
ribotypes. Therefore, there was need for study that incorporated various ribotypes of 
SLPs. Furthermore, the recognition by immune cells is crucial for clearance, 
however, C. difficile initially interacts with more dynamic environment of colonic 
mucosa. Hasegawa et al. demonstrated that chemokines secreted during C. difficile 
infection and essential for the recruitment of the neutrophils, were predominantly 
secreted by colonic epithelial cells (Hasegawa et al. 2011). Therefore, here we 
presented how SLPs from the two most common C. difficile ribotypes interacted 
with colonic tissue ex vivo. This allowed mimicking the actual environment in the 
gut, where C. difficile interacts not only with cells of the immune system but also the 
mucosal barriers.  
We demonstrated that there was higher expression of the proinflammatory cytokines 
IL-23, IL-6 and IL-17 and the anti-inflammatory cytokine IL-10 by SLPs RT 027 
relative to the expression induced by RT 001. Furthermore, we demonstrated that 
key chemokines, MIP1α and MIP2α were induced by SLPs RT027. MIP2α was 
shown to be a potent neutrophil chemoattractant and activator (Sadighi Akha et al. 
2013). While switching on the immune response is essential for clearance, the 
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overproduction of chemokines and sudden influx of phagocyting cells may augment 
the infection site. Pender et al. demonstrated that elevated levels of MIP1α during 
intestinal infections (macrophage inflammatory protein 1α, MIP-1α) are responsible 
for exacerbated colitis in Inflammatory Bowel Disease (IBD) patients (Pender et al. 
2005). We also observed decreased levels of MCP1 and RANTES. The MCP1 
chemokine has previously been shown to be induced early during infection with 
enteric parasite Trichuris muris, however its expression was dependent on elevated 
expression of TNFα (DeSchoolmeester et al. 2006). We also observed decrease in 
TNFα expression, therefore we concluded that at this time point post-stimulation, 
this chemokine is not induced yet. Furthermore, Hasegawa et al. suggested that 
MCP1 is not essential for the initial recruitment of the neutrophils during infection 
with C. difficile (Hasegawa et al. 2011). Interestingly, we also observed the decrease 
of expression of RANTES when stimulated with RT 001 and RT 027. This 
chemokine has been shown to be upregulated when the gut microbiota was 
disturbed, leading to elevated IL-6 cytokine secretion and inflammatory state in the 
gut (Hu et al. 2013). While we observed that RANTES was downregulated 
significantly by RT 001, this decrease was less pronounced by RT 027. Overall, we 
demonstrated that SLP RT 027 can activate a more potent immune response or that it 
has a better adherence to the colonic epithelium, as evidenced by relatively higher 
expression of cytokines and chemokines when stimulated with RT 027 relative to RT 
001. Additionally, we have noticed that ex vivo stimulation with LPS, which 
supposed to be a positive control for SLP stimulation, did not stimulate the 
expression of cytokines, chemokines and TLRs as anticipated. The stimulation of 
cells of immune system such as macrophages and dendritic cells usually results in 
increase of expression and secretion of cytokines and TLRs (Lynch 2014, 
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unpublished). This was not observed in the case of ex vivo stimulation of colonic 
tissue. This could be due to the fact that colonic environment is more complex than 
single immune cells, and furthermore there were no previous reports of stimulating 
ex vivo colon culture with LPS and measuring cytokine, chemokine and TLR 
expression that our results could be compared with.  
Ausiello et al. indicated the host’s immune recognition and excessive recruitment of 
key inflammatory cells actually results in exacerbated reaction and further epithelial 
damage and this could be an unexpected virulence strategy employed by C. difficile 
(Ausiello et al. 2006). This strategy may indeed be utilised by C. difficile RT 027, as 
indicated by a most recent study from our group (Lynch 2014, unpublished). 
Our further analysis indicated that ex vivo stimulation with SLPs RT 001 and RT 
027, resulted in different level of expression of key mucosal integrity proteins, 
mucins and tight junction proteins. The mucins are secretory proteins, which are 
highly glycosylated and hydrophilic (Bansil & Turner 2006). They are important 
components of GI tract homeostasis, as disruption or inappropriate expression could 
predispose to infectious disease (McGuckin et al. 2011).  
The expression of mucins and secretion of mucus from goblet cells is a tightly 
regulated process, largely influenced by the composition of commensals (Kamada et 
al. 2013). It is a great example of how GI microbiota and host cooperate in symbiotic 
relationship in order to fend off invading pathogens. For example, short-chain fatty 
acids (SCFA), the by-products of commensal metabolism, signal through the colonic 
epithelium to increase the mucus secretion (Xu et al. 2013). In our study, we 
observed upregulation of MUC2, MUC5AC, MUC6 and MUC13 and MUC20 when 
stimulated with SLP RT 027. This indicates a potent response from host mucosal 
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barriers and to our knowledge, the effect of SLPs on the expression of mucins has 
not yet been investigated.  
Some previous studies reported the role that C. difficile may play in mucus 
composition, however it involved the infection with whole pathogen. C. difficile 
infection have been shown to induce MUC1 secretion in humans, presumably as a 
protective measure (Linden et al. 2008). Branka et al. demonstrated that toxins 
actually reduce the mucin secretion and this, altogether with increased neutrophil 
recruitment by elevated IL-8, directly contributes to exacerbated epithelial 
inflammation (Branka et al. 1997). Furthermore, C. difficile has been shown to 
utilise the glycans sourced from mucins as energy source, which indicated that this 
pathogen may directly influence the composition of mucus (Ng et al. 2013). This 
correlates with previous studies presenting the evidence that enteric pathogens 
actively influence the secretion of mucins. MUC1 secretion was increased by 
Citrobacter rododentium infection in mice (Linden et al. 2008). This is supposed to 
be a host reaction to increase the thickness of the mucus to trap the pathogens and 
exclude them from interaction with epithelium and immune receptors such as TLRs. 
On the other hand, Vibrio cholera induces the mucin expression in order to increase 
the binding surface for its mucin adhesins, to aid the colonisation (Juge 2012).  
Furthermore, mucins play immunomodulatory functions. Shen et al. demonstrated 
that MUC1 has an anti-inflammatory role in gut homeostasis, while MUC13 resulted 
in proinflammatory reactions and both of these mucins regulated the chemokine 
MIP2α secretion (Sheng et al. 2013). In this chapter we presented that SLPs RT 027 
significantly reduced MUC1 expression and significantly upregulated the expression 
of MUC13. Moreover, the observed that MIP2α is significantly upregulated when 
stimulated with SLP RT 027. Therefore, we propose that SLPs RT 027 may actively 
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modulates the mucosal environment by downregulating the anti-inflammatory 
factors such MUC1 and elevating proinflammatory MUC1 and MIP2α. 
The downregulation of MUC1 has further consequences, as MUC1 has been shown 
to supress the expression of TLRs such as TLR2, TLR3, TLR4, TLR5, TLR7 and 
TLR9 (Ueno et al. 2008). In this study, we observed that expression of TLR2, TLR4, 
TLR5 and TLR9 was upregulated by the stimulation with RT 001 and RT 027. 
However, this upregulation was more pronounced with RT 027, again indicating 
more potent response of the immune system to this ribotype. The increase in these 
receptors on the surface of the colonic epithelium may result in exacerbated immune 
response and cell recruitment. The activation of TLR2 is important for the 
maturation of Tregs and IL-10 cytokine secretion (Round et al. 2011). In recent 
study conducted by our group, we observed that infection with RT 027 resulted in 
upregulation of anti-inflammatory IL-10, in order to dampen the host’s clearance 
mechanisms (Lynch 2014, unpublished). In this study, we observed upregulation of 
both TLR2 and IL-10 expression in response to SLP RT 027 ex vivo. This may 
suggest that early on during the infection the pathogen may switch on the mechanism 
that delays the clearance.  
Finally, we examined the expression of tight junction genes. The formation of tight 
junction proteins between cells of the epithelial layer of the GI tract provide the 
protective barrier from pathogens, while allowing the basic function of nutrient 
absorption via pores (Knoop et al. 2015). It is well-established that C. difficile toxins 
affect the cell actin cytoskeleton and tight junction proteins, in order to induce 
apoptosis, fluid accommodation and destruction of the colonic epithelium (Voth & 
Ballard 2005). Adhesion of C. difficile to Caco-2 cells was significantly increased 
when tight junction proteins were disrupted by chemical treatment, indicating the 
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importance of the integrity of the epithelium in the process of colonisation (Cerquetti 
2002). On the other hand, Shigella toxin was demonstrated to directly decrease the 
expression of tight junction proteins (Sakaguchi et al. 2002). This evidence indicates 
that enteric pathogens directly target not only the integrity of the epithelium by 
destroying it, but also by modulating the key proteins at the expression level. 
However, little is known about the effect of other clostridial virulence factors such as 
SLPs on expression of tight junction proteins during the early stage of colonisation 
and induction of the immune response. We observed that stimulation with SLP RT 
027 downregulated the expression of tight junction proteins ex vivo, occludin and e-
cadherin. Kucharzik et al. suggested that decreased expression of tight junction 
genes may play a role in enhanced permeability of colonic mucosal barriers in IBD 
patients (Kucharzik et al. 2001). We again observed that RT 027 induced the 
downregulation of both tight junction genes, suggesting that this may be an 
additional mechanism employed by the pathogen to invade the host. The increased 
permeability of the mucosal barriers allows for influx of inflammatory cells but also 
allows pathogen to breach the mucosal barriers and enter the blood system (Ng et al. 
2010). Other enteric pathogens also actively modulate the expression of tight 
junction proteins. During infection with H. pylori, tight junction proteins expression 
was found to be decreased, which further contributed to disease pathogenesis by 
increased permeability at the epithelial barrier, however the exact mechanism was 
not revealed in this study (Zhang et al. 2014). In contrast, we observed that SLP RT 
001 induced occludin, but not e-cadherin. Increased expression of tight junction 
genes could be interpreted as a host protective response to defend from the pathogen 
invasion. Pott & Hornef indicated that innate immune stimulation at the mucosal 
surfaces leads to reinforcement of tight junction proteins, along with increased 
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expression of antimicrobial peptides (Pott & Hornef 2012). Therefore, we propose 
that SLP RT 001 induced the host protective response, as observed by the induction 
of occludin.  
Previous studies by Bianco et al. and Vohra and Poxton suggested that ribotype and 
SLP recognition by immune system was not linked to the severity of the infection 
(Bianco et al. 2011; Vohra & Poxton 2012). However, in this chapter we 
demonstrated that SLPs of two ribotypes elicit different immune and mucosal 
response. Furthermore, the observed immune expression pattern presented more 
pronounced response to SLP RT 027. This correlates with clinical symptoms elicited 
by hypervirulent RT 027 (Rao et al. 2014).   
The exact role of SLPs in modulating the mucus composition is yet to be determined, 
as there is a dynamic network of interactions between the immune and mucosal 
components. However, we demonstrated that SLPs RT 027 induce the more potent 
immune and mucosal response. More proinflammatory tone of the response is 
supposed to aid the pathogen invasion in the gut. This immediately suggests that the 
interaction between the host epithelium and SLP RT 027 is more efficient. This 
could be influenced by the prompt recognition of SLPs by immune system or more 
successful adherence of this ribotype.   
Therefore next it is important to examine the factors that may influence the 
interaction of SLPs with colonic epithelium. While SLPs have been shown to be 
essential for the adherence of the pathogen to the colonic epithelium (Merrigan et al. 
2013), the exact mechanism remains unclear. As it is evident that the SLPs from 
various strains differ in sequence and molecular weight, we would like to examine 
next whether the SLPs are glycosylated. The differences in glycosylation patterns 
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between different ribotypes could account for the different responses from the 
colonic tissue ex vivo, presented in this chapter.  
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CHAPTER 4 GLYCOSYLATION OF SURFACE 
LAYER PROTEINS 
4. 1 INTRODUCTION 
 
CDI is associated with several virulence factors (Borriello et al. 1990). As already 
mentioned, toxins contribute to epithelial damage (Rupnik 2005), however they are 
not secreted until the late phase of growth (Hundsberger et al. 1997), furthermore, 
not all toxigenic ribotypes result in disease (Kuehne et al. 2010). Consequently, 
toxins alone cannot fully explain C. difficile pathogenesis.  
This has prompted the search for additional virulence factors that provide C. difficile 
with colonisation advantage. This includes enhanced germination of spores of 
hypervirulent strains (Carlson et al. 2015), and their use of secondary bile acids 
(Buffie et al. 2014; Merrigan et al. 2010). Conversely, the surface of the bacterium is 
covered with various proteins that may facilitate binding to the host epithelium and 
evading the immune response. The exact mechanism of adhesion remains unknown 
despite very active research in the area of C. difficile physiology.  
To date, several surface-associated proteins have been investigated as adherence 
factors, such as flagella (Tasteyre et al. 2001; Twine et al. 2009; Janoir et al. 2013), 
protease Cwp84 (Bradshaw et al. 2014; Chapetón Montes et al. 2013) and Cwp66 
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(Waligora et al. 1999), the fibronectin binding protein Fbp68 (Waligora et al. 2001; 
Barketi-Klai et al. 2011) and the GroEL heat-shock protein (Hennequin et al. 2001; 
Péchiné et al. 2013). 
Our research is focused on SLPs, which have been previously shown to be 
implicated in the adhesion of C. difficile to GI tissues, but exact mechanism remains 
unknown (Calabi et al. 2002; Spigaglia et al. 2013). Furthermore, Merrigan et al. has 
demonstrated that SLPs are essential for C. difficile binding to host (Merrigan et al. 
2013). S-layers are very important features that are evolved in some Eubacteria and 
Archaea. Interestingly, the S-layer is ubiquitous and occurs on both Gram-positive 
and Gram-negative bacteria, indicating the evolutionary need for this surface feature 
(Sleytr & Beveridge 1999). The proteins that constitute the S-layer are often the most 
abundant of the cellular proteins, indicating the importance of the S-layer for the 
function of the bacterium (Fagan & Fairweather 2014). In Bacillus 
stearothermophilus, S-layer proteins constitute up to 15% of the total protein 
secretion (Kuen et al. 1994). The fact that the S-layer is often lost during laboratory 
cultivation, when no growth pressure is applied or nutrient competition, 
demonstrates the importance of S-layer to withstand the harsh environmental 
conditions (Debabov 2004).  
Several functions for the S-layer have been described, including serving as a 
protective coat, molecular sieve or scaffolding for enzymes, but also it may be 
involved in the cell adhesion and surface recognition, and therefore serve as 
virulence factor (Sára & Sleytr 2000). Indeed our group has already demonstrated a 
role for SLPs in pathogen recognition (Ryan et al. 2011). Fagan and Fairweather 
indicated that S-layer of C. difficile is essential for cell growth of this pathogen 
(Fagan & Fairweather 2014). 
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Today we know that glycosylation occurs in all three domains of life, Archeae, 
Bacteria and Eukaryota (Eichler 2013; Nothaft & Szymanski 2010). Remarkably, it 
was the investigation of human pathogens that led to the discovery that prokaryotic 
cells also utilise glycosylation to enrich their protein structures. Specifically, it was 
the surface appendages, such as pili or flagella that have been shown to be 
glycosylated (Schäffer & Messner 2004). It soon led to the discovery that S-layer 
proteins are the main class of prokaryotic glycoproteins (Messner et al. 2008; 
Schäffer et al. 2001; Wang et al. 2012). S-layers may be modified with glycan 
chains reaching up to 150 sugar subunits, as opposed to glycan chains of non-S-layer 
proteins, which were built with up to 20 glycans (Messner et al. 2008; Ristl et al. 
2011). 
It is evident that glycosylation on the cell surface or the S-layer, which represent the 
contact zone of pathogen with host environment, may contribute to bacterial 
colonisation, and possible immune evasion. Human pathogens, such E. coli 
recognise and adhere to the surface of the intestinal epithelium via specific 
glycoproteins (Wang et al. 2012). Other human pathogen, Tannerella forsythia 
actively modify the glycosylation of its cell surface to suit the pathogenic strategy 
(Posch et al. 2011). Furthermore, glycosylation on the surface of C. jejuni protects 
the pathogen from proteases present in the GI tract (Alemka et al. 2013). 
Glycosylation of SLPs is very common among other species of bacteria, including 
Paenibacillus alvei. This bacterial species used glycosylation of SLPs to anchor the 
S-layer within the cell wall (Janesch et al. 2013).  
In the previous chapter we demonstrated that SLPs were able to elicit mucosal 
immune response ex vivo. Furthermore, the ability to affect the magnitude and 
polarisation of the response depended on the ribotype of C. difficile. It has previously 
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been demonstrated that molecular weights of both SLPs subunits greatly differ 
between different ribotypes (Calabi et al. 2001; Karjalainen et al. 2002). Knowing 
this, we next wanted to examine whether there are any post-translational 
modifications to SLPs, such as glycosylation. This may explain the difference in 
molecular weights between the ribotypes, while also possibly the differences in 
adherence to host tissue and recognition by host’s immune system. Differences in 
glycosylation could contribute to immune evasion of certain ribotypes and could 
contribute to the disease outcome. 
SLPs of C. difficile were previously investigated for the presence of glycosylation, 
however the studies only included one strain (Cerquetti et al. 1992), four ribotypes 
(Calabi et al. 2001) or seven ribotypes (Qazi et al. 2009). The results from these 
studies were contradicting. Here we investigate SLPs from ribotypes RT 001, RT 
002, RT 014, RT 027, RT 046 and RT 078 for the presence of glycosylation.  
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4. 2 RESULTS 
 
4. 2. 1. LMW and HMW Subunits of SLPs RT 001, RT 002, RT 027 and RT 078 
Differ in Molecular Weights.   
Crude and purified samples of SLP RT 001, RT 002, RT 027 and RT 078, total 
10µg, were run on 10% (w/v) polyacrylamide gels and stained with Commassie 
Brilliant Blue. Purification efficiency between crude preparation and purified 
samples is observed in the case of all ribotypes. Furthermore, sizes of High 
Molecular Weight (HMW) and Low Molecular Weight (LMW) subunits of SLP 
differ between the ribotypes. The LMW Subunit of ribotype 001 weighs 35 kDa, 
while the HMW subunit had an estimated weight of 54 kDa. In the case of ribotype 
002, the LMW subunit showed an estimated weight of 40 kDa, while the HMW 
subunit weighed 56kDa. The LMW subunit of ribotype 027 weighed 37 kDa, while 
The HMW subunit weighed 55 kDa. In the case of ribotype 078, the LMW subunit 
weighed 36 kDa, while the HMW subunit was the heaviest of all ribotype subunits, 
with estimated weight of 70 kDa (Figure 4. 1).  
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Figure 4. 1 Comparison of SLPs RT 001, RT 002, RT 027 and RT 078 ribotypes of C. 
difficile. 10µg of crude and purified samples of SLP (ribotype 001, 027 and 078) were run 
on 10% (w/v) SDS polyacrylamide gel and stained with Coomassie Brilliant Blue. 
Purification efficiency between crude and pure samples is easily observed. Furthermore, the 
difference in molecular weights between different ribotypes is also recognised. Red arrow 
indicates estimated weight of High Molecular Weight Subunit (~55 kDa); green arrow 
indicates estimated weight of Low Molecular Weight Subunit (~35 kDa). 
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4. 2. 2 SLPs from RT 001, RT 002, RT 027 and RT 078 Demonstrated Absence 
of Glycosylation When Stained with Periodic Acid-Schiff Staining. 
The SLPs from major pathogenic ribotypes of C. difficile differ in molecular 
weights. Post-translational modifications, such as glycosylation, could be 
contributing to differences in molecular weights. Purified samples of SLPs from RT 
001, RT 002, RT 027, and RT 078 were resolved on SDS PAGE and stained with 
periodic acid-Schiff reagent.  
Two bands corresponding to the LMW subunit and the HMW subunit were detected 
in the case of all examined ribotypes, as expected at approximately 35 kDa and 55 
kDa, respectively. None of the SLPs subunits demonstrated the change of colour to 
purple when stained with Schiff reagent, as opposed to positive control, horseradish 
peroxidase (HRP) (Figure 4. 2). This indicated that SLPs subunits of RT 001, RT 
002 RT 027 and RT 078 may not be modified with sugar residues that are in cis-diol 
confirmation.  
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Figure 4. 2 SLPs from RT 001, RT 002, RT 027 and RT 078 demonstrated absence of 
glycosylation with periodic acid-Schiff staining. SLPs from RT 001, RT 002, RT 027 and 
RT 078 (10 µg total of purified protein samples) were separated on 15% (w/v) SDS 
polyacrylamide gels and stained with Commassie Brilliant Blue. Gels were stained with 
Periodic Acid-Schiff Staining kit. Soybean Trypsin Inhibitor (SBT) was used as a negative 
control (remained blue) and Horseradish Peroxidase (HRP) was used as a positive control 
(stained magenta). None of the crude and purified SLP ribotypes indicated presence of 
glycosylation.  
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4. 2. 3 Crude S-layer and Purified SLPs from RT 001, RT 002, RT 027 and RT 
078 Were Blotted and Probed With Lectins for Various Glycosylation Patterns. 
Lectins are specific carbohydrate-binding proteins. We used a range of plant lectins 
to explore glycosylation patterns on the SLPs from ribotypes used in this study. We 
searched for the most common carbohydrate structures found on bacterial proteins, 
mannose (ConA, NPL and LCA), N-Acetylglucosamine (AAL, GSL II and ECL), N-
Acetylgalactosamine (PNA, Jacalin, GSL I and DBA) and sialic acid (SNA). Using 
multiple lectins for each of these carbohydrate structures was essential, as 
carbohydrates form unique and extensive chain structures. We included crude 
samples of S-layer extract (RT 001C, RT 002C, RT 027C and RT 078C) but also as 
the purified proteins (RT 001P, RT 002P, RT 027P and RT 078P). 
 
4. 2. 3. 1 Crude S-layer and Purified SLPs from RT 001, RT 002, RT 027 and 
RT 078 Were Probed for Mannose with ConA, NPL, LCA and GNL Lectins. 
Mannose residues were probed with ConA (Figure 4. 3 A), NPL (Figure 4. 3 B), 
LCA (Figure 4. 3 C) and GNL (Figure 4. 3 D).  
Mannose signal was detected from all crude S-layer samples in the form of core 
mannose when probed with ConA (Figure 4. 3 A), terminal or high mannose probed 
with NPL (Figure 4. 3 B), α-mannose probed with LCA (Figure 4. 3 C) and (α-1,3)-
mannose when probed with GNL (Figure 4. 3 D). However, none of the detected 
bands was identified as SLP subunit. Interestingly, a >250kDa protein detected in 
RT 078C was demonstrated to be a heavily mannose-glycosylated, developing signal 
from all mannose-specific lectins used.  
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In the case of purified samples, a weak signal was detected for ribotype RT 002P and 
RT 078P when probed for core mannose with ConA (Figure 4. 3 A) and ribotype RT 
002P, RT 027P and RT 078P when probed for α-mannose with LCA (Figure 4. 3 C). 
In each case, these bands correspond to both SLP subunits. Purified ribotypes RT 
001, RT 002, RT 027 and RT 078 demonstrated a lack of glycosylation signal when 
probed for terminal or high mannose probed with NPL (Figure 4. 3 B) and (α-1,3)-
mannose when probed with GNL (Figure 4. 3 D). RT 001 was the only ribotype that 
consistently presented no mannose residues when probed by ConA, NPL, LCA and 
GNL. 
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Mannose 
 
 
 
Figure 4. 3 Lectin blotting examination of SLPs isolated from RT 001, RT 002, RT 027 
and RT 078 demonstrated presence of mannose. SLPs from ribotype RT 001, RT 002, RT 
027 and RT 078 were resolved on SDS PAGE (10 µg of crude S-layer isolation and purified) 
and probed for presence of core mannose residues with ConA (A), high or terminal mannose 
with NPL (B), α-mannose with LCA (C) or (α-1-3) mannose with GNL (D) by lectin 
blotting (1 in 2000 dilution of biotinylated lectin in lectin buffer). In all cases, crude sample 
demonstrated glycosylation signal, while purified samples presented very light or no signal. 
Abbreviations: 001C: RT 001 crude; 001P: RT 001 purified; 002C: RT 002 crude; 002P: RT 
002 purified; 027C: RT 027 crude; 027P: RT 027 purified; 078C: RT 078 crude; 078P: RT 
078 purified.  
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4. 2. 3. 2 Crude S-layer and Purified SLPs from RT 001, RT 002, RT 027 and 
RT 078 were Probed for N-Acetylgalactosamine with PNA, Jacalin, GSL I, 
DBA and SBA Lectins. 
N-Acetylgalactosamine residues were examined by PNA, Jacalin, GSL I, DBA and 
SBA lectins (Figure 4. 4).  
Crude SLP extract of all ribotypes demonstrated a glycosylation signal for 
Galactosyl-(β-1,3)-N-Acetylgalactosamine when probed with PNA (Figure 4. 4 A) 
or Jacalin (Figure 4. 4 B), α-N-Acetylgalactosamine or α-Galactose when probed 
with GSL I (Figure 4. 4 C), α-N-Acetylgalactosamine when probed with DBA 
(Figure 4. 4 D) and α-/β-N-Acetylgalactosamine with SBA (Figure 4. 4 E). None of 
the detected bands was identified as SLP subunit. 
Purified proteins of RT 001P, RT 002P, RT 027P and RT 078P demonstrated lack of 
Galactosyl-(β-1,3)-N-Acetylgalactosamine when probed with PNA (Figure 4. 4 A) 
and Jacalin (Figure 4. 4 B). However, all those ribotypes produced faint signals when 
probed for α-N-Acetylgalactosamine or α-galactose with GSL I (Figure 4. 4 C) and 
α-N-Acetylgalactosamine with DBA (Figure 4. 4 D). Faint bands corresponding to 
subunits of RT 001P and RT 002P were detected when probed for α-/β-N-
Acetylgalactosamine with SBA (Figure 4. 4 E). No glycosylation was detected in the 
case of RT 027P and RT 078P. 
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N-Acetylgalactosamine 
 
 
Figure 4. 4 Lectin blotting examination of SLPs isolated from RT 001, RT 002, RT 027 
and RT 078 demonstrated presence of N-Acetylgalactosamine. SLPs from RT 001, RT 
002, RT 027 and RT 078 were resolved on SDS PAGE (10 µg of crude S-layer isolation and 
purified) and probed for presence of Galactosyl-(β-1,3)-N-Acetylgalactosamine with PNA 
(A) and with Jacalin (B), α-N-Acetylgalactosamine or α-galactose with GSL I (C) and α-N-
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Acetylgalactosamine with DBA (D) and terminal α-/β-N-Acetylgalactosamine with SBA by 
lectin blotting (E) (1 in 2000 dilution of biotinylated lectin in lectin buffer). In all cases, 
crude sample demonstrated glycosylation signal, while purified samples presented very light 
or no signal. Abbreviations: 001C: RT 001 crude; 001P: RT 001 purified; 002C: RT 002 
crude; 002P: RT 002 purified; 027C: RT 027 crude; 027P: RT 027 purified; 078C: RT 078 
crude; 078P: RT 078 purified.  
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4. 2. 3. 3. Crude S-layer and Purified SLPs from RT 001, RT 002, RT 027 and 
RT 078 Were Probed for N-Acetylglucosamine with AAL, GSL II and ECL 
Lectins. 
N-Acetylglucosamine residues were examined by probing with AAL (Figure 4. 5 A), 
GSL II (Figure 4. 5 B) and ECL (Figure 4. 5 C). The crude S-layer extract 
demonstrated signal for all ribotypes when probed for Fucose-(α-1,6)-N-
Acetylglucosamine with AAL (Figure 4. 5 A), α- or β-N-Acetylglucosamine when 
probed with GSL II (Figure 4. 5 B) and Galactosyl-(β-1,4)-N-Acetylglucosamine 
when probed with ECL (Figure 4. 5 C). None of the detected bands was identified as 
either SLP subunit. A heavily glycosylated protein, >250 kDa in size, appeared in 
RT 078C samples when probed with all these lectins.  
In the case of purified samples, very faint signals developed when probed for 
Fucose-(α-1,6)-N-Acetylglucosamine with AAL (all ribotypes) (Figure 4. 5 A), α- or 
β-N-Acetylglucosamine when probed with GSL II (RT 001P and RT 002P) (Figure 
4. 5 B) and Galactosyl-(β-1,4)-N-Acetylglucosamine when probed with ECL (RT 
027P and RT 078P) (Figure 4. 5 C). These bands corresponded to both SLP subunits. 
Purified RT 027P and RT 078P demonstrated lack of this type of glycosylation when 
probed with GSL II while RT 001P and RT 002P demonstrated a lack of this type of 
glycosylation when probed with ECL. 
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N-Acetylglucosamine 
 
 
 
Figure 4. 5 Lectin blotting examination of SLPs isolated from RT 001, RT 002, RT 027 
and RT 078 demonstrated presence of N-Acetylglucosamine. SLPs from RT 001, RT 
002, RT 027 and RT 078 were resolved on SDS PAGE (10 µg of crude S-layer isolation and 
purified) and probed for presence of and probed for presence of Fucose-(α-1,6)-N-
Acetylglucosamine with AAL (A), α/β-N-Acetylglucosamine with GSL II (B) or Galactosyl-
(β-1,4)-N-Acetylglucosamine with ECL (C) by lectin blotting (1 in 2000 dilution of 
biotinylated lectin in lectin buffer). In all cases, crude sample demonstrated glycosylation 
signal, while purified samples presented very light or no signal. Abbreviations: 001C: RT 
001 crude; 001P: RT 001 purified; 002C: RT 002 crude; 002P: RT 002 purified; 027C: RT 
027 crude; 027P: RT 027 purified; 078C: RT 078 crude; 078P: RT 078 purified. 
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4. 2. 3. 4 Crude S-layer and Purified SLPs from RT 001, RT 002, RT 027 and 
RT 078 were Probed for Sialic Acid with SNA and MAL II Lectins. 
Sialic acid was probed with SNA (Figure 4. 6 A) and MAL II lectins (Figure 4. 6 B).  
All crude S-layer samples demonstrated heavy glycosylation when probed for 
Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid with SNA (Figure 4. 6 A) and Galactosyl-(α-
2,6)/(α-2,3)-Sialic Acid-(β-1,4)-N-Acetylgalactosamine with MAL II (Figure 4. 6 
B). However, none of the detected bands could be identified as SLP subunit. Again, 
>250 kDa protein was detected in RT 078C sample.  
None of the examined ribotypes demonstrated sialic acid glycosylation in purified 
samples (Figure 4. 6 A and B). 
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Sialic Acid 
 
 
 
 
Figure 4. 6 Lectin blotting examination of SLPs isolated from RT 001, RT 002, RT 027 
and RT 078 demonstrated presence of sialic acid. SLPs from RT 001, RT 002, RT 027 
and RT 078 were resolved on SDS PAGE (10 µg of crude S-layer isolation and purified) and 
probed for presence of Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid with SNA (A) and Galactosyl-
(α-2,6)/(α-2,3)-Sialic Acid-(β-1,4)-N-Acetylgalactosamine with MAL II (B) by lectin 
blotting (1 in 2000 dilution of biotinylated lectin in lectin buffer). In all cases, crude sample 
demonstrated glycosylation signal, while purified samples presented very light or no signal. 
Abbreviations: 001C: RT 001 crude; 001P: RT 001 purified; 002C: RT 002 crude; 002P: RT 
002 purified; 027C: RT 027 crude; 027P: RT 027 purified; 078C: RT 078 crude; 078P: RT 
078 purified.  
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4. 2. 4 Purified SLPs RT 001, RT 002, RT 027 and RT 078 Were Probed for 
Glycosylation Using Enzyme-Linked Lectin Assay (ELLA). 
To confirm the identity of the signal from lectin blotting, purified samples of all 
ribotypes were examined by ELLA.  
4. 2. 4. 1 ELLA Conditions for Probing for Mannose with ConA and NPL 
Lectins. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for 
mannose residues with ConA and NPL lectins (Figure 4. 7 and Figure 4. 8). Initial 
assays (Figure 4. 7 A and Figure 4. 8 A) presented high background reading when 
probed with TBST buffer only, especially from HRP. 
This invalidated the signals detected from actual lectin probing. Optimisation of the 
assay included washing technique, addition of Ca
2+
/Mg
2+
/Mn
2+
 ions for lectin 
stability and use of synthetic blocking solution with no carbohydrate residues. The 
signal for the proteins probed with TBST was below the threshold (shaded bars) 
(Figure 4. 7 B and Figure 4. 8 B). However, the signal from HRP as positive control 
was not detected in any case, and this invalidated the potential signals from lectins. 
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Figure 4. 7 ELLA conditions were optimised for probing SLPs with ConA lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of core 
mannose residues using ELLA with biotinylated ConA. Horseradish Peroxidase protein 
(HRP) was used as positive control, while Soybean trypsin (SBT) and PBS were used as 
negative controls. Samples were probed with TBST as negative control for lectin specificity. 
Threshold signal was considered at 0.2 OD. A: Initial screening showed a very high 
background reading for TBST-probed samples. B: Optimised assay demonstrated TBST-
probed samples below threshold signal, while none of SLP ribotypes demonstrated core 
mannose glycosylation. 
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Figure 4. 8 ELLA conditions were optimised for probing SLPs with NPL lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
terminal or high mannose residues using ELLA with biotinylated NPL. Horseradish 
Peroxidase protein (HRP) was used as positive control, while Soybean trypsin (SBT) and 
PBS were used as negative controls. Samples were probed with TBST as negative control 
for lectin specificity. Threshold signal was considered at 0.2 OD. A: Initial screening 
showed a very high background reading for TBST-probed samples. B: Optimised assay 
demonstrated TBST-probed samples below threshold signal, while none of SLP ribotypes 
demonstrated terminal or high mannose glycosylation. 
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4. 2. 4. 2 ELLA Conditions for Probing for N-Acetylgalactosamine With Jacalin 
and SBA Lectins. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for N-
Acetylgalactosamine residues with Jacalin and SBA lectins (Figure 4. 9 and Figure 
4. 10). Initial assays (Figure 4. 9 A and Figure 4. 10 A) presented high background 
reading when probed with TBST buffer only, especially from HRP. Optimisation of 
the assay included washing technique, addition of Ca
2+
/Mg
2+
/Mn
2+
 ions for lectin 
stability and use of synthetic blocking solution with no carbohydrate residues. The 
signal for the proteins probed with TBST was below the threshold (shaded bars) 
(Figure 4. 9 B and Figure 4. 11 B). However, the signal from HRP as positive 
control was only detected when probed with Jacalin and not with SBA lectin, 
therefore the assay required further optimisation. Negative control for the assay was 
above the threshold (Figure 4.9 A and B). 
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Figure 4. 9 ELLA conditions were optimised for probing SLPs with Jacalin lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
Galactosyl-(β-1,3)-N-Acetylgalactosamine using ELLA with biotinylated Jacalin. 
Horseradish Peroxidase protein (HRP) was used as positive control, while Soybean trypsin 
(SBT) and PBS were used as negative controls. Samples were probed with TBST as negative 
control for lectin specificity. Threshold signal was considered at 0.2 OD. A: Initial screening 
showed a very high background reading for TBST-probed samples. B: Optimised assay 
demonstrated TBST-probed samples below threshold signal, while none of SLP ribotypes 
demonstrated Galactosyl-(β-1,3)-N-Acetylgalactosamine glycosylation. 
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Figure 4. 10 ELLA conditions were optimised for probing SLPs with SBA lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
terminal α/β-N-Acetylgalactosamine using ELLA with biotinylated SBA. Horseradish 
Peroxidase protein (HRP) was used as positive control, while Soybean trypsin (SBT) and 
PBS were used as negative controls. Samples were probed with TBST as negative control 
for lectin specificity. Threshold signal was considered at 0.2 OD. A: Initial screening 
showed a very high background reading for TBST-probed samples. B: Optimised assay 
demonstrated TBST-probed samples below threshold signal, while none of SLP ribotypes 
demonstrated terminal α/β-N-Acetylgalactosamine glycosylation. 
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4. 2. 4. 3 ELLA Conditions for Probing for N-Acetylglucosamine With AAL, 
GSL II and ECL Lectins. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for N-
Acetylglucosamine residues with AAL, GSL II and ECL lectins (Figure 4. 11, Figure 
4. 12 and Figure 4. 13). Initial assays (Figure 4. 11 A, Figure 4. 12 A and Figure 4. 
13 A) presented high background reading when probed with TBST buffer only, 
especially from HRP. Also negative controls presented signal above the threshold 
initially (Figure 4. 11 A). Optimisation of the assay included washing technique, 
addition of Ca
2+
/Mg
2+
/Mn
2+
 ions for lectin stability and use of synthetic blocking 
solution with no carbohydrate residues. The signal for the proteins probed with 
TBST was below the threshold (shaded bars) (Figure 4. 11 B, Figure 4. 12 B and 
Figure 4. 13 B). However, the signal from HRP as positive control was only detected 
when probed with ECL and not with AA or GSL II lectin, therefore the assay 
required further optimisation. 
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Figure 4. 11 ELLA conditions were optimised for probing SLPs with AAL lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
Fucose-(α-1,6)-N-Acetylglucosamine using ELLA with biotinylated ALL. Horseradish 
Peroxidase protein (HRP) was used as positive control, while Soybean trypsin (SBT) and 
PBS were used as negative controls. Samples were probed with TBST as negative control 
for lectin specificity. Threshold signal was considered at 0.2 OD. A: Initial screening 
showed a very high background reading for TBST-probed samples. B: Optimised assay 
demonstrated TBST-probed samples below threshold signal, while none of SLP ribotypes 
demonstrated Fucose-(α-1,6)-N-Acetylglucosamine. 
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Figure 4. 12 ELLA conditions were optimised for probing SLPs with GSL II lectin. 
SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
α/β-N-Acetylglucosamine using ELLA with biotinylated GSL II. Horseradish Peroxidase 
protein (HRP) was used as positive control, while Soybean trypsin (SBT) and PBS were 
used as negative controls. Samples were probed with TBST as negative control for lectin 
specificity. Threshold signal was considered at 0.2 OD. A: Initial screening showed a very 
high background reading for TBST-probed samples. B: Optimised assay demonstrated 
TBST-probed samples below threshold signal, while none of SLP ribotypes demonstrated 
α/β-N-Acetylglucosamine glycosylation. 
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Figure 4. 13 ELLA conditions were optimised for probing SLPs with ECL lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
Galactosyl-(β-1,4)-N-Acetylglucosamine using ELLA with biotinylated ECL. Horseradish 
Peroxidase protein (HRP) was used as positive control, while Soybean trypsin (SBT) and 
PBS were used as negative controls. Samples were probed with TBST as negative control 
for lectin specificity. Threshold signal was considered at 0.2 OD. A: Initial screening 
showed a very high background reading for TBST-probed samples. B: Optimised assay 
demonstrated TBST-probed samples below threshold signal, while none of SLP ribotypes 
demonstrated Galactosyl-(β-1,4)-N-Acetylglucosamine glycosylation. 
CHAPTER 4                                                           GLYCOSYLATION OF SLPS 
169 
4. 2. 4. 4 ELLA Conditions for Probing for Sialic Acid with SNA Lectin. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for sialic 
acid residues with SNA lectin (Figure 4. 14). Initial assay (Figure 4. 14 A) presented 
high background reading when probed with TBST buffer only, especially from HRP. 
Optimisation of the assay included washing technique, addition of Ca
2+
/Mg
2+
/Mn
2+
 
ions for lectin stability and use of synthetic blocking solution with no carbohydrate 
residues. The signal for the proteins probed with TBST was below the threshold 
(shaded bars) (Figure 4. 14 B). However, the signal from HRP as positive control 
was not detected and therefore the assay required further optimisation. 
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Figure 4. 14 ELLA conditions were optimised for probing SLPs with SNA lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid using ELLA with biotinylated SNA. Horseradish 
Peroxidase protein (HRP) was used as positive control, while Soybean trypsin (SBT) and 
PBS were used as negative controls. Samples were probed with TBST as negative control 
for lectin specificity. Threshold signal was considered at 0.2 OD. A: Initial screening 
showed a very high background reading for TBST-probed samples. B: Optimised assay 
demonstrated TBST-probed samples below threshold signal, while none of SLP ribotypes 
demonstrated Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid glycosylation. 
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4. 2. 4. 5 Positive Controls for ELLA. 
Positive controls are an essential part of every assay. HRP did not prove to be a 
universal positive control for all previous ELLA assays when probed with various 
lectins for different glycosylation patterns. Additionally, HRP was included in PAS 
glycoprotein staining kit, however it was not a suitable positive control for ELLA, as 
it may interfere with the ELLA detection system that utilises the active form of HRP. 
Therefore, we examined various glycoproteins as potential positive controls for 
different lectins (Figure 4. 15). Asialofetuin, fetuin, invertase and transferrin were 
investigated as positive controls for the individual lectins used to examine the 
glycosylation patterns of SLP. Only SLPs RT 001 and RT 027 were used, as these 
samples were available in abundance. 
Asialofetuin produced signal above threshold for Galactosyl-(α-2,6)/(α-2,3)-Sialic 
Acid when probed with SNA, additionally, this assay produced signal for PBS 
(Figure 4. 15 A). Asialofetuin did not demonstrate presence of Galactosyl-(α-2,3)/(α-
2,6)-Sialic Acid or Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid-(β-1,4)-N-
Acetylgalactosamine when probed with MAL II (Figure 4. 15 B). Fetuin proved to 
be sufficient positive control for NPL probing for terminal or high mannose (Figure 
4. 15 C), however it did not demonstrate presence of (α-1,3)-mannose when probed 
with GNL (Figure 4. 15 D). Invertase was examined as positive control for 
Galactosyl-(β-1,4)-N-Acetylglucosamine, however it did not demonstrate this type 
of glycosylation when examined with ECL (Figure 4. 15 E). Finally transferrin was 
examined as potential positive control for core mannose residues and probed with 
ConA and it produced sufficient signal to be considered suitable control for this type 
of glycosylation (Figure 4. 15 F).   
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Overall, this part of the optimisation aimed to match a potential control with suitable 
lectin. This proved to be very time-consuming and therefore we decided to examine 
glycosylation of four positive controls along with each assay for any further analysis.  
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Figure 4. 15 Asialofetuin, fetuin, invertase and transferrin were examined as positive 
controls for ELLA. Asialofetuin was examined as positive control for sialic residues and it 
probed with biotinylated SNA (A) and MAL II (B). Fetuin was examined as positive control 
for detection of mannose residues and it was probed by NPL (C) and GNL (D). Invertase 
was examined as positive control for N-Acetylglucosamine and it was probed with ECL (E). 
Transferrin was examined as positive control for core mannose residues and it was probed 
with ConA (F). All positive controls were probed along with two SLPs, RT 001 and RT 027. 
PBS was used as negative control; samples were probed with TBST as negative control for 
lectin specificity. Threshold signal was considered at 0.2 OD.  
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4. 2. 4. 6 TBST is Sufficient Negative Control for ELLA. 
Also, when all the assay preparation techniques were verified such as washing and 
blocking buffer, we examined again the background signal produced by TBST buffer 
probing only. We determined that TBST is suitable negative control for the assay as 
the reading was below threshold (Figure 4. 16). For any analysis, the total ELLA 
reading was corrected for the background signal by deducting the reading of TBST 
buffer probing from the reading of each of other ELLA assays.  
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Figure 4. 16 TBST buffer was used as negative control for probing SLPs and positive 
controls in ELLA. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078, along with 
four positive controls were probed with TBST buffer only. Minimal signal was detected, 
consistent with background reading. Threshold signal was considered at 0.2 OD. 
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4. 2. 4. 7 SLPs Did Not Demonstrate Presence of Mannose When Probed with 
ConA, NPL and LCA. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for 
presence of core mannose with ConA (Figure 4. 17), high or terminal mannose with 
NPL (Figure 4. 18) and α-mannose with LCA (Figure 4. 19).  
Probing for core mannose with ConA presented threshold signal for presence of this 
type of glycosylation in RT 046 and RT 078, however since the signal from PBS 
(negative control) was also close to threshold, it was concluded that SLP RT 046 and 
RT 078 does not present this type of glycosylation.  
None of the other ribotypes under investigation demonstrated signal required to 
confirm presence of glycosylation, and therefore we concluded that SLPs RT 001, 
RT 002, RT 014, RT 027, RT 046 and RT 078 are not modified with mannose. 
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Figure 4. 17 SLPs were probed for core mannose with ConA lectin. SLP RT 001, RT 
002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of core mannose 
using ELLA with biotinylated ConA. Four positive controls with known glycosylation 
patterns were used fetuin, glucose oxidase, thyroglobulin and asialofetuin and these 
interacted with lectins in a manner that was consistent with the glycan structures expected to 
be present on the surface of each glycoprotein. PBS and TBST were used as negative 
controls and the readings were corrected for background reading with TBST. Threshold 
signal was considered at 0.2 OD. None of SLPs ribotypes demonstrated presence of core 
mannose. 
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Figure 4. 17 SLPs were probed for terminal and high mannose with NPL lectin. SLP 
RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
terminal or high mannose using ELLA with biotinylated NPL. Four positive controls with 
known glycosylation patterns were used fetuin, glucose oxidase, thyroglobulin and 
asialofetuin and these interacted with lectins in a manner that was consistent with the glycan 
structures expected to be present on the surface of each glycoprotein. PBS and TBST were 
used as negative controls. Threshold signal was considered at 0.2 OD. None of the ribotypes 
demonstrated presence of terminal or high mannose. 
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Figure 4. 18 SLPs were probed for α-mannose with LCA lectin. SLP RT 001, RT 002, 
RT 014, RT 027, RT 046 and RT 078 were analysed for presence of α-mannose using ELLA 
with biotinylated LCA. Four positive controls with known glycosylation patterns were used 
fetuin, glucose oxidase, thyroglobulin and asialofetuin and these interacted with lectins in a 
manner that was consistent with the glycan structures expected to be present on the surface 
of each glycoprotein. PBS and TBST were used as negative controls. Threshold signal was 
considered at 0.2 OD. None of the ribotypes demonstrated presence of α-mannose. 
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4. 2. 4. 8 SLPs Did Not Demonstrate Presence of N-Acetylgalactosamine When 
Probed with PNA, Jacalin, SBA, GSL I and DBA. 
SLPs RTs 001, 002, 014, 027, 046 and 078 were probed for presence of Galactosyl-
(β-1,3)-N-Acetylgalactosamine with PNA (Figure 4. 20), for Galactosyl-(β-1,3)-N-
Acetylgalactosamine with Jacalin (Figure 4. 21), α-N-Acetylgalactosamine or α-
galactose with GSL I (Figure 4. 22) and α-N-Acetylgalactosamine with DBA (Figure 
4. 23).  
Probing for Galactosyl-(β-1,3)-N-Acetylgalactosamine with Jacalin presented 
threshold signal for presence of this type of glycosylation in RT 046 and RT 078, 
however since the signal from PBS (negative control) was also close to threshold, it 
was concluded that SLP RT 046 and RT 078 does not present this type of 
glycosylation.  
None of the other ribotypes under investigation demonstrated signal required to 
confirm presence of glycosylation, and therefore we concluded that SLPs RT 001, 
RT 002, RT 014, RT 027, RT 046 and RT 078 are not modified with N-
Acetylgalactosamine.
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Figure 4. 20 SLPs were probed for Galactosyl-(β-1,3)-N-Acetylgalactosamine with PNA 
lectin. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for 
presence of Galactosyl-(β-1,3)-N-Acetylgalactosamine using ELLA with biotinylated PNA. 
Four positive controls with known glycosylation patterns were used fetuin, glucose oxidase, 
thyroglobulin and asialofetuin and these interacted with lectins in a manner that was 
consistent with the glycan structures expected to be present on the surface of each 
glycoprotein. PBS and TBST were used as negative controls and the readings were corrected 
for background reading with TBST. Threshold signal was considered at 0.2 OD. None of the 
ribotypes demonstrated presence of Galactosyl-(β-1,3)-N-Acetylgalactosamine. 
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Figure 4. 21 SLPs were probed for Galactosyl-(β-1,3)-N-Acetylgalactosamine with 
Jacalin lectin. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed 
for presence of Galactosyl-(β-1,3)-N-Acetylgalactosamine using ELLA with biotinylated 
Jacalin. Four positive controls with known glycosylation patterns were used fetuin, glucose 
oxidase, thyroglobulin and asialofetuin and these interacted with lectins in a manner that was 
consistent with the glycan structures expected to be present on the surface of each 
glycoprotein. PBS and TBST were used as negative controls. Threshold signal was 
considered at 0.2 OD. None of the ribotypes demonstrated presence of Galactosyl-(β-1,3)-N-
Acetylgalactosamine. 
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Figure 4. 22 SLPs were probed for α-N-Acetylgalactosamine or α-galactose with GSL I 
lectin. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for 
presence of α-N-Acetylgalactosamine and α-Galactose using ELLA with biotinylated GSL I. 
Four positive controls with known glycosylation patterns were used fetuin, glucose oxidase, 
thyroglobulin and asialofetuin and these interacted with lectins in a manner that was 
consistent with the glycan structures expected to be present on the surface of each 
glycoprotein. PBS and TBST were used as negative controls. Threshold signal was 
considered at 0.2 OD. None of the ribotypes demonstrated presence of α-N-
Acetylgalactosamine or α-Galactose. 
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Figure 4. 23 SLPs were probed for α-N-Acetylgalactosamine with DBA lectin. SLP RT 
001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of α-N-
Acetylgalactosamine using ELLA with biotinylated DBA. Four positive controls with 
known glycosylation patterns were used fetuin, glucose oxidase, thyroglobulin and 
asialofetuin and these interacted with lectins in a manner that was consistent with the glycan 
structures expected to be present on the surface of each glycoprotein. PBS and TBST were 
used as negative controls. Threshold signal was considered at 0.2 OD. None of the ribotypes 
demonstrated presence of α-N-Acetylgalactosamine. 
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4. 2. 4. 9 SLPs Did Not Demonstrate Presence of N-Acetylglucosamine When 
Probed With AAL, GSL II and ECL. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for 
presence of Fucose-(α-1,6)-N-Acetylglucosamine with AAL (Figure 4. 24), α- or β-
N-Acetylglucosamine with GSL II (Figure 4. 25) and Galactosyl-(β-1,4)-N-
Acetylglucosamine with ECL (Figure 4. 26).  
Probing for Fucose-(α-1,6)-N-Acetylglucosamine with AAL presented threshold 
signal for presence of this type of glycosylation in RT 046 and RT 078, however 
since the signal from PBS (negative control) was also close to threshold, it was 
concluded that SLP RT 046 and RT 078 does not present this type of glycosylation.  
None of the other ribotypes under investigation demonstrated signal required to 
confirm presence of glycosylation, and therefore we concluded that SLPs RT 001, 
RT 002, RT 014, RT 027, RT 046 and RT 078 are not modified with N-
Acetylglucosamine.
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Figure 4. 24 SLPs were probed for (α-1,6)-Fucose-N-Acetylglucosamine with AAL 
lectin. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for 
presence of Fucose-(α-1,6)-N-Acetylglucosamine using ELLA with biotinylated AAL. Four 
positive controls with known glycosylation patterns were used fetuin, glucose oxidase, 
thyroglobulin and asialofetuin and these interacted with lectins in a manner that was 
consistent with the glycan structures expected to be present on the surface of each 
glycoprotein. PBS and TBST were used as negative controls and the readings were corrected 
for background reading with TBST. Threshold signal was considered at 0.2 OD. None of the 
ribotypes demonstrated presence of Fucose-(α-1,6)-N-Acetylglucosamine. 
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Figure 4. 25 SLPs were probed for α- or β-N-Acetylglucosamine with GSL II lectin. 
SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for presence of 
α- or β-N-Acetylglucosamine using ELLA with biotinylated GSL II. Four positive controls 
with known glycosylation patterns were used fetuin, glucose oxidase, thyroglobulin and 
asialofetuin and these interacted with lectins in a manner that was consistent with the glycan 
structures expected to be present on the surface of each glycoprotein. PBS and TBST were 
used as negative controls. Threshold signal was considered at 0.2 OD. None of the ribotypes 
demonstrated presence of α- or β-N-Acetylglucosamine. 
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Figure 4. 26 SLPs were probed for Galactosyl-(β-1,4)-N-Acetylglucosamine with ECL 
lectin. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for 
presence of Galactosyl-(β-1,4)-N-Acetylglucosamine using ELLA with biotinylated ECL. 
Four positive controls with known glycosylation patterns were used fetuin, glucose oxidase, 
thyroglobulin and asialofetuin and these interacted with lectins in a manner that was 
consistent with the glycan structures expected to be present on the surface of each 
glycoprotein. PBS and TBST were used as negative controls. Threshold signal was 
considered at 0.2 OD. None of the ribotypes demonstrated presence of Galactosyl-(β-1,4)-
N-Acetylglucosamine. 
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4. 2. 4. 10 SLPs Did Not Demonstrate Presence of Sialic Acid When Probed with 
SNA. 
SLPs RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were probed for 
presence of Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid with SNA (Figure 4. 27).  
Probing for Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid with SNA presented threshold 
signal for presence of this type of glycosylation in RT 046 and RT 078, however 
since the signal from PBS (negative control) was also close to threshold, it was 
concluded that SLP RT 046 and RT 078 does not present this type of glycosylation.  
None of the other ribotypes under investigation demonstrated a signal required 
confirming presence of glycosylation, and therefore we concluded that SLPs RT 001, 
RT 002, RT 014, RT 027, RT 046 and RT 078 are not modified with Galactosyl-(α-
2,6)/(α-2,3)-Sialic Acid. 
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Figure 4. 25 SLPs were probed for Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid with SNA 
lectin. SLP RT 001, RT 002, RT 014, RT 027, RT 046 and RT 078 were analysed for 
presence of Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid using ELLA with biotinylated SNA. Four 
positive controls with known glycosylation patterns were used fetuin, glucose oxidase, 
thyroglobulin and asialofetuin and these interacted with lectins in a manner that was 
consistent with the glycan structures expected to be present on the surface of each 
glycoprotein. PBS and TBST were used as negative controls and the readings were corrected 
for background reading with TBST. Threshold signal was considered at 0.2 OD. None of the 
ribotypes demonstrated presence of Galactosyl-(α-2,6)/(α-2,3)-Sialic Acid. 
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4. 3 DISCUSSION 
There has been enormous progress in CDI research in recent years and this has 
contributed to a better understanding of the disease mechanisms, as presented in 
multiple reviews (Sun & Hirota 2015; Solomon 2013; Madan & Petri Jr 2012). 
However, the steps involving adherence of C. difficile and subsequent colonisation 
still remain unclear.  
In this chapter, we aimed to determine whether SLPs from RT 001, RT 002, RT 014, 
RT 027, RT 046 and RT 078 are glycosylated, as we wanted to determine whether 
any glycosylation differences may have implications for adherence and virulence. 
We were able to show that SLPs derived from various ribotypes have different 
molecular weights subunits, which correlates with other studies (Calabi et al. 2001; 
Karjalainen et al. 2002; Eidhin et al. 2006). Also, Mauri et al. proposed that 
predicted molecular weights may differ from molecular weights estimated by SDS 
PAGE, which suggested post-translational modification, such as glycosylation 
(Mauri et al. 1999).  
Previous research indicated that the S-layer of C. difficile isolated with EDTA 
contained up to 9% glycan moieties (Cerquetti et al. 1992). However, this study only 
involved one ribotype of SLP. Therefore, we proceeded with PAS staining for an 
initial screening of four SLPs ribotypes, RT 001, RT 002, RT 027 and RT 078. We 
observed no colour change in SLPs, as opposed to the positive control, HRP. Qazi et 
al. indicated that commercial glycosylation detection kits may be unreliable (Qazi et 
al. 2009). However, the lack of glycosylation signal in our experiment does not 
entirely rule out the possibility of glycosylation, as PAS staining does not engage 
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with carbohydrates with carbons that are not directly involved in glycosidic linkages 
or carbohydrate link closure (Mantle & Allen 1978).  
Qazi et al. also suggested that the previous positive detection of glycans in SLPs was 
in fact due to contamination from cell wall peptidoglycan during the isolation and 
purification procedure (Qazi et al. 2009). Qazi et al. have used low pH glycine, 
while Cerquetti et al. used 8 M urea in Tris/HCl to extract the S-layer(Qazi et al. 
2009; Cerquetti et al. 1992). We have used the same approach in an isolation of the 
S-layer as Cerquetti et al., but these authors do not specify the purification 
procedure. Therefore we suggest that our FPLC protocol with 0.3 M NaCl gradient 
optimised for each ribotype was sufficient to remove any impurities and cell wall 
contaminants from isolation procedure. This was confirmed by two clear bands 
corresponding to HMW and LMW subunits of SLPs on SDS PAGE, as presented in 
Chapter 3.  
The initial experiments did not confirm the presence of glycosylation on SLPs, 
however PAS staining did not eliminate the possibility of the glycan moieties on 
SLPs. Therefore we proceeded to examine SLPs with range of plant lectins, which 
were used for lectin blotting and ELLA. 
Lectins are specific carbohydrate binding proteins, each lectin has from two to 
multiple carbohydrate recognition sites (Berg et al. 2002). The single interaction 
between lectins binding site and carbohydrate is relatively weak but the sum of the 
total interactions is extremely strong (Weis & Drickamer 1996).  
Lectins selected for the screening included plant lectins that are specific for glycans 
presented on the bacterial surface (Leriche et al. 2000). This included group of 
mannose-specific lectins (ConA, NPL, LCA and GNL), N-Acetylgalactosamine-
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specific lectins (PNA, Jacalin, GSL I, SBA and DBA), N-Acetylglucosamine-
specific lectins (AAL, GSL II and ECL) and sialic acid-specific lectin (SNA and 
MAL II). To our knowledge, there was no previous research carried out on SLPs RT 
001, RT 002, RT 014, RT 027, RT 046 and RT 078 with use of these lectins.  
Initially, we examined RT 001, RT 002, RT 027 and RT 078, and we used crude S-
layer extract and purified SLPs. The samples were separated on SDS PAGE and 
blotted onto nitrocellulose membrane. We wanted to determine whether there are 
differences in glycosylation between the total S-layer (which comprises SLPs and 
other surface-associated proteins) and purified SLPs. 
These four ribotypes were chosen, as they represent the wide spectrum of virulence, 
from mild RT 001 to hypervirulent RT 027. SDS PAGE separated various fractions 
and subunits of proteins found in the samples, while denaturing conditions allowed 
presenting these proteins in non-native confirmation, exposing any potential 
glycosylation sites. 
Crude samples of all the ribotypes demonstrated glycosylation when probed with all 
14 lectins. However, none of the signals was identified as either subunit of SLPs. 
Similar approach was used by Cerquetti et al. (2000), where these authors used 
commercially available kit with four lectins and probed SLPs of six strains. These 
authors also confirmed the presence of glycosylation on total S-layer extract, which 
is consistent with our results.  
In the case of purified SLPs, lectin blotting presented inconclusive results, indicating 
the possibility of glycosylation in some of the ribotypes. However, there was also a 
possibility of insufficient lectin washing, as lectins are known for their adhesive 
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properties and extensive washing is important for the lectin binding in blotting (Cao 
et al. 2013). 
As we reached an inconclusive result whether SLPs present glycosylation, this was 
opposed to observations made by Cerquetti et al., which confirmed at all six strains 
of SLPs were glycosylated (Cerquetti et al. 2000). 
Since the lectin blotting experiments were inconclusive, we decided to employ an 
additional analytical method, ELLA, to verify the potential glycosylation signals. We 
proceeded with purified SLPs probing in native confirmation (two subunits 
associated together). This technique is high throughput, which allowed us to include 
more ribotypes of SLPs.  
The initial screening included optimisation of washing techniques, as lectins are 
known to be very difficult to wash off. Therefore, probing of proteins with plant 
lectins is also known to be difficult, as the lectins require individual optimised 
blocking and washing techniques (Brooks & Hall 2012). Furthermore, it was 
important to adjust the blocking solution. Carbohydrate-free solution was used, as 
recommended by other groups (Thompson et al. 2011). This allowed us to reduce the 
background signal from TBST buffer probing below the threshold signal. Also, 
initially HRP was used in all assays as a positive control. However, the exact 
composition of HRP glycosylation was unknown and in the case of some lectin 
probing there was no signal from HRP, which invalidated the results. Therefore, 
HRP could not be considered a universal positive control for ELLA.  Additionally, 
HRP and SBT were initially proposed as positive control for ELLA experiments to 
keep it consistent with positive controls used for Periodic-Schiff Staining. However, 
this may interfere with ELLA assay as HRP is used as an enzyme in the colorimetric 
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reaction used for detection. For this reason, other glycoproteins were matched for 
ELLA in these experiments.  
 Other glycoproteins were considered as positive controls, and we aimed to optimise 
a positive control for each lectin used. Four glycoproteins with known glycosylation 
patterns were initially selected, as recommended by the previous research 
(Thompson et al. 2011; Cerquetti et al. 2000; Lee et al. 2013) and were screened 
along with SLPs RT 001 and 027. In the case of some lectins it was possible to 
match specific glycoproteins, however other were unsuccessful. The lack of 
detection of glycosylation signal from glycoproteins with known glycan composition 
may be due to nature of the glycosidic linkages might introduce some steric 
hindrance, or one may need a larger concentration of glycan structures on the protein 
to detect binding (Larrgy 2011). For this reason and additionally, due to low stock of 
SLPs (no sufficient amount to carry out optimisation of matching lectin with 
glycoprotein positive control, we decided to include four glycoproteins with known 
glycosylation patterns, in order to ensure the variety of glycan structures when 
probing with each lectin. This proved to be successful approach, as in the most cases 
at least one glycoprotein showed signal for glycosylation, except for DBA and GSL I 
lectins, which validated the ELLA assays.  
Overall, none of the ribotypes presented a glycosylation signal when examined by 
ELLA. This led us to the conclusion that SLPs RT 001, RT 002, RT 014, RT 027, 
RT 026 and RT 078 of C. difficile are not glycosylated. This is consistent with the 
conclusions reached by Qazi et al. (2009). These authors carried out mass 
spectroscopy analysis on SLPs from six ribotypes, including RT 001, RT 010, RT 
012, RT 016, RT 017, RT 027 and RT 053 and did not determine the presence of any 
glycans.  
CHAPTER 4                                                           GLYCOSYLATION OF SLPS 
196 
Moreover, Qazi et al. determined that predicted molecular weights are equal to 
observed molecular weights when measured by mass spectroscopy. These authors 
suggested that possible differences between the predicted molecular weights and 
differences observed on SDS PAGE are due to aberrant migration of proteins 
through the gel matrix rather than presence of post-translational modification (Qazi 
et al. 2009). However, this study did not include SLPs RT 002, RT 014, RT 046 or 
RT 078, which were examined in this chapter.  
Also, Calabi et al. carried out the enzymatic digestion of SLPs from four strains in 
order to remove potential glycosylation, however that did not change the mobility of 
the SLPs, indicating that SLPs were not glycosylated (Calabi et al. 2001). 
While SLPs were demonstrated not to present glycosylation, other features on the 
surface of C. difficile have been previously shown to be glycosylated, with suspected 
implications for virulence of this pathogen.  
This included the glycosylation of flagellum. Twine et al. determined that mutations 
leading to a change in flagellar glycosylation lead to loss of mobility by C. difficile 
(Twine et al. 2009). Furthermore, other studies concluded that the flagellar 
glycosylation evolved with virulence and aimed to subvert the host immune response 
(Stabler et al. 2009). However, Stevenson et al. determined that glycosylation of the 
flagella is not necessary for virulence, but it may have implications in adherence 
(Stevenson et al. 2015).  
Reid et al. determined the presence of highly conserved surface polysaccharides 
among studied strains (Reid et al. 2012). However, these glycans were shown to be 
associated with lipids. Furthermore, C. difficile toxins were shown to be glycosylated 
and this allows them to modulate host physiology (Voth & Ballard 2005).  
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The glycosylation of the pathogen might also be utilised for therapeutic purposes. 
Bertolo et al. explored the surface polysaccharide PSII as an potent immunogenic 
adjuvant for the C. difficile toxin vaccine (Bertolo et al. 2012). Also, Dingle et al. 
discovered a new insertion in the S-layer genome cassette, that turned out to be a 
novel S-layer glycosylation cluster (Dingle et al. 2013). These authors suggested that 
this cluster codes for rhamnose biosynthesis pathway. However, we did not test the 
SLPs for the presence of rhamnose because from all the lectins available for us in 
ELLA assay or lectin blotting, rhamnose-binding lectin was not available at the time. 
Nonetheless, as this sugar is unique to bacteria, it represents an attractive drug target.  
Glycosylation of C. difficile is a very dynamic evolutionary process that involves 
several virulence factors and the understanding of these evolutionary processes can 
contribute to our knowledge of temporal changes and geographical differences in the 
epidemiology of CDI.  
There was potential for the glycosylation of SLPs from ribotypes examined in this 
chapter, as indicated by literature review carried out prior to this study. This post-
translational modification could account for the observed differences between 
predicted and observed molecular weights, but also the differences in molecular 
weights of subunits of different ribotypes. Furthermore, we hypothesised that the 
various glycosylation patterns on SLPs from different ribotypes may contribute to 
virulence, understood here as adhesion to host mucosal surfaces, recognition by 
immune system and evading the clearance mechanisms.  
In this chapter, we determined that the SLPs from ribotypes used in this study are not 
glycosylated. However, the question remains about how the differences in SLPs 
sequences contribute to initial colonisation of the pathogen and infection outcome. 
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The glycosylation still remains important for the host-pathogen interactions as there 
is evidence in the literature that the glycosylation state of the gut changes during the 
susceptibility and infection. Therefore, next, we would like to investigate the 
glycosylation patterns on the mucosal surface of the colonic epithelium to search for 
factors that may have implications for C. difficile adherence and colonisation.  
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CHAPTER 5 THE ROLE OF GLYCOSYLATION IN 
CLOSTRIDIUM DIFFICILE INFECTION 
5. 1 INTRODUCTION 
 
The GI tract is an example of an interface of dynamic interactions between the host 
and commensal microbiota cooperating together to keep pathogens at bay. This 
complex network requires a balanced system to be ready to destroy any potential 
threats. This process, known as colonisation resistance, is a key to maintain the 
integrity of the mucosal epithelium (Britton & Young 2012). Simultaneously, it does 
not augment an immune response when recognising self or commensal antigens.  
Host and commensals employ several mechanisms to prevent infection at the colonic 
mucosal surface. This includes production of a mucus layer that prevents microbes 
from interacting with the epithelial barrier. While mucus is produced by epithelial 
cells, it is the commensals that influence the composition of mucus, often in response 
to invading pathogens (Jakobsson et al. 2015). Furthermore, commensals regulate 
antimicrobial peptide secretion into the inner layer of mucus (Littman & Pamer 
2011). This renders the zone sterile from both commensals and pathogens and 
prevents both from interacting with TLRs and avoiding the unnecessary activation of 
the immune system (Johansson et al. 2008; McGuckin et al. 2011). 
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In the previous chapter we examined the surface proteins, SLPs, from various strains 
of C. difficile for the presence of glycosylation. The differences in the glycosylation 
may have accounted for the differences in the molecular weights of SLPs of various 
strains. Also, this could have contributed to the initial colonisation and adherence, 
and subsequent severity of infection. However, we determined that the SLPs of C. 
difficile lack glycosylation patterns, therefore the glycosylation does not contribute 
to the initial adhesion and colonisation of the pathogen in this context. Nevertheless, 
we came to appreciate the importance of glycosylation in the host-pathogen 
interactions. Therefore next, we wanted to explore whether glycosylation on the 
surface of the colon contributes to the susceptibility to infection with C. difficile. 
Specifically, we wanted to correlate any differences in glycosylation patterns on the 
colonic epithelium with the initial pathogen adherence, colonisation, and subsequent 
disease severity. 
As already mentioned, commensals play a major role in maintaining the homeostasis 
in the gut, therefore, it is important for the host to support these commensals (Ubeda 
& Pamer 2013). The host fulfils this role by supplying the nutrients for the 
commensals, namely, sugars utilised for the energy purposes. However, the 
commensals also actively modulate the host metabolism to produce glycans that 
benefit the microbiota (Freitas & Chantal 2000). Specifically, the glycans are 
displayed on the mucus layer that covers the epithelium. Mucus is composed of 
heavily glycosylated proteins called mucins, and commensals remove the glycans 
from the surface of the mucus by enzymatic digestion (Jakobsson et al. 2015).  
As already described above, the host and microbiota maintain mutualistic 
relationship that both parties benefit from. This host-microbiota system is a tightly 
regulated network of interactions, and when this balance is perturbed due a 
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disturbance of the microbiota, it may have a detrimental effect on the health of the 
host (Min & Rhee 2015).   
Most commonly, the commensal microbiota is disturbed by the antibiotic treatment. 
While administration of antibiotics facilitates the clearance of invading pathogens, it 
also causes long-term shifts in the microbial community of the gut (Sekirov et al. 
2008; Robinson & Young 2010; Antonopoulos et al. 2009). Also, the disturbance in 
microbiota has an effect on host’s inability to clear any invading pathogens. For 
instance, microbial disruption with metronidazole, neomycin and vancomycin 
increased the colonisation rate of vancomycin-resistant Enterococcus (VRE) due to 
decreased secretion of antimicrobial peptide RegIIIγ by the host (Brandl et al. 2008). 
Antibiotic-induced disturbance in microbiota and subsequent lack of colonisation 
resistance is a key step in establishing C. difficile infection (Britton & Young 2014; 
Theriot et al. 2014). This mechanism is illustrated by the fact that hospital patients 
undergoing the antibiotic treatment are the major group at risk of developing the CDI 
(Huang et al. 2009). 
While most of the reports about C. difficile infection attribute the susceptibility to the 
lack of colonisation resistance, antibiotic treatment, and presumably eradication of 
microbiota, has some further implications. For instance, this includes the glycans 
availability as nutrient sources. Due to low numbers of commensal microbes, surface 
glycans become available for energy utilisation by opportunistic pathogens such as 
Salmonella typhimurium (Ng et al. 2013). Furthermore, lack of stimulation from 
microbiota may influence the composition of glycans (Jakobsson et al. 2015).  
We wanted to examine this well-defined “susceptibility state” to infection with C. 
difficile, specifically, whether the lack of commensals and their homeostatic effect 
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may influence the glycosylation state of the host. Specifically, we wanted to 
determine whether the glycosylation patterns on the surface of the colonic tissue may 
contribute to C. difficile adherence and subsequent colonisation if the nutrient niche 
was beneficial for the pathogen.  
We developed an animal model of in vivo susceptibility to C. difficile infection. It 
was based on previous studies, including our own, where animals were treated with 
antibiotics to eradicate the microbiota, and then challenged with C. difficile (Chen et 
al. 2008; Lynch 2014, unpublished). This treatment was proven to be sufficient to 
render the animals susceptible in studies carried out by Chen et al. (2008) and Lynch 
(2014, unpublished), as mice succumbed to infection and developed all clinical 
symptoms of the disease. However, in our study, we treated animals with the 
antibiotics and we ceased the model at the susceptibility state, rather than 
challenging the animals with the pathogen. The aim was to understand and define the 
factors that render the animals susceptible to the pathogen. To our knowledge, no 
previous C. difficile susceptibility studies have been reported in the literature. 
First, we examined the glycosylation status of the gut in the susceptibility state to 
infection with C. difficile. The aim was to correlate any changes in the glycosylation 
on the surface of the epithelium with an environment that benefits the pathogen 
during initial stages of invasion. 
Furthermore, knowing the role commensals play in maintaining the homeostasis in 
the gut, we examined how the disturbance in the microbiota influences the 
expression of mucosal immune response such as expression of cytokines, 
chemokines and TLRs as well as epithelial integrity barrier, including expression of 
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mucins, tight junction proteins and antimicrobial peptides. The aim was to determine 
if these factors further contribute to pathogen invasion.  
The susceptibility model allowed us to identify key factors that despite their 
protective properties may have benefited the pathogen in the susceptibility state. 
Therefore, we next used an in vivo infection model to examine if these factors play a 
role in resolving this infection. For this we used in vivo infection with C. difficile RT 
001. This ribotype of C. difficile is characterised by the mild outcome of infection 
and we have demonstrated previously that animals infected with this pathogen 
resolve infection by the end of the study at day 7 (Lynch 2014, unpublished; Ryan et 
al. 2011). We examined the glycosylation patterns on the surface of the colonic 
epithelium during infection. Specifically, we examined the terminal glycans, fucose 
and sialic acid, as they have been previously shown to be important nutrients for C. 
difficile (Ng et al. 2013) and commensal recovery (Chow & Lee 2008). Furthermore, 
we examined the expression of IL-22 cytokine, as it is known to be essential for the 
epithelial barrier recovery.  
5. 2 RESULTS 
5. 2. 1 Susceptibility to C. difficile in vivo Induces an Environment That 
Supposed to be Protective for the Host in the Colon. 
Mice underwent antibiotic treatment to render them susceptible to C. difficile. 
However, rather than challenging them with the pathogen, animals were sacrificed 
and examined for the factors that may contribute to the state of susceptibility of the 
host to the pathogen. We examined the effect of antibiotic-induced disturbance of 
microbiota on the glycosylation presented on the surface of the colonic epithelium. 
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Furthermore, we examined the expression of inflammatory markers such as 
cytokines, chemokines and TLRs but also key mucosal integrity proteins such as 
mucins, tight junction proteins and antimicrobial peptides. Also, the signalling 
pathway of key mucosal cytokine IL-22 was examined.  
5. 2. 1. 1 The Efficacy of the Animal Model of C. difficile Susceptibility Was 
Monitored.  
In order to confirm consumption of the relevant antibiotic concentrations required to 
induce the susceptibility to C. difficile, water intake was monitored daily. The 
average water consumption per animal was then normalised to 30 g body weight 
(BW) and was used to convert the dosage into the actual consumption of the 
antibiotic (Figure 5. 1 A). All animals in the study consumed above the minimum 
recommended dose of antibiotics, as per outlined in Table 2. 16 (Figure 5. 1 B – F). 
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Figure 5. 1 Efficacy of the in vivo susceptibility model was ensured by monitoring water 
intake and corresponding antibiotic dosage. Female C57BL/6J mice had ad libitum access 
to water with antibiotics from day 0 to day 3. Water intake (A) was calculated as 
consumption per day per 30 g of body weight (BW). No significant difference was seen 
between two groups as determined by Repeated Measures ANOVA with Bonferroni post-
test. Next, the volume of water was correlated with antibiotic dosage ingested, kanamycin 
(B), gentamicin (C), colistin (D), metronidazole MANAGEMENT and vancomycin (F). All 
animals under investigation ingested the dosage of all antibiotics recommended to eradicate 
the microbiota. 
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5. 2. 1. 2 Mice Treated With Antibiotics Experienced Significant Loss of 
Weight. 
Animals under investigation were weighed daily at approximately the same time, to 
monitor any adverse effects that the treatment could have induced (severe diarrhea 
etc.). A weight loss above 15% was considered a threat for animal welfare and if 
reached, animals were to be sacrificed immediately. However, no animals in this 
study reached this state.  
Day 0 weight was considered as 100% for each animal in the study and any weight 
change was converted into % of initial weight (Figure 5. 2). The antibiotic treatment 
group reached significant weight loss on day 3 of the antibiotic treatment, which was 
also the lowest average weight this group had reached (p≤0.001). The significant 
weight loss was maintained between the groups until the end of the study (p≤0.001). 
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Figure 5. 2 Animals treated with antibiotics experienced significant weight loss from 
day 3 to day 7. Female C57BL/6J mice were weighed daily and weight change was 
expressed as % of total weight relative to day 0. Results for each day are then mean of 
control group (n=4) and treatment group (n=4). Repeated Measures ANOVA with 
Bonferroni post-test was used to determine the significance between the groups on given day 
and the overall significance between control and treatment groups (*p≤0.05, **p≤0.01 and 
***p≤0.001). 
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5. 2. 1. 3 Mice Treated with Antibiotics Experienced Significant Increase in 
Daily Disease Index. 
Animals under investigation were scored on a daily disease index, at approximately 
the same time each day, to monitor any adverse effects that the treatment could have 
induced. The factors measured on this index included appearance, behaviour, water 
intake and weight change (Appendix D) (Wolfensohn & Lloyd 2012).  
The animals in the antibiotic treatment group had a significant increase in their daily 
disease index from day 3 (p≤0.001). This increase peaked at day 4, and it was 
maintained until the end of the study (Figure 5. 3). Furthermore, the difference 
between control and antibiotic-treated groups was shown to be extremely significant 
(p≤0.001). None of the animals was scored above 9 points, which was considered as 
adverse reaction with recommendation for removing from the study. 
Additionally, we observed some heterobarbering among C57BL/6J mice. It was 
observed that animals over the age of 15 weeks were more prone to barbering. There 
was one severe case of heterobarbering among animals prior to this study. The 
barbered animal experienced severe wounds. There was a possibility that this could 
have induced the inflammatory reaction and this animal was removed from the group 
before the study. For that reason, we did not include any animals over the age of 15 
weeks in our studies, to avoid any discrepancies.  
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Figure 5. 3 Animals treated with antibiotics experienced significant increase in Daily 
Disease Index. Female C57BL/6J mice were scored daily for the behaviour, appearance, 
water intake, weight loss and stool consistency. Results for each day are mean of control 
group (n=4) and treatment group (n=4). Repeated Measures ANOVA with Bonferroni post-
test was used to determine the significance between the groups on given day and the overall 
significance between control and treatment groups (*p≤0.05, **p≤0.01 and ***p≤0.001). 
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5. 2. 1. 4 Antibiotic Treatment Does Not Induce Colitis in Mice.  
Mice were sacrificed after 7 days of the antibiotic regiment and the tissue was 
harvested. The colon was weighed (Figure 5. 4 A) and measured (Figure 5. 4 B – C). 
There was no significant difference in weight or length of the colon, as determined 
by Student’s t-test. However, the macroscopic examination of the harvested colon 
led us to the conclusion that the structure of the colons from the antibiotic treatment 
group was less coiled and tense.  
Finally, the structure of the epithelium was examined by H&E staining and no 
differences between two groups was determined (Figure 5. 4 D). This led us to the 
conclusion that antibiotic treatment does not induce colitis in mice.   
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Figure 5. 4 Disturbance of microbiota due to antibiotic treatment does not induce 
colitis. Female C57BL/6J mice were treated with cocktail of antibiotics for 3 days, followed 
by IP injection of clindamycin on day 5. Animals were sacrificed on day 7 and colitis-
associated factors were investigated (control group n=4 and treatment group n=4), colon 
weight (A), colon length (B) and (C), and H&E staining of colon structure (D). Student’s t-
test was used to determine significance. No significant changes between the groups were 
determined. 
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5. 2. 1. 5 Distribution of Fucose Glycosylation on the Surface of Colonic Tissue 
Changes Upon Antibiotic Treatment.  
The surface of the colonic tissue was examined for fucose glycosylation with use of 
fluorescently-labelled lectins, as this is a glycan commonly present on the outermost 
of the glycan chains.  
Fucose residues were examined by AAL which is specific for fucose-(α-1,6)-N-
Acetylglucosamine and by UEA I specific for α-Fucose (Figure 5. 5). Both lectins 
were tagged with FITC, presented in green. To visualise the structure of the colon, 
DNA of the epithelial cells was stained with DAPI, presented in red. The staining 
with AAL is visualised in Figure 5. 5 A and B, and the distribution of the 
glycosylation summarised in Table 1. Fucose glycosylation was upregulated upon 
antibiotic treatment, specifically, fucose glycosylation signal was upregulated in 
intestinal lumen and in the middle and upper crypts. This glycosylation diminished 
from the lamina propria and stem cells and it was not changed on the surface 
epithelium.   
Furthermore, fucose glycosylation was probed with UEA I, as visualised in  
Figure 5. 5 C and D, while the distribution of glycosylation is summarised in Table 
1. Fucose glycosylation was upregulated upon antibiotic treatment, as the goblet 
cells and all parts of the crypts presented glycosylation signals compared to control. 
The fucose signal diminished from the lamina propria and stem cells, and it had not 
changed in the intestinal lumen and surface epithelium. 
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Figure 5. 5 Fucose residues on the surface of the intestinal epithelium were probed with 
AAL and UEA I lectins. Mice were treated with autoclaved water (control group) or 
antibiotic cocktail (treatment group) for 7 days and sacrificed. Colon was removed, rolled 
using Swiss roll technique, preserved in formaline and embedded in paraffin. Tissue was cut 
into 6 µm sections and probed with 5 µg/ml of lectin conjugated with FITC tag, AAL (A and 
B) and UEA I (C and D). Samples were mounted with VECTASHIELD® HardSet 
Mounting Medium with DAPI (to visualise epithelial structure). Samples were visualised 
using Olympus BX51 Fluorescent Microscope (FITC: green; DAPI: red). 
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5. 2. 1. 6 Distribution of Sialic Acid Glycosylation on the Surface of Colonic 
Tissue Changes Upon Antibiotic Treatment.  
The surface of the colonic tissue was examined for sialic acid glycosylation with the 
use of fluorescently-labelled lectins, as this is a glycan commonly present on the 
outermost of the glycan chains. 
Surface sialic acid glycosylation was measured with SNA specific for Galactosyl-(α-
2,6)/(α-2,3)-Sialic Acid, MAL I specific for Galactosyl-(α-2,3)-Sialic Acid and 
WGA specific for all forms of sialic acid (Figure 5. 6). The staining with SNA is 
visualised in Figure 5. 6 A and B, and it is summarised in Table 1. The glycosylation 
signal upregulated in lower crypts and submucosa, while it was presented at the same 
level on surface epithelium, lamina propria, stem cells, middle and upper crypts and 
its intensity lowered its intensity in muscular mucosae.  
When stained with MAL I (presented in Figure 5. 6 C and D), the glycosylation 
signal diminished from the surface epithelium, lamina propria and stem cells. Only 
goblet cells presented higher glycosylation signal compared to controls.  
Glycosylation probing with WGA (visualised in Figure 5. 6 E and F, and 
summarised in Table 1) presented the same level on the surface epithelium, however, 
the glycosylation signal diminished in the crypts when compared treatment group to 
the control group. There was increase in signal from stem cell and submucosa, when 
probed with this lectin. 
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Figure 5. 6 Sialic Acid residues on the surface of the intestinal epithelium were probed 
with SNA, MAL I and WGA lectins. Mice were treated with autoclaved water (control 
group) or antibiotic cocktail (treatment group) for 7 days and sacrificed. The colon was 
removed, rolled using the Swiss roll technique, preserved in formaline and embedded in 
paraffin. Tissue was cut into 6 µm sections and probed with 5 µg/ml of lectin conjugated 
with FITC tag, SNA (A and B), MAL I (C and D) and WGA (E and F). Samples were 
mounted with VECTASHIELD® HardSet Mounting Medium with DAPI (to visualise 
epithelial structure). Samples were visualised using Olympus BX51 Fluorescent Microscope 
(FITC: green; DAPI: red). 
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5. 2. 1. 7 Fucose Presented on the Colonic Surface is Upregulated by the 
Antibiotic Treatment, While Sialic Acid is Downregulated. 
In order to quantify the glycosylation signal, the total fluorescence of the images 
presented in the previous two sections was measured. This was possible because all 
the images taken for a given lectin were captured under the same conditions and 
comparable surface of the tissue section (FITC and DAPI exposure, and 
magnification). A total of five images per condition were measured.  
As presented in Figure 5. 7, there was a significant increase in fucose glycosylation 
upon antibiotic treatment when probed with AAL (p≤0.05) and UEA I (p≤0.05). 
Sialic acid residues were decreased upon antibiotic treatment when measured with 
SNA, MAL I and WGA. This included a significant downregulation in sialic acid 
measured by MAL I (p≤0.01) and WGA (p≤0.01).  
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Figure 5. 7 Terminal fucose is upregulated in susceptibility state, while terminal sialic 
acid is downregulated. Terminal glycans on the surface of colonic epithelium from mice 
treated with antibiotic cocktail were examined using FITC-labelled lectins, fucose specific 
lectins, AAL and UEA I and sialic specific lectins, SNA, MAL I and WGA. Total 
fluorescence signal was measured using Image J and corrected for the background 
fluorescence. A minimum of five images were taken for given condition, control group n=4 
and treatment group n=4. Results are mean ±SD and Student’s two-tailed t test with Mann-
Whitney U post-test was carried out to search for statistical significance (*p≤0.05, **p≤0.01, 
***p≤0.001). 
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5. 2. 1. 8 Distribution of N-Acetylgalactosamine Glycosylation on the Surface of 
Colonic Tissue Changes Upon Antibiotic Treatment.  
The surface of the colonic tissue was examined for N-Acetylgalactosamine 
glycosylation with the use of fluorescently-labelled lectins, as this type of 
glycosylation comprises the core glycosylation. 
N-Acetylgalactosamine were examined by DBA specific for α-N-
Acetylgalactosamine and PNA specific for Galactosyl-(β-1,3)-N-
Acetylgalactosamine (Figure 5. 8).  
Glycosylation staining with DBA is visualised in Figure 5. 8 A and B, and 
distribution of glycosylation within the epithelial structure is summarised in Table 1. 
The glycosylation signal increased on the surface epithelium, within goblet cells, and 
all the parts of the crypts. The signal remained the same within the intestinal lumen.  
Furthermore, when stained with PNA (Figure 5. 8 C and D), the signal was 
upregulated on the surface epithelium, stem cells, while it remained the same in the 
lamina propria. Glycosylation signal diminished from goblet cells and submucosa. 
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Figure 5. 8 N-Acetylgalactosamine residues on the surface of the intestinal epithelium 
were probed with DBA and PNA lectins. Mice were treated with autoclaved water (control 
group) or antibiotic cocktail (treatment group) for 7 days and sacrificed. Colon was 
removed, rolled using Swiss roll technique, preserved in formaline and embedded in 
paraffin. Tissue was cut into 6 µm sections and probed with 5 µg/ml of lectin conjugated 
with FITC tag, DBA (A and B) and PNA (C and D). Samples were mounted with 
VECTASHIELD® HardSet Mounting Medium with DAPI (to visualise epithelial structure). 
Samples were visualised using Olympus BX51 Fluorescent Microscope (FITC: green; 
DAPI: red). 
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5. 2. 1. 9 Distribution of N-Acetylglucosamine Glycosylation on the Surface of 
Colonic Tissue Changes Upon Antibiotic Treatment.  
The surface of the colonic tissue was examined for N-Acetylglucosamine 
glycosylation with the use of fluorescently-labelled lectins, as this type of 
glycosylation comprises the core glycosylation. 
N-Acetylglucosamine residues were examined by GSL II and sWGA specific for α- 
or β-N-Acetylglucosamine (Figure 5. 9). 
Glycosylation staining with GSL II is visualised in Figure 5. 9 A and B, and 
distribution of glycosylation within the epithelial structure is summarised in Table 1. 
The glycosylation signal increased on the surface epithelium, within goblet cells, and 
lower crypts, while the glycosylation signal diminished from the middle crypts.  
Furthermore, when stained with sWGA, the signal remained the same, but only the 
glycosylation within the middle crypts has changed from strong staining to a low 
level of signal (Figure 5. 9 C and D). 
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Figure 5. 9 N-Acetylglucosamine residues on the surface of the intestinal epithelium 
were probed with GSL II and sWGA lectins. Mice were treated with autoclaved water 
(control group) or antibiotic cocktail (treatment group) for 7 days and sacrificed. Colon was 
removed, rolled using Swiss roll technique, preserved in formaline and embedded in 
paraffin. Tissue was cut into 6 µm sections and probed with 5 µg/ml of lectin conjugated 
with FITC tag, GSL II (A and B) and PNA (C and D). Samples were mounted with 
VECTASHIELD® HardSet Mounting Medium with DAPI (to visualise epithelial structure). 
Samples were visualised using Olympus BX51 Fluorescent Microscope (FITC: green; 
DAPI: red). 
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5. 2. 1. 10 Distribution of Mannose Glycosylation on the Surface of Colonic 
Tissue Changes Upon Antibiotic Treatment.  
The surface of the colonic tissue was examined for mannose glycosylation with use 
of fluorescently-labelled lectins, as this type of glycosylation is found within the core 
and terminal glycosylation. 
Mannose was examined by ConA specific core mannose (Figure 5. 10). 
Glycosylation staining with ConA was visualised in Figure 5. 10 A and B, and 
distribution of glycosylation within the epithelial structure is summarised in Table 1. 
The glycosylation signal was upregulated in the muscular mucosae and submucosa, 
while it diminished from the middle and upper crypts. The mannose glycosylation 
signal remained at the same level on the surface epithelium, lamina propria, stem 
cells and lower crypts. 
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Figure 5. 10 Mannose residues on the surface of the intestinal epithelium were probed 
with ConA lectin. Mice were treated with autoclaved water (control group) or antibiotic 
cocktail (treatment group) for 7 days and sacrificed. Colon was removed, rolled using Swiss 
roll technique, preserved in formaline and embedded in paraffin. Tissue was cut into 6 µm 
sections and probed with 5 µg/ml of ConA lectin conjugated with FITC tag. Samples were 
mounted with VECTASHIELD® HardSet Mounting Medium with DAPI (to visualise 
epithelial structure). Samples were visualised using Olympus BX51 Fluorescent Microscope 
(FITC: green; DAPI: red). 
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5. 2. 1. 11 N-Acetylgalactosamine, N-Acetylglucosamine and Mannose Presented 
on the Colonic Surface are Changed by the Antibiotic Treatment. 
In order to quantify the glycosylation signal, total fluorescence of the images 
presented in previous sections was measured. This was possible because all the 
images taken for a given lectin were captured under the same conditions and 
comparable surface of the tissue section (FITC and DAPI exposure, and 
magnification). A total of five images per condition were measured.  
As presented in Figure 5. 11, there was a significant increase in α-N-
Acetylgalactosamine upon antibiotic treatment when measured by DBA (p≤0.05) 
and significant decrease in Galactosyl-(β-1,3)-N-Acetylgalactosamine when probed 
by PNA (p≤0.05). Furthermore, there was upregulation of N-Acetylglucosamine 
glycosylation upon antibiotic treatment when probed by GSL II and sWGA, and this 
included a significant increase of glycosylation when probed with GSL II (p≤0.05). 
Finally, there was significant downregulation in the mannose residues on the surface 
of colonic epithelium upon antibiotic treatment (p≤0.05). 
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Figure 5. 11 Core glycans of the colonic epithelium are changed upon antibiotic 
treatment. Core glycans on the surface of the colonic epithelium from mice treated with 
antibiotic cocktail were examined using FITC-labelled lectins, N-Acetylgalactosamine 
specific lectins DBA and PNA, N-Acetylglucosamine specific lectins GSL II and sWGA, 
and core mannose-specific lectin ConA. Total fluorescence signal was measured using 
Image J and corrected for the background fluorescence. A minimum of five images were 
taken for a given condition, control group n=4 and antibiotic group n=4. Results are the 
mean ±SD and Student’s two-tailed t test with Mann-Whitney U post-test was carried out to 
search for statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001). 
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Table 5. 1 Distribution of glycosylation on colonic surface epithelium observed during susceptibility state. Susceptibility was induced in mice upon 
antibiotic treatment (Anti.). Glycosylation structures commonly observed on the colonic epithelium were examined by several lectins. Distribution of 
glycosylation signal within colon structure and its intensity was scored as +++ denoting extremely strong staining; ++ denoting strong staining; + some staining 
present; lack of signal was left blank. 
Lectin binding site  
of the structure  
of colonic epithelium 
Sialic Acid Fucose N-Acetylgalactosamine N-Acetylglucosamine Mannose 
SNA MAL I WGA AAL UEA I DBA PNA GSL II sWGA ConA 
Control Anti. Control Anti. Control Anti. Control Anti. Control Anti. Control Anti. Control Anti. Control Anti. Control Anti. Control Anti. 
Intestinal lumen        + + + + +     + +   
Surface epithelium + + +  + + + + + +  +  +  ++   + + 
Lamina propria + + +  +  +  +    + +     + + 
Goblet cells    +      +  + +   +     
Stem cells + + +   ++ +  +     +     ++ ++ 
Crypt of 
Lieberkühn 
Lower  +   +++ ++    + + +++   + ++ + + + + 
Middle + +   ++ +  +  +  ++   +  ++ + +  
Upper + +   +   +  ++  +     + + +  
Muscular mucosae ++ +                  ++ 
Submucosa  +    +       +       + 
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5. 2. 1. 12 Antibiotic-Induced Disturbance of the Microbiota Leads to a Mild 
Proinflammatory Profile in the Colon as Determined by Cytokine, Chemokine 
And TLRs Expression. 
In order to determine how antibiotic treatment and disturbance in the microbiota 
affected the colon, expression of key inflammatory markers, such as cytokines 
(Figure 5. 12), chemokines (Figure 5. 13) and TLRs expression (Figure 5. 14) were 
examined by RT qPCR 
The expression of the proinflammatory cytokines IL-12, IL-23, IL-1β and TGFβ 
were upregulated upon antibiotic treatment, while there was a minor increase in 
expression of IL-17 (4-fold, 5-fold, 15-fold, 5-fold and 12-fold, respectively), 
including a significant increase in expression of IL-1β (p<0.001). Expression of IL-6 
was significantly decreased to 0.25-fold. Notably, antibiotic treatment significantly 
increased expression of the anti-inflammatory cytokine IL-10 6-fold (p<0.001). 
There was also a decrease in the expression of IL-2 and TNFα, 0.25-fold and 0.5-
fold, respectively (Figure 5. 5).  
Furthermore, expression of the chemokines MIP1α and MIP2α were downregulated 
(0.25-fold, both), including a significant decrease in MIP2α (p<0.001). There was a 
minor change in expression of MCP1. Only RANTES was shown to be increased in 
its expression (6-fold) (Figure 5. 6). 
The expression of TLRs was also affected by the disturbance in the microbiota. The 
expression of TLR5 was downregulated 0.5-fold and TLR9 was also downregulated 
0.5 fold, while there was a minor change in expression of TLR4. Only expression of 
TLR2 was increased (15-fold) (Figure 5. 7). However, none of these changes in 
expression were significant.  
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Figure 5. 12 Antibiotic treatment leads to a mild proinflammatory profile in the colon. 
Female C57BL/6J mice were treated with antibiotic cocktail for 3 days, followed by IP 
injection of clindamycin on day 5. Mice were sacrificed on day 7 and colons were removed. 
Tissue from each sample was homogenised, mRNA was extracted and normalised amounts 
of mRNA were converted into cDNA. The cDNA was mixed with primers for Il12a, Il23, 
Il1b, Il2, Il6, Il10, Il17, Tnfa and Tgfb and FAST SYBR Mastermix. Samples were assayed 
in triplicate and analysed on LightCycler®96. Groups were compared using relative 
quantitation. After normalising samples to geometric mean of two endogenous controls, 
Ppia and B2m, expression of control sample was normalised to 1, and expression in 
treatment group is shown relative to this value. Results are means ±SD of 4 mice/control and 
4 mice/antibiotic. Mann-Whitney U test was carried out to search for statistical significance 
(*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5. 13 Antibiotic treatment leads to changes in chemokine expression in the 
colon. Female C57BL/6J mice were treated with antibiotic cocktail for 3 days, followed by 
IP injection of clindamycin on day 5. Mice were sacrificed on day 7 and colons were 
removed. Tissue from each sample was homogenised, mRNA was extracted and normalised 
amounts of mRNA were converted into cDNA. The cDNA was mixed with primers for Ccl3 
(MIP1α), Cxcl2 (MIP2α), Ccl2 (MCP1) and Ccl5 (RANTES) and FAST SYBR Mastermix. 
Samples were assayed in triplicate and analysed on LightCycler®96. Groups were compared 
using relative quantitation. After normalising samples to geometric mean of two endogenous 
controls, Ppia and B2m, expression of control sample was normalised to 1, and expression in 
treatment group is shown relative to this value. Results are means ±SD of 4 mice/control and 
4 mice/antibiotic. Mann-Whitney U test was carried out to search for statistical significance 
(*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5. 14 Antibiotic treatment leads to changes in expression of TLRs in the colon. 
Female C57BL/6J mice were treated with antibiotic cocktail for 3 days, followed by IP 
injection of clindamycin on day 5. Mice were sacrificed on day 7 and colons were removed. 
Tissue from each sample was homogenised, mRNA was extracted and normalised amounts 
of mRNA were converted into cDNA. The cDNA was mixed with primers for Tlr2, Tlr4, 
Tlr5 and Tlr9 and FAST SYBR Mastermix. Samples were assayed in triplicate and analysed 
on LightCycler®96. Groups were compared using relative quantitation. After normalising 
samples to geometric mean of two endogenous controls, Ppia and B2m, expression of 
control sample was normalised to 1, and expression in treatment group is shown relative to 
this value. Results are means ±SD of 4 mice/control and 4 mice/antibiotic. Mann-Whitney U 
test was carried out to search for statistical significance (*p<0.05, **p<0.01, ***p<0.001). 
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5. 2. 1. 13 Antibiotic Treatment Alters the Expression of Mucins, Tight Junction 
Proteins and Antimicrobial Peptides in the Colon. 
We investigated the effects of antibiotic treatment and microbiota disruption on the 
mucosal integrity markers by examining the expression of mucins (Figure 5. 15), 
tight junction proteins and antimicrobial peptides (Figure 5. 16).  
Nine mucin genes were investigated. Muc1, Muc2, Muc3, Muc4, Muc4 and  Muc15 
were upregulated expression upon antibiotic treatment (7.5-fold, 10-fold, 10-fold, 
25-fold, 4-fold and 5-fold, respectively). There was a minor change in expression of 
Muc20. This included a significant increase in the most abundant colonic mucin, 
Muc2 (p<0.05). The expression of Muc5ac and Muc6 were decreased, 0.1-fold and 
0.2-fold, respectively (Figure 5. 16 A).  
In order to determine the most prevalently expressed mucins, we carried out a 
relative expression study with mucin genes (Figure 5. 16 B). Expression of all the 
mucins was presented relative to Muc1, in the control group and antibiotic treatment 
group. We determined that Muc1, Muc2, Muc3, Muc4 and Muc13 are the most 
prevalently expressed in colon, before and after antibiotic treatment. 
Furthermore, the expression of tight junction proteins were also examined. The 
expression of both, Cdh1 and Ocln was upregulated upon the antibiotic treatment, 5-
fold and 1.5-fold, respectively (Figure 5. 16). However, this increase is expression 
was not significant.  
Finally, the expression of the antimicrobial peptide gene, Reg3g was decreased and 
this change was also non-significant (Figure 5. 16).  
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Figure 5. 15 Antibiotic treatment affected the expression of mucins in colonic tissue. 
Female C57BL/6J mice were treated with antibiotic cocktail for 3 days, followed by IP 
injection of clindamycin on day 5. Mice were sacrificed on day 7 and colons were removed. 
Tissue from each sample was homogenised, mRNA was extracted and normalised amounts 
of mRNA were converted into cDNA. The cDNA was mixed with primers for Muc1, Muc2, 
Muc3, Muc4, Muc5ac, Muc6, Muc13, Muc15 and Muc20 and FAST SYBR Mastermix. 
Samples were assayed in triplicate and analysed on LightCycler®96. Groups were compared 
using relative quantitation. After normalising samples to geometric mean of two endogenous 
controls, Ppia and B2m, expression of control sample was normalised to 1, and expression in 
treatment group is shown relative to this value (A). Relative levels of mucin expression were 
analysed with same approach but expression of all mucins was presented relative to Muc1 
(B). Results are means ±SD of 4 mice/control and 4 mice/antibiotic. Mann-Whitney U test 
was carried out to search for statistical significance (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5. 16 Antibiotic treatment upregulated the expression of tight junction proteins 
CDH1 and OCLN and downregulated the expression of antimicrobial peptide REGIIIγ 
in colon. Female C57BL/6J mice were treated with antibiotic cocktail for 3 days, followed 
by IP injection of clindamycin on day 5. Mice were sacrificed on day 7 and colons were 
removed. Tissue from each sample was homogenised, mRNA was extracted and normalised 
amounts of mRNA were converted into cDNA. The cDNA was mixed with primers for 
Cdh1, Ocln and Reg3g and FAST SYBR Mastermix. Samples were assayed in triplicate and 
analysed on LightCycler®96. Groups were compared using relative quantitation. After 
normalising samples to geometric mean of two endogenous controls, Ppia and B2m, 
expression of control sample was normalised to 1, and expression in treatment group is 
shown relative to this value. Results are means ±SD of 4 mice/control and 4 mice/antibiotic. 
Mann-Whitney U test was carried out to search for statistical significance (*p<0.05, 
**p<0.01, ***p<0.001). 
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5. 2. 1. 14 Antibiotic Treatment Induces the Expression of Enzymes Involved in 
Fucose and Sialic Acid Glycosylation.  
 
Next, we investigated the effects of antibiotic treatment and microbiota disruption on 
the expression of two glycosylating enzymes, fucose glycosylating enzyme Fut2 
(fucosyltransferase 2,) and sialic acid glycosylating enzyme Nans (sialic acid 
synthase enzyme) (Figure 5. 17). The expression of Fut2 was increased 3.5-fold 
upon antibiotic treatment. Also the expression of Nans increased 3.5-fold upon 
antibiotic treatment. Both changes were shown to be non-significant.  
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Figure 5. 17 Antibiotic treatment increases expression of fucose and sialic acid 
glycosylation genes Fut2 and Nans. Female C57BL/6J mice were treated with antibiotic 
cocktail for 3 days, followed by IP injection of clindamycin on day 5. Mice were sacrificed 
on day 7 and colons were removed. Tissue from each sample was homogenised, mRNA was 
extracted and normalised amounts of mRNA were converted into cDNA. The cDNA was 
mixed with primers for Fut2 and Nans and FAST SYBR Mastermix. Samples were assayed 
in triplicate and analysed on LightCycler®96. Groups were compared using relative 
quantitation. After normalising samples to geometric mean of two endogenous controls, 
Ppia and B2m, expression of control sample was normalised to 1, and expression in 
treatment group is shown relative to this value. Results are means ±SD of 4 mice/control and 
4 mice/antibiotic. Mann-Whitney U test was carried out to search for statistical significance 
(*p<0.05, **p<0.01, ***p<0.001). 
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5. 2. 1. 15 Antibiotic Treatment Alters the Expression of IL-22 Pathway in the 
Colon. 
In order to investigate how the mucosal clearance pathway was affected by the 
antibiotic treatment, we examined the expression of Il22b and Stat3.  
Expression of Il22b was downregulated to 0.1-fold. The expression of transcription 
factor Stat3 was also downregulated (0.75-fold). Both results were shown to be non-
significant (Figure 5. 18).  
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Figure 5. 18 Antibiotic treatment downregulated the expression of Il22b and Stat3. 
Female C57BL/6J mice were treated with antibiotic cocktail for 3 days, followed by IP 
injection of clindamycin on day 5. Mice were sacrificed on day 7 and colons were removed. 
Tissue from each sample was homogenised, mRNA was extracted and normalised amounts 
of mRNA were converted into cDNA. The cDNA was mixed with primers for Il22b and 
Stat3 and FAST SYBR Mastermix. Samples were assayed in triplicate and analysed on 
LightCycler®96. Groups were compared using relative quantitation. After normalising 
samples to geometric mean of two endogenous controls, Ppia and B2m, expression of 
control sample was normalised to 1, and expression in treatment group is shown relative to 
this value. Results are means ±SD of 4 mice/control and 4 mice/antibiotic. Mann-Whitney U 
test was carried out to search for statistical significance (*p<0.05, **p<0.01, ***p<0.001). 
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5. 2. 2 C. difficile RT 001 Modulates the Intestinal Environment to Support 
Pathogenicity  
Thus far we have demonstrated that the host employs several mechanisms to 
compensate for the lack of commensal microbiota and protect it from a potential 
invasion by a pathogen. Specifically, we demonstrated that fucose, a glycan 
preferred by the commensals and not available for C. difficile, was increased on the 
surface of the epithelium. Furthermore, the availability of sialic acid, the glycan of 
choice for C. difficile, was limited. 
In this part of the study we next wanted to examine how the glycosylation on the 
surface of the surface of the epithelium is affected by infection with the C. difficile 
RT 001. This ribotype is known as a mild strain and in our previous study we were 
able to demonstrated that animals recovered from infection by the end of the study at 
day 7 (Lynch 2014, unpublished).  
Two groups of mice underwent antibiotic treatment and then one group was 
challenged with C. difficile RT 001, respectively, while the control group was 
allowed to recover commensal microbiota. Colonic tissue was examined for the 
presence of fucose and sialic acid glycosylation, as well as the expression levels of 
glycosylation enzymes, FUT2 and NANS enzymes, and of IL-22 cytokine. 
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5. 2. 2. 1 Fucose Residues on the Surface of the Colonic Epithelium Did Not 
Change During Infection with C. difficile RT 001 and Increased Post-Infection. 
Colonic tissue was harvested from mice infected with C. difficile RT 001 on day 3 
and day 7 days post infection. The surface of the epithelium was examined for 
fucose glycosylation with use of fluorescently-labelled lectin UEA I, specific for α-
Fucose (Figure 5. 19).  
The staining with UEA I is visualised in Figure 5. 19 A – D, and the distribution of 
the glycosylation summarised in Table 2. On day 3 post–infection, fucose 
glycosylation diminished from goblet and stem cells and also lower crypts, when 
compared RT 001 to control group. On day 7 post-infection, the fucose glycosylation 
diminished slightly at the columnar surface epithelium, but also increased in goblet 
cells, when compared RT 001 to control group.  
Fucose glycosylation did not change between control group and RT 001 group on 
day 3 post-infection when the total fluorescence was measured. By day 7 post-
infection, the fucose glycosylation increased in both groups relative to day 3. This 
increase was higher in the RT 001 group relative to the control group (Figure 5. 19 
E), however these changes were not significant.  
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Figure 5. 19 Fucose residues on the surface of the colonic epithelium changed post-
infection with C. difficile RT 001. C57BL/6J mice were pre-treated with antibiotic cocktail 
for 7 days. On day 7, mice were infected with C. difficile RT 001. Mice were sacrificed on 
day 3 or day 7 post-infection, and colon was removed, rolled using Swiss roll technique, and 
stored at -80°C. Tissue was cut into 6 µm sections and probed with 5 µg/ml of UEA I lectin 
conjugated with FITC tag. Samples were mounted with VECTASHIELD® HardSet 
Mounting Medium with DAPI. Samples were visualised using Olympus BX51 Fluorescent 
Microscope using FITC and DAPI filters (FITC: green; DAPI: red). Total fluorescence 
signal was measured using Image J and corrected for the background fluorescence. Student 
t-test was carried out to search for statistical significance (*p<0.05, **p<0.01, ***p<0.001).  
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5. 2. 5. 2 Sialic Acid Presented on the Surface of Colonic Tissue Was Increased 
Early During Infection with RT 001 and Decreased Post-Infection. 
Colonic tissue was harvested from mice infected with C. difficile RT 001, on day 3 
and day 7 post-infection. Surface sialic acid glycosylation was probed with WGA 
specific for all forms of sialic acid (Figure 5. 20). 
The staining with WGA is visualised in Figure 5. 20 A – D, and the distribution of 
the glycosylation summarised in Table 2. On day 3 post-infection, the sialic acid 
glycosylation diminished from the most exposed parts of the epithelium, including 
the intestinal lumen and columnar surface epithelium, when compared RT 001 to 
control. However, the sialic acid increased in other parts of the epithelial structure 
such as lamina propria, goblet cells, stem cells, and middle and upper crypts, as wells 
as muscular mucosae. On day 7 post-infection, the sialic acid diminished from most 
of the epithelial structures, the glycosylation signal was only present at the columnar 
surface epithelium and muscular mucosae, when compared RT 001 to control.  
In order to quantify the glycosylation signal, total fluorescence of the glycosylation 
signal was measured (Figure 5. 20 E). On day 3 post-infection, there was a 
significant increase in total fluorescence, when compared RT 001 to control 
(p<0.001). By day 7 post infection, the total fluorescence of the control increased 
(relative to day 3), while the total fluorescence of RT 001 group decreased (relative 
to day 3). The difference between control and RT 001 was shown to be significant 
(p<0.001). 
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Figure 5. 20 Sialic acid residues on the surface of the colonic epithelium increased early 
during infection with C. difficile RT 001 and decreased post-infection. C57BL/6J mice 
were pre-treated with antibiotic cocktail for 7 days. On day 7, mice were infected with C. 
difficile RT 001. Mice were sacrificed on day 3 or day 7 post-infection, and colon was 
removed, and preserved in Optimum Cutting Medium and stored at -80°C. Tissue was cut 
into 6 µm sections and probed with 5 µg/ml of WGA lectin conjugated with FITC tag. 
Samples were mounted with VECTASHIELD® HardSet Mounting Medium with DAPI. 
Samples were visualised using Olympus BX51 Fluorescent Microscope using FITC and 
DAPI filters (FITC: green; DAPI: red). Total fluorescence signal was measured using Image 
J and corrected for the background fluorescence. Student t-test was carried out to search for 
statistical significance (*p<0.05, **p<0.01, ***p<0.001). 
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Table 5. 2 Fucose and sialic acid glycosylation profile of the colonic surface epithelium observed during 
infection with C. difficile RT 001. Glycosylation structures commonly observed on the colonic epithelium were 
examined by lectins, UEA I and WGA. Distribution within structure and its intensity was scored as +++ 
denoting extremely strong staining; ++ denoting strong staining; + some staining present; lack of signal was left 
blank. 
Lectin binding site  
of the structure  
of colonic epithelium 
Sugar 
UEA I (Fucose) WGA (Sialic acid) 
Control 
Day 3 
RT 001  
Day 3 
Control 
Day 7 
RT 001 
Day 7 
Control 
Day 3 
RT 001  
Day 3 
Control 
Day 7 
RT 001  
Day 7 
Intestinal lumen +  ++ ++ +    
Columnar surface epithelium  + +++ ++ ++ + +++ + 
Lamina propria      + ++  
Goblet cells +  ++ +++  + ++  
Stem cells +    + ++ +  
Crypt of Lieberkühn 
Lower +    +  ++  
Middle +++ ++ ++ ++ + + ++  
Upper +++ +++ +++ +++ ++ + ++  
Muscular mucosae      + ++ + 
Submucosa     + ++ ++  
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5. 2. 2. 3 The Expression of Il22b and Glycosylation Enzymes Fut2 and Nans in 
Colonic Tissue Was Altered 3 Days and 7 Days Post-Infection with C. difficile 
RT 001. 
In order to examine how infection with RT 001 affects the mucosal barrier recovery 
and glycosylation activity, the expression of Il22b, Fut2 and Nans was examined in 
colonic tissue (Figure 5. 21).  
On day 3 post-infection, the expression of Il22b was decreased significantly during 
infection with RT 001 to less than 0.1-fold expression level, relative to the control 
group (p≤0.001). On day 7 post-infection, the expression of Il22b in RT 001 returned 
to the expression level compared with control group.  
The fucosylation gene Fut2was significantly downregulated both on day 3 and day 7 
post-infection, 0.75-fold and 0.25-fold, respectively (p≤0.05).  
Furthermore, the sialic acid glycosylation gene Nans was shown to be significantly 
upregulated 4-fold on day 3 post-infection with RT 001 (p≤0.05). By day 7 post-
infection, the expression of Nans during infection with RT 001 returned to the 
expression level compared with control group.  
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Figure 5. 21 The expression of Il22b, Fut2 and Nans in colonic tissue is altered 3 days 
and 7 days post-infection with C. difficile. Female C57BL/6J mice were treated with 
antibiotic cocktail for 3 days, followed by IP injection of clindamycin on day 5. Mice were 
then challenged with C. difficile RT 001. Animals were sacrificed on day 3 and day 7 post-
infection. Tissue from each sample was homogenised, mRNA was extracted and normalised 
amounts of mRNA were converted into cDNA. The cDNA was mixed with primers for 
Il22b, Fut2 and Nans and FAST SYBR Mastermix. Samples were assayed in triplicate and 
analysed on LightCycler®96. Groups were compared using relative quantitation. After 
normalising samples to geometric mean of two endogenous controls, Ppia and B2m, 
expression of control sample was normalised to 1, and expression in treatment group is 
shown relative to this value. Results are means ±SD of 4 mice/control, 6 mice/RT 001, for 
day 3 and day 7. One-way ANOVA test with Newman-Keuls Multiple Comparison tests 
were carried out to search for statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001). 
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5. 3 DISCUSSION 
In this chapter, we examined the factors that may contribute to susceptibility to the 
infection with C. difficile. Specifically, we wanted to determine if glycosylation 
influences the colonisation with this pathogen or indeed its course of infection. 
The susceptibility state to infection with C. difficile is attributed to antibiotic use and 
previous studies induced susceptibility in animals by antibiotic treatment, including 
our own (Chen et al. 2008; Theriot et al. 2015; Lynch 2014, unpublished; Ryan et al. 
2011). However, there are no previous reports of studies that have examined the 
susceptibility state to C. difficile infection to define the factors that render the 
animals susceptible to the infection.  
In a previous study in our laboratory, animals succumbed to infection with C. 
difficile RT 001 and RT 027 and developed full pathophysiological effects of colitis 
(Lynch 2014, unpublished). Antibiotics used in the in vivo model had a wide 
spectrum of action, and mimicked the immunocompromised state of patients by 
eradicating the majority of the commensal microbiome.  
However, in the susceptibility model presented in this chapter the animals were not 
challenged with C. difficile. Therefore, in order to ensure that each mouse ingested 
the recommended amount of antibiotics to eradicate microbiota and induce the state 
of susceptibility, we monitored the water intake. Each animal under the study 
consumed less water than expected for C57BL/6J strain at this age (Bachmanov et 
al. 2002). However, all consumed at least the minimum recommended dosage of 
each of the antibiotics, therefore we consider these animals susceptible.  
The animals from the susceptibility group presented with significant weight loss, 
which was an unexpected observation. The weight loss is usually observed when full 
CHAPTER 5                                   ROLE OF GLYCOSYLATION IN C. DIFFICILE INFECTION 
 
247 
colitis is observed, either chemically induced with dextran sulphate sodium (DSS-
induced colitis) (Melgar 2005) or due to infection with a pathogen such as C. 
rodentium (Bergstrom et al. 2010). None of the authors inducing susceptibility in 
mice with antibiotic treatment reported weight loss prior to infection with C. difficile 
(Chen et al. 2008; Akha et al. 2012; Bassis et al. 2014). The observed effect of 
weight loss could be due to increased levels of defecation and mild diarrhoea, which 
we observed in this group, however it could be also due to decreased level of feed 
consumption which we did not monitor in this study.  
Furthermore, a significant increase in daily disease index was also observed. Again, 
this was unexpected, as the animals were not challenged with an infectious agent and 
we did not anticipate these symptoms. Using the same antibiotic regiment, Chen et 
al. monitored disease progression with a scoring system, however only after animals 
were inoculated with C. difficile and not during the antibiotic pre-treatment(Chen et 
al. 2008).  
Due to significant weight loss and increase in daily disease index, the physiological 
symptoms of colitis were also examined. There was no change in the colon weight 
and length, as well as no change in the structure of colonic epithelium. This was 
anticipated, as only mice infected with infectious agents such as C. rodentium exhibit 
pathogenic structures and increased colon weight due to infiltration of immune cells 
(Koroleva et al. 2015).  
Since we determined that antibiotic treatment did not induce colitis, we then moved 
next to examine the factors that may influence the susceptibility state. Overall, we 
determined that antibiotic treatment and presumably the eradication of microbiota 
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induced several changes in the host, most of them recognised as protective 
mechanisms.  
Initially, we examined a range of glycans that are found on mucins. This included 
glycans that comprise the core in the glycan chains, N-Acetylglucosamine, N-
Acetylgalactosamine and mannose (Liquori et al. 2012). The second group included 
glycans that are found in terminal positions in glycan chains, fucose and sialic acid 
and are important nutrient sources for commensals and pathogens (Varki 2008). 
We demonstrated that the distribution of fucose on the epithelium shifted towards the 
surface and it significantly increased upon antibiotic treatment. The surface 
presentation of fucose is important in this context, as we proposed that increased 
levels of fucose may play an essential role for commensal recovery. The glycans 
have to be presented not only in the terminal sequences in order for commensal to 
remove the glycans from the glycosylation chain. The fact that the fucose shifts 
towards the surface in antibiotic-treated animals, may support the hypothesis that 
fucose is presented here for the commensal benefit.  This increase correlated with the 
increased expression of fucosylation enzyme, FUT2. The increased fucosylation 
presented on the surface of the epithelium has an enormous impact on the recovery 
of compromised commensals because fucose is used by microbiota as a preferred 
energy source. Therefore, fucose-digesting enzymes are constitutively expressed and 
readily available in commensal bacteria, while pathogens have to switch the 
metabolism to fucose and express the appropriate enzymes (Hooper & Xu 1999). 
Pickard et al. has shown during infection with C. rodentium that the increase in 
fucose is a mechanism employed by the host to actively enhance the commensal 
recovery (Pickard et al. 2014). This profile correlates with our model, as antibiotic-
treated mice try to support the microbiota and fucose may enhance this recovery.  
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Another terminal glycan, sialic acid, is an important energy supply for C. difficile 
during infection (Ng et al. 2013). Therefore, we anticipated that sialic acid may be 
upregulated in the susceptibility state, which could contribute to colonisation of C. 
difficile. To our surprise we observed a significant decreased in sialic acid residues 
upon antibiotic treatment. However, when we examined the expression levels of 
sialic acid synthase gene, NANS we found it to be upregulated in the susceptibility 
state. The lower levels of sialic acid on the surface of the epithelium, despite 
upregulation of NANS, may be explained by the lack of mannose that we also 
observed. As determined by the lectin probing, mannose residues decreased upon 
antibiotic treatment. Interestingly, mannose, in form of N-acetylmannosamine 6-
phosphate is a substrate for NANS (sialic acid synthase) to form sialic acid (Hao et 
al. 2005; Tanner 2005). We observed that NANS expression was increased in the 
susceptibility state but there was no increase in sialic acid residues as determined by 
the lectin probing. We propose that the lack of sialic acid on the surface of the 
epithelium in the susceptibility state is due to the limited supply of mannose, despite 
the increased expression of sialic synthase enzyme.  
Additionally, sialic acid has a reversible relationship with fucose. In the human GI 
tract, under healthy conditions, there is an increasing gradient of surface sialic acid 
from the ileum to the colon associated with a reversed gradient of fucose, both 
presented on mucins (Robbe et al. 2003). However, this ratio is inverted when the 
host is compromised, with high fucose and low sialic acid presented on the surface 
of colonic epithelium. This is the exact relationship that we observed in the 
susceptibility state, as there was a significant increase in fucose with significant 
downregulation of sialic acid. This suggests that antibiotic treatment induces a 
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profile of terminal glycans that is essential for the commensal recovery (high fucose) 
and disadvantages the growth of C. difficile (low sialic acid).  
Core glycans are not essential for bacterial growth, as demonstrated by the lack of 
enzymes catabolising N-Acetylgalactosamine or N-Acetylglucosamine in a genome 
of pathogens such as E. coli (Fabich et al. 2008). In this study, we observed that 
antibiotic treatment increased the N-Acetylglucosamine when probed with both GSL 
II and sWGA. Tobisawa et al. demonstrated that increased N-Acetylglucosamine 
residues on mucins in the colon is correlated with a protective mechanism employed 
to prevent the massive leukocyte infiltration (Tobisawa et al. 2010). However, the 
increased levels of this glycan may benefit C. difficile during infection, as N-
Acetylglucosamine has been shown to mediate binding of C. difficile toxin 
(Castagliuolo et al. 1998). Its position within the core of the glycan chain may aid 
the delivery of the toxin closer to the epithelial surface especially that the N-
Acetylglucosamine residues increased in lower parts of the crypts of the epithelium.   
Overall, here we show that the susceptibility state induced changes in the 
glycosylation present on the colonic surface. Specifically, we determined that the 
host presents the glycans that can promote the commensal recovery (fucose), and 
limit the glycans that could benefit the pathogen (sialic acid). This finding was 
unexpected, as we anticipated that the glycosylation profile may benefit the pathogen 
rather than the commensals. However, our further finding of an increase in A-
Acetylglucosamine supports an environment that C. difficile may thrive in, through 
enhanced toxin binding.   
Therefore, while our findings demonstrated that the glycosylation status of the gut 
may influence the susceptibility of the host to infection with C. difficile, it was clear 
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that other factors may also contribute. In particular, given that antibiotic-treated host 
becomes immunocompromised, as mice challenged with C. difficile succumb to 
infection unlike immunocompetent mice (Chen et al. 2008; Lynch 2014, 
unpublished), therefore we wanted the examine this immunocompromised state in 
order to determine the factors that may render these animals susceptible to the 
infection.    
Commensals are actively involved in stimulating the immune response and mucosal 
integrity barrier, and this suggested that any change in microbiota due to antibiotic 
treatment may influence this balance (Min & Rhee 2015). Therefore, we next 
examined the expression of these factors to correlate any changes with susceptibility 
to the infection. 
We determined that antibiotic treatment increased the inflammatory state presented 
in the colon, as evidenced by upregulated expression of proinflammatory cytokines 
IL-12, IL-23 and IL-1β. These cytokines are essential for initiating the immune 
response (Charo & Ransohoff 2006). The susceptibility state induced by the 
antibiotic treatment and anticipated lack of microbiota, may explain this 
proinflammatory tone. This is due to the lack of immunosuppressive effect that the 
microbiota has on the gut environment. Versalovic et al. suggested that commensal 
microbiota may have an anti-inflammatory effect on the GI tract, and therefore when 
this signal is eradicated, the proinflammatory pathways may be activated (Versalovic 
et al. 2008).  
We also observed that chemokines, MCP1, MIP2α and MIP1α, were downregulated 
in the susceptibility state. These chemokines are essential for neutrophil recruitment 
(Fournier & Parkos 2012; Rydström & Wick 2009; Ohtsuka et al. 2001), and their 
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absence may suggest that the recruitment of the immune cells was repressed. 
Possibly it was a mechanism employed to prevent an augmented immune response to 
recovering microbiota. Interestingly, one of the chemokines, RANTES was 
upregulated in the susceptibility state. This chemokine is also essential for neutrophil 
recruitment and clearance of infection. However Hu et al. demonstrated that aberrant 
microbiota induced colitis in mice specifically via excessive induction of RANTES 
(Hu et al. 2013). While the upregulation of RANTES may not contribute to the 
infection, it may be detrimental during the early stage of the infection with C. 
difficile.  
Possibly to counteract this proinflammatory effect, we observed an increase in 
expression of two major anti-inflammatory cytokines, IL-10 and TGFβ. These 
cytokines play key role in regulating and repressing expression of proinflammatory 
cytokines (Ouyang et al. 2011). Kang et al. reported that IL-10 and TGFβ synergise 
together to inhibit induction of proinflammatory cytokines when microbiota is 
disturbed (Kang et al. 2008). However the induction of these two cytokines may 
have a detrimental effect on the host. IL-10 and TGFβ may supress the normal host 
inflammatory responses, leading to persisting chronic infection via induction of an 
anergic state (Mege et al. 2006). Furthermore, induction of IL-10 by pathogens such 
as Mycobacterium tuberculosis or Candida albicans, followed by induction of Tregs 
is known as an immune evasion mechanism that impairs clearance (Ouyang et al. 
2011). In our previous study, we also demonstrated that more persistent infection of 
C. difficile RT 027 was due to upregulated IL-10 expression, to dampen the 
clearance and maintain the infection (Lynch 2014, unpublished). 
The protective environment induced in the colon upon the antibiotic treatment was 
further evidenced by downregulation of 3 out of 4 investigated TLRs. Intestinal 
CHAPTER 5                                   ROLE OF GLYCOSYLATION IN C. DIFFICILE INFECTION 
 
253 
epithelial cells have very low basal expression of TLRs to tolerate the commensal 
antigens and the expression of TLRs is expected to increase upon stimulation with 
high loads of antigens in order to facilitate proinflammatory signalling (Moncada et 
al. 2003). We observed downregulated levels of TLR4, TLR5 and TLR9 in the 
susceptibility model. This could be a mechanism employed by host to dampen the 
immune response, as proinflammatory pathways were already induced and no further 
recognition by TLRs is required. 
Furthermore, Ueno et al. suggested that the downregulation of TLR2, TLR4, TLR5 
and TLR9 is a direct response to increased expression of MUC1 (Ueno et al. 2008). 
This is consistent with our observations as MUC1 expression in increased in the 
susceptibility state. However, TLR2 was increased in our study, contrary to Ueno et 
al. study. These authors carried out this investigation on cell line, while our in vivo 
study involved a dynamic environment. 
Signalling via TLR2 is important for commensal recognition and Treg expansion to 
maintain the immunologic tolerance (Round et al. 2011). This includes the 
commensal Bacillus fragilis that require TLR2 signalling to promote regulatory T 
cell-mediated immune tolerance (Thaiss et al. 2014).  
Furthermore, the upregulation in expression of TLR2 has been shown to be essential 
to strengthen the mucosal barriers by enhancing the tight junction expression (Yuki 
et al. 2011). Similarly, TLR2 knockout mice presented incompetent and permeable 
epithelial barrier due to downregulated tight junction genes (Kuo et al. 2013). In our 
study we observed that both tight junction genes were upregulated in the 
susceptibility state and we propose this is due to upregulated TRL2 expression. 
Therefore, the upregulation of TLR2 is a desirable mechanism in a situation where 
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the microbiota is compromised and the host employs mechanisms to recover the 
commensals. Along with tight junction proteins, we examined other factors 
contributing to the mucosal integrity barrier, namely mucin expression and 
antimicrobial peptide, REGIIIγ. 
We determined that upon antibiotic treatment, MUC1, MUC2, MUC3, MUC4 and 
MUC13 were induced upon antibiotic treatment but also they were the most 
prevalently expressed. However, it may not be just the direct effect of antibiotics on 
the mucus-secreting epithelium but also the lack of the mucus-stimulating signal 
form commensal bacteria (Wlodarska et al. 2011). For example, probiotic microbes 
induce MUC3 transcription and extracellular secretion in order to reduce the 
adherence of a pathogenic strain of E. coli (Mack et al. 2003). Furthermore, two 
mice populations maintained under the same conditions, but with distinct microbiota 
compositions, displayed different compositions of mucus one group with an 
impenetrable barrier, while other group displayed easily penetrable mucus 
(Jakobsson et al. 2014). Also, MUC2-deficient mice presented a thinner mucus layer 
in the colon and were hypersensitive to DSS-induced colitis (Petersson et al. 2011). 
Increased expression and secretion of mucins in infection is a desired host response 
to pathogen invasion, as a thicker mucus layer may act to exclude the invading 
bacteria from interacting with the epithelium. During infection with C. rodentium, 
there is increased expression of MUC1 in the colonic epithelium (Lindén et al. 
2008). Also, Salmonella infection induces expression of MUC2 in the colon and 
MUC2-deficient mice demonstrated dramatic susceptibility to infection (Zarepour et 
al. 2013). Furthermore, Chu et al. has demonstrated that recognition of Mycoplasma 
pneumoniae via TLR2 directly stimulated mucus production (Chu et al. 2005). In 
our study, we observed the increased expression of key mucins, and we propose that 
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this is another protective mechanism employed by the host to defend from 
anticipated pathogen invasion. This mechanism may be largely influenced by the 
upregulated TLR2 expression. 
RegIIIγ is an important antimicrobial peptide that is retained in the mucus upon its 
secretion and it generates the physical separation between the epithelium and 
microbiota. This antimicrobial peptide is constitutively expressed in the gut under 
healthy conditions (Hansson 2012). In our study we determined that in the 
susceptibility state, expression of RegIIIγ was decreased. This is consistent with the 
previous studies, as Brandl et al. also observed downregulation of RegIIIγ upon 
antibiotic treatment in mice (Brandl et al. 2008). This is a desirable response, as 
increased levels of antimicrobial peptide could impair recovering commensals. 
Furthermore, Kamada et al. determined that during infection, the expression of 
RegIIIγ is induced by IL-22 cytokine (Kamada et al. 2013). Therefore, the down 
regulated levels of REGIIIγ expression may be a direct result of downregulated 
expression of IL-22 we also observed in our susceptibility study.  
Finally, we examined the expression of IL-22, an essential cytokine for maintaining 
homeostasis at the epithelial barrier in the gut. The ligation of IL-22 to its receptor in 
the intestine has been shown to induce a wide spectrum of action, including 
expression of antimicrobial peptides (Zheng et al. 2008) and mucins MUC1, MUC3, 
MUC10 and MUC13 (Sugimoto & Ogawa 2008), as well as the fucosylation genes 
FUT2 (Pham et al. 2014). Finally, it induces pathways involved in the proliferation 
and anti-apoptotic pathways (Sonnenberg et al. 2010).  
In the susceptibility model, we determined that expression of IL-22 and its 
downstream signalling molecule STAT3 was downregulated. This was an 
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unexpected finding, as the mucosal barrier was compromised due to aberrant 
microbiota, and upregulation, rather than downregulation, of this cytokine in order to 
restore the balance was anticipated.  
Overall, we demonstrated that the induction of susceptibility in the host resulted in 
triggering several protective mechanisms. These include an environment that 
promotes commensal recovery with fucose-rich glycans, increased TLR2 expression 
and repressed antimicrobial peptides. Furthermore, TLR2 enhances tight junction 
proteins and mucins production. Finally, we observed mild proinflammatory tone of 
the gut could promptly protect the host from anticipated pathogen invasion. 
However, we also identified several mechanisms that are supposed to be protective 
to the host. Nevertheless, the pathogen may take advantage of them, and they may be 
key to explain what makes the animals susceptible. Specifically, it is the 
upregulation of IL-10 and TGFβ, cytokines known for their anti-inflammatory 
properties. Overexpression of these cytokines has been previous shown to be 
responsible for repressing the normal host inflammatory responses (Ouyang et al. 
2011). In the context of C. difficile colonisation, this may suggest that the pathogen 
may successfully colonise the gut while evading immune response and clearance. 
Furthermore, IL-22 expression was downregulated; therefore, the epithelial barrier 
may be severely compromised at molecular level, despite the fact that no colitis was 
observed upon antibiotic treatment. Finally, the high expression levels of TLR2 and 
RANTES may support the development of colitis. The overexpression of TLR2 may 
contribute to the disease pathology as bacterial products may exacerbate acute 
inflammation via this receptor, also signalling thought TLR2 induces the secretion of 
IL-10 which may further induce the immunosuppressive environment which is 
beneficial for C. difficile (Zhang et al. 2015). Additionally, the excessive expression 
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of RANTES has been shown to specifically induce colitis in mice with aberrant 
microbiota (Hu et al. 2013) and this could also be beneficial for C. difficile.   
Therefore next, we wanted to examine how these factors influence the course of C. 
difficile infection in order to correlate these factors with recovery and clearance. 
Specifically, we looked at the terminal glycan profile and their corresponding 
glycosylation enzyme expression but also the expression of IL-22.  
We observed that 3 days post-infection, the expression of IL-22 is completely 
repressed. This correlates with the observations made by Lynch (2014, unpublished), 
3 days post-infection the animals suffer from severe infection, epithelial damage and 
large bacterial load as determined by CFU counts. The lack of IL-22 expression may 
have an immediate implication for recovery of the epithelium, as its structure is 
collapsed and IL-22-induced proliferation signal are required to re-build the 
epithelium. As the lack of the recovery signals is beneficial for the pathogen, this 
possesses a question whether pathogen actively modulate the IL-22 signalling to 
repress this host protective mechanism. Alternatively, the lack of commensal-derived 
signal may explain the reduction of IL-22 expression. By day 7 post-infection, the 
pathogen is cleared and the epithelial barrier is recovered. This corresponds with 
expression of IL-22 that similar to the control group, which suggests that IL-22 may 
be important in restoring the epithelium.  This commensal microbiota-IL-22 axis is 
largely unexplored and enhancing this signal may be an attractive therapeutic 
alternative in CDI. 
IL-22 is known to regulate fucosylation by induction of FUT2 (Pham et al. 2014; 
Pickard et al. 2014) and we demonstrated that fucosylation is insignificantly 
decreased on day 3 post-infection when compared to control group and this 
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correlated with downregulation of FUT2 expression. As already mentioned, 
pathogen may actively repress IL-22 signalling, and one of the downstream factors 
affected by lack of IL-22 would be the lack of fucosylation signal, known to have a 
beneficial role in recovering commensals (Pham et al. 2014). The recovery of the 
commensals would be essential for recovering the colonisation resistance, therefore 
abolishing this IL-22-fucosyaltion-commensal axis is beneficial for C. difficile.  
Finally, we show that sialic acid residues and NANS expression are upregulated on 
day 3 post-infection, the time point corresponding to the peak of the infection and 
pathogen count as demonstrated by Lynch (Lynch 2014, unpublished). By the end of 
the study (day 7 post-infection), as the animals recover from the infection, we also 
observe downregulation of sialic acid metabolism, both at glycan level, but also the 
expression level. This suggests that the pathogen may actively induce the sialic acid 
metabolism to maintain the infection. Overall, in the infection model, we observed 
that the glycans preferred by the commensals are actively repressed by the pathogen, 
while the sialic acid is induced.  
To conclude, we determined that the glycosylation status in the gut did not fully 
explain how the host became susceptible to infection with C. difficile, as we show 
that the glycans displayed on the epithelial surface in fact aid the commensal 
recovery. However, it seems, that certain actions induced by the host to protect it 
from an anticipated invasion, such as high IL-10 and TLR2 expression, in fact may 
tip the balance over in favour of the pathogen. These factors may define the 
susceptibility of the animals to C. difficile infection.  
The glycosylation environment becomes important during the infection, as 
demonstrated with the abundance of sialic acid that was observed, and this correlates 
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with high pathogen counts (Lynch 2014, unpublished). However, we observed the 
recovery of these animals and it may be due to delay action of IL-22 cytokine. 
Therefore, the exact role IL-22 in pathogenicity of C. difficile should be examined 
next.  
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The recent years brought have about remarkable advances in our understanding of 
the complexity of host-microbiota interactions, both in health and disease states. This 
has allowed for further elucidation of the mechanisms employed by opportunistic 
pathogens such as C. difficile. Due to the importance of commensals in colonisation 
resistance, disturbances in the normal microbiota, as is seen with antibiotic 
treatment, has an immediate effect on pathogen invasion (Zhang et al. 2015). This is 
due to the increased availability of nutrients and space and a relative lack of 
inhibitory metabolites (Britton & Young 2014). 
C. difficile pathogenicity has largely been attributed to the actions of its toxins 
(Rupnik 2005; Genth et al. 2008; Voth & Ballard 2005; Young & Hanna 2014). 
Increased awareness of the role that the toxins play in damaging the epithelium led to 
the proposal of therapies involving immunisation against TcdA and TcdB, however 
to date, these vaccines have not proved effective in clinical settings (Mizrahi et al. 
2014; Foglia et al. 2012). While toxins are known to play a detrimental role in 
damaging the epithelial barrier, they are not secreted until a later phase of infection 
(Hundsberger et al. 1997; Janoir et al. 2013). Furthermore, not all infectious 
ribotypes of C. difficile secrete toxins (Kuehne et al. 2010). Therefore, the 
pathogenesis of CDI cannot solely be attributed to toxins alone. This has prompted 
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the search for additional virulence factors, as the mechanisms of colonisation and 
adherence remain unknown. 
We have previously shown that the surface of C. difficile is essential for the 
recognition of the pathogen by the host immune system. Specifically, SLPs are 
recognised by TLR4 (Ryan et al. 2011) and elicit an immune response that leads to 
the clearance of the pathogen (L. E. Collins et al. 2014). Given that these proteins 
coat up to 99% of the surface of C. difficile (Fagan et al. 2009; Calabi & Fairweather 
2002), it is likely that SLPs are the first surface antigens that the host encounters. For 
this reason, we wanted to determine whether SLPs are essential for the C. difficile 
adherence and colonisation. In previous studies carried out in our laboratory only 
SLPs from one ribotype of C. difficile were used (Ryan et al. 2011; Collins et al. 
2014). Therefore, our first objective was to develop methods to grow a range of 
clinically relevant ribotypes of C. difficile and to isolate their SLPs. This allowed us 
to build a library of SLP stocks used for various projects within our laboratory and 
by our collaborators.  
Two C. difficile ribotypes used in this project, RT 001 and RT 027, are associated 
with two different clinical outcomes and are the most common isolated ribotypes 
from patients suffering from CDI in Europe and USA (Barbut et al. 2007; Cheknis et 
al. 2009). We showed that SLPs from these ribotypes, elicited distinct immune 
responses in colonic tissue ex vivo. This suggested that SLPs interact with the 
colonic tissue, but also that this interaction is ribotype-dependent. 
Our findings prompted the question about the structure of SLPs and their role in 
mediating the interaction between the pathogen and colonic tissue. As evident from 
the literature, SLPs differ in the amino acid sequence between the ribotypes 
CHAPTER 6                                                                                                     GENERAL DISCUSSION 
 262  
(Mccoubrey & Poxton 2001) and also, the predicted molecular weights of SLPs are 
often different from molecular weights observed (Calabi et al. 2001). This suggested 
the possibility of post-translational modifications. Other enteric pathogens such as H. 
pylori and E. coli modify their surface proteins by addition of glycans and these 
glycosylated proteins are thought to enhance their pathogenicity (Champasa et al. 
2013; Wang et al. 2012).  
Glycosylation plays an important role in host-pathogen interactions, and 
glycosylated proteins and receptors often facilitate the interaction between both. 
Much of the knowledge regarding the prokaryotic glycosylation was derived from 
studies on S-layers of archaea and bacteria (Schäffer et al. 2001). E. coli does not not 
have S-layer, but surface adhesins have been shown to be glycosylated (Benz & 
Schmidt 2001). Also, the glycosylation of other surface appendages such as flagella, 
in enteric pathogens such as C. jejuni (Alemka et al. 2013) and H. pylori (Champasa 
et al. 2013), has been recently described. Most of the described bacterial 
glycoproteins are surface-associated, and this suggests that they may have an 
important role in pathogenicity including adhesion, protection from proteolytic 
cleavage, antigenic variation and immune evasion (Szymanski & Wren 2005). We 
suggested that differential glycosylation of SLPs from various ribotypes may 
account for the differences in molecular weights. This could also have implications 
for the initial interaction with the host surface and the subsequent immune response 
elicited, and may explain the differences in virulence between ribotypes.  
In order to explore this hypothesis, we probed SLPs from a range of ribotypes for the 
presence of various glycan structures. However, even though we examined a range 
of ribotypes using different methods, we determined that SLPs were not 
glycosylated.  
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Therefore, the theory that the glycosylation on the surface of C. difficile may 
contribute to colonisation and immune evasion was no longer viable. However, this 
did not exclude the role of glycosylation in host-pathogen interaction and our focus 
switched to the glycosylation profile of the colonic environment and its role in 
pathogen colonisation. Specifically, we looked at the susceptibility state to C. 
difficile infection. Many in vivo studies of C. difficile infection have been reported in 
the literature (Chen et al. 2008; Seekatz et al. 2015; Abt et al. 2015; Ferreyra et al. 
2014; Sun et al. 2011), but to our knowledge, there have been no studies focused on 
determining the factors that may contribute to the susceptibility to infection. 
The antibiotic regiment administered to the mice in our study, previously has been 
shown to result in the eradication of the vast majority of the gut microbiota and we 
expected the similar shifts in the composition of commensals (Chen et al. 2008). 
Commensals present in the gut are responsible for actively shaping the intestinal 
environment. For instance, commensals have the ability to modulate the glycans 
presented on the surface of the epithelium to suit their nutritional requirements 
(Freitas et al. 2002). The absence of commensals and their stimulatory effects can 
therefore lead to changes in this environment. For that reason, we examined the 
glycosylation profile of the colonic epithelium. We wanted to explore whether this 
altered environment would benefit C. difficile during colonisation.  
Sialic acid has been shown previously to be essential during the C. difficile infection 
as a source of energy for the pathogen (Ng et al. 2013; Ferreyra et al. 2014). With 
this in mind, we anticipated that antibiotic-treated mice would present with an 
abundance of sialic acid in the gut. As a result, C. difficile would be in an advantaged 
position to invade the host. Surprisingly, we determined that inducing the 
susceptibility state in mice by antibiotic treatment, results in decreased levels of 
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sialic acid with concurrent increase in the levels of fucose. This is similar to the 
profile presented in an immunocompromised state, where upregulated fucosylation is 
regarded as a protective mechanism to recover compromised microbiota (Pickard & 
Chervonsky 2015; Pham et al. 2014; Robbe et al. 2003). C. difficile lacks the 
enzymes essential for fucose digestion (Ng et al. 2013), therefore, the glycosylation 
profile observed in the susceptibility state was an unexpected finding. It seems that 
the glycosylation patterns on the surface of the epithelium aid in the commensal 
recovery and repress pathogen invasion, contrary to our predictions.  
Considering that the glycosylation profile did not play a major role in the 
susceptibility, we also examined other factors that could have been affected by the 
antibiotic treatment and anticipated disturbance of the microbiota. Specifically, we 
looked at the host immune response and the integrity of mucosal barrier. Again, we 
found several changes that could be regarded as protective mechanisms. This 
included the mild proinflammatory profile of cytokines, together with 
downregulation of chemokines with the exception of the RANTES and TLRs with 
the exception of TLR2. The upregulation of TLR2 may have a protective effect as 
TLR2 is known for its role in supporting microbiota recovery and promoting gut 
homeostasis via induction of Tregs (Thaiss et al. 2014; Round et al. 2011). Also 
TLR2 has been shown to enhance the expression of tight junction proteins (Yuki et 
al. 2011; Frosali et al. 2015) and mucin secretion (Chu et al. 2005). The 
upregulation of tight junction proteins may lead to strengthening of the epithelial 
barrier, while the upregulation of mucin secretion allows for a thicker mucus layer, 
preventing the microbes from interacting with the epithelium. However, the 
upregulated levels of TLR2 may play a detrimental role for the host during the 
invasion by C. difficile, as high bacteria antigen load stimulates TLR2 signalling, 
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which contributes to exacerbated acute inflammation (Zhang et al. 2015). This may 
be one of the factors contributing to the acute colitis observed during C. difficile 
infection. 
TLR2 may also influence the mucin secretion, as it has been previously reported that 
infection with Haemophilus influenzae results in increased expression of MUC2 via 
TLR2 and TGFβ signalling (Jono et al. 2002). This is consistent with our 
observation, as we determined that most prevalently expressed mucins, including 
MUC1, MUC2, MUC3, MUC4 and MUC13 were upregulated in susceptibility state, 
and this may be a direct result of the upregulated expression of TLR2 and TGFβ. In 
turn, the increased secretion of mucins may have a dampening effect on TLR 
expression. Ueno et al. have reported that increased expression of MUC1 correlated 
with decreased expression of TLR4, TLR5 and TLR9 (Ueno et al. 2008), which is 
consistent with our observations. MUC1 may repress the expression of these TLRs 
to dampen the immune response, as proinflammatory pathways are already activated. 
Suppression of the immune response during resolution of infection is essential to 
prevent over-stimulation of the immune system which can result in autoimmunity. 
Therefore the susceptibility model allowed us to identify a range of mechanisms that 
may be in place to protect the host from anticipated pathogen invasion, but also 
mechanisms that may directly contribute to the microbiota recovery.  
However, among these protective mechanisms we identified several factors that may 
be utilised by C. difficile to take advantage and colonise the gut. This included the 
upregulated expression of IL-10 and TGFβ. These cytokines are essential for 
maintaining the balance in the immune response via their anti-inflammatory and 
regulatory properties (Kang et al. 2008). However, overexpression of these cytokines 
may in fact result in an overly immunosuppressive environment, where the host is 
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not able to mount an efficient immune response to invading pathogens (Mege et al. 
2006). In our previous study we demonstrated that it is this upregulation of IL-10 
that contributes to the prolonged infection seen with C. difficile RT 027 (Lynch 
2014, unpublished). IL-10 has been shown to delay the immune response, enabling 
the pathogen to successfully colonise the colon and secrete toxins, causing the 
damage to the epithelium. In this study we demonstrated that levels of anti-
inflammatory IL-10 and TGFβ may be increased at earlier stage, prior to infection, 
which contributes to the susceptibility of the host.  
Furthermore, in our study we observed upregulated levels of the chemokine 
RANTES. This upregulation may contribute to disease progression and damage of 
the epithelial barrier. The primary function of chemokines is to orchestrate the 
recruitment of immune cells, such as neutrophils, to the site of infection (Charo & 
Ransohoff 2006). While the controlled recruitment of these cells is desirable for the 
clearance of pathogens, excessive presence of neutrophils may be detrimental for the 
host and result in colitis (Fournier & Parkos 2012). Large numbers of neutrophils are 
responsible for initiating a cascade of proinflammatory signalling that results in 
further recruitment of immune cells. The excessive proinflammatory signalling also 
results in damage to the epithelial structure (Hu et al. 2013). Despite the fact that 
antibiotic treatment does not induce colitis, the epithelial barrier may be 
compromised at the molecular level due to low expression of IL-22. This 
compromised epithelial barrier may be desirable for C. difficile, as this allows for 
delivery of the toxin directly to intestinal epithelial cells and subepithelial layer, 
resulting in further propagation of infection.  
Another interesting observation in the susceptibility model was the upregulation of 
N-Acetylglucosamine in the core structures of the mucus. The increase of N-
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Acetylglucosamine in intestinal mucins has been shown to have protective function 
in chemically-induced colitis in mice. In this model of chemically-induced colitis, 
the epithelial structure was not compromised and this was attributed to N-
Acetylglucosamine preventing the excessive recruitment of immune cells to the site 
of inflammation (Tobisawa et al. 2010). Therefore, the abundance of N-
Acetylglucosamine that we observed in susceptibility state may be a desired 
mechanism, as dampened infiltration of immune cells such as neutrophils may 
prevent excessive inflammation. However, the abundance of this glycan may in fact 
provide C. difficile with an additional advantage during invasion, as N-
Acetylglucosamine is the main receptor for the C. difficile toxins (Castagliuolo et al. 
1998). Due to its core position within the glycan chains, the toxins may adhere 
closely to the epithelium thus damaging the epithelium more effectively.  
Finally, we examined the expression of IL-22, an essential cytokine for regulation of 
immunity, inflammation and the tissue homeostasis in the GI tract (Sonnenberg et al. 
2011). IL-22 is expressed by immune cells such as neutrophils (Sadighi Akha et al. 
2013) and Th17 cells (Min & Rhee 2015) but also epithelial cells (Pham et al. 2014) 
in response to trauma and epithelial damage. This cytokine is unusual among other 
interleukins, as it does not directly act on immune cells but rather it aids the recovery 
of the epithelial layer (Sabat et al. 2014). Its main role is to induce anti-apoptotic and 
proliferation pathways to restore the epithelial layer (Mühl 2013). Furthermore, it 
also induces the expression of antimicrobial peptides such as REGIIIγ (Zheng et al. 
2008), fucosylation genes such as FUT2 (Pham et al. 2014; Pickard et al. 2014) and 
mucins such as MUC1, MUC3, MUC10 and MUC13 (Sonnenberg et al. 2010; 
Zenewicz et al. 2007; Radaeva et al. 2004). This wide spectrum of genes induced by 
IL-22 highlights its importance in restoring the epithelial barrier integrity (Hasegawa 
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et al. 2014). In our susceptibility study, we did not anticipate an increase in IL-22, as 
the antibiotic treatment did not breach the epithelial barrier and no infectious agent 
was introduced. Notably we observed downregulated IL-22 expression in 
susceptibility state, which was in agreement with the findings of Behnsen et al. 
(Behnsen et al. 2014). According to this study, the downregulation of IL-22 
prevented antimicrobial peptide expression, which is thought to aid in commensal 
recovery. This correlates well with our observations, as concurrent with 
downregulation of IL-22 expression, we observed downregulation of REGIIIγ. 
However, this may be another protective mechanism utilised by C. difficile to its 
advantage to colonise the gut.  
The susceptibility model allowed us to identify several factors that may predispose 
an individual to infection with C. difficile. Next, we wanted to examine these factors 
during the course of infection with C. difficile RT 001. Our study has highlighted the 
change of glycosylation during the C. difficile RT 001 infection. On day 3 post-
infection with RT 001, there was a significant increase in sialic acid metabolism, as 
demonstrated by the increase of sialic acid on the surface of the epithelium and also 
by the increased expression of sialic acid synthase, NANS. This increase correlated 
with the peak of infection and pathogen load on day 3 (Lynch 2014, unpublished). 
By the end of the study, when the pathogen was cleared, both sialic acid and NANS 
were downregulated, relative to the control groups. While this correlates with the 
previous studies highlighting the importance of sialic acid in maintain CDI (Ng et al. 
2013), it also possesses the question whether the pathogen actively modulate the 
sialic acid metabolism to suit its virulence during the infection and benefit from 
abundance of this nutrient. 
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Given that IL-22 plays an essential role in restoring the mucosal barrier, especially 
following pathogen invasion (Hasegawa et al. 2014), we also examined the 
expression of IL-22 during infection with C. difficile RT 001. IL-22 induces 
proliferation and anti-apoptotic pathways, antimicrobial peptides, mucin secretion 
and fucosylation (Sonnenberg et al. 2011), therefore its activity during recovery 
from pathogen-induced colitis is highly desirable. In our infection model, we 
observed downregulation of IL-22 expression during the initial stage of infection 
with C. difficile RT 001, which corresponds with the extensive epithelial damage 
observed during this stage of infection (Lynch 2014, unpublished). However, when 
the infection is resolved, and the recovery and restoration of the epithelial structure 
takes place, secretion of IL-22 returns to control levels. We propose that IL-22 may 
play an important role in recovery following infection with C. difficile. The role of 
IL-22 in the course of C. difficile infection has only recently been investigated. IL-
22-deficient mice display increased mortality rates during C. difficile infection due to 
damage to the epithelium caused by excessive neutrophil recruitment (Jafari et al. 
2013). This suggests that IL-22 may have anti-inflammatory properties in this 
context. Also, induction of the antimicrobial peptide REGIIIγ by IL-22 has been 
shown to be beneficial in clearance of C. difficile (A. A. Sadighi Akha et al. 2015). 
In depth investigation of the role of IL-22 in clearance of the pathogen and recovery 
of the intestinal epithelium is warranted. This is particularly important in the context 
of the C. difficile ribotypes that result in prolonged infection and excessive damage 
to the epithelium, as this suggests that the action of IL-22 may be impaired in this 
case. Better understanding of the role of IL-22 in C. difficile clearance may allow for 
design and development of both novel therapeutic targets and treatments. 
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Overall, in this study we have demonstrated how the susceptibility state induces 
changes in glycosylation patterns, immune responses, and the epithelial barrier 
integrity that may render the host vulnerable to invasion by C. difficile. Furthermore, 
we demonstrated that although the glycosylation may not contribute to susceptibility, 
however it plays pivotal role in maintaining the infection. Also, we have 
demonstrated that induction of IL-22 may be important for the clearance of the 
pathogen. These findings provide further insight into the mechanisms involved in 
CDI infection and may also contribute to future therapies designed for its treatment.  
The main problem that CDI patients face currently is the lack of new therapies, high 
antibiotic resistance rates and high reoccurrence rate among patients. The main 
group at risk to develop CDI are elderly and immunocompromised patients admitted 
to hospitals (Rodriguez et al. 2014). Antibiotics that are effective against C. difficile 
have been discovered recently, however they have not been introduced into clinical 
application as of yet. These include thuricin CD (Rea et al. 2010) and teixobactin 
(Ling et al. 2015), both with a narrow specificity against C. difficile. While Ling et 
al. claims that there was no detectable resistance at the time of the study, it is a 
common knowledge that hospital-associated pathogens, including C. difficile RT 
027, are exceptionally progressive in obtaining resistance against drugs (Cotter et al. 
2013; Tenover et al. 2012). Therefore, there is an urgent need to design new, 
alternative approaches to treat CDI.   
Faecal Microbiota Transplant (FMT) has proven to be the most effective therapy 
against CDI in recent years (Di Bella et al. 2015). This therapy is known to restore 
not only commensal microbiota but also the associated commensal-derived 
metabolites such as bile salts (Weingarden et al. 2014), short-chain fatty acids 
(SCFA) (Wlodarska et al. 2015) and the faecal microRNAs (Liu et al. 2015). The 
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recommended donor is usually a domestic partner; however the recent use of 
antibiotics or immunosuppressants, travel or disease may exclude this person as a 
suitable donor. Furthermore, there is a high risk of transmitting disease agents that 
are not currently screened for under laboratory conditions (Rohlke & Stollman 
2012). Also, Weil & Hohmann highlighted the differences in composition in 
microbiota between lean and obese people and its possible effect on the recipient’s 
health (Weil & Hohmann 2015). Ridaura et al. reported that mice harbouring 
microbiota from obese people gathered more adipose tissue, while the mice with 
microbiota from lean population maintained a healthy weight (Ridaura et al. 2013). 
These findings suggest that, while FMT proved to be effective in restoring the 
balance in the colon post-infection with C. difficile, we do not know the full effect 
that transferring microbiota from one person to another may have on the patients.  
In a recent report Seekatz et al. suggested that the success of the FMT therapy is due 
to the restoration of a specific community structure, and not the whole microbiome 
of the donor (Seekatz et al. 2015). Similarly, Buffie et al. were able to identify a 
single strain of commensal bacteria, Clostridium scindens that has the ablity to 
restore the colonisation resistance against C. difficile in mice (Buffie et al. 2014). 
This bacterium restored the secondary bile acid balance, known to have an inhibitory 
effect on C. difficile vegetative cells. These authors proposed that the precise 
microbiome reconstitution may be an interesting alternative to FMT. The main 
advantage of this approach is that only defined and beneficial organisms are 
introduced to the recipient rather than an unknown mix of faecal matter. In other 
study, it has been demonstrated that co-administration of the antibiotics along with 
Saccharomyces boulardii yeast significantly reduced the occurrence of CDI disease 
among hospital patients (McFarland et al. 1994).  
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All of these studies point to a new direction that CDI treatment may take in the 
future. While there is still an urgent need for antibiotics to deal with outbreaks of the 
disease, future therapies may involve the use of CDI-tailored probiotics and 
prebiotics as a preventative measure against this disease. As mentioned previously, 
some beneficial organisms, such as C. scindens, have already been identified as 
efficient in outcompeting C. difficile (Buffie & Pamer 2013). Furthermore, the 
probiotic bacteria can also stimulate the mucosal barrier by inducing the secretion of 
mucus from intestinal epithelial cells (Mack et al. 2003).  
In our study, but also in previous projects (Ng et al. 2013; Ferreyra et al. 2014), the 
importance of sialic acid as a nutrient source for C. difficile has been highlighted. We 
therefore suggest that commensals that utilise sialic acid as a nutrient source could 
represent a candidate probiotic bacteria. When introduced to the host, these probiotic 
bacteria would directly compete with C. difficile for nutrients and energy, which 
could contribute to resolving the infection. 
Furthermore, recent advances in our understanding of the immune response in 
susceptibility state should be utilised to stimulate the immune system in 
immunocompromised patients. Our results now indicate that this may include the 
stimulation of IL-22 or counteracting the immunosuppressive actions of 
overexpressed IL-10 and TGFβ. Various therapies that involve modulation of these 
cytokines to treat inflammatory conditions have been reported in the literature (Sabat 
et al. 2014; Llorente et al. 2000; Marafini et al. 2013; Guo et al. 2014). Also, 
supplementing the diet with prebiotics that stimulate the expansion of commensals 
that may modulate these immune responses could be a viable therapeutic approach. 
Specifically, our study suggests an important role for fucose in supporting 
commensal microbiota and restoring colonisation resistance. This suggests a 
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possibility of formulating a prebiotic treatment that could be administrated to 
immunocompromised patients at risk of developing CDI. This supplementation with 
sugars such as fucose would promote an environment that supports commensals and 
prevent C. difficile from thriving. Ultimately, patients at risk of developing CDI may 
receive a preventative treatment upon admission to the hospital. It may be a tailored 
mix of ingredients that stimulates both the immune system and commensals, known 
as prebiotics, and a mix of probiotic bacteria that would challenge C. difficile at 
several metabolic and lifestyle levels.  
Targeting the risk of CDI at an early stage of susceptibility may prove a more 
feasible method to eradicate this pathogen, rather than treating the fully manifested 
infection. The data presented in this thesis may aid the development of a novel 
therapeutic plan and provide alternatives to use of antibiotics.  
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APPENDIX A – BUFFERS AND SOLUTIONS 
Clostridium difficile washing solution. Made up in dH2O to 1 L. HCl was used 
to adjust pH to pH 7.4. Solution was used ice cold to wash harvested C. difficile 
cells. 
Tris:HCl 50 mM 
 
S-layer isolation solution. Solution was made fresh on the day. Made up in 
dH2O to 100 ml. HCl was used to adjust pH to pH 8.3. Protease inhibitor was 
added and left to dissolve. Incubation was carried out at 37°C for 90 min. 
Tris:HCl 50 mM 
Urea 8 M 
Protease inhibitor 5 tablets per 100 ml 
 
S-layer dialysis buffer. Made up in dH2O to 5 L x 4. HCl was used to adjust pH 
to pH 8.5. Solution was used at 4°C, changed every 2 h. 
Tris:HCl 20 mM 
 
FPLC Elution Buffer (Buffer A). Made up in dH2O to 2 L and pH was adjusted 
with HCl to pH 8.5. 
Tris:HCl 20 mM 
 
FPLC Elution Buffer (Buffer B). Made up in dH2O to 2 L and pH was adjusted 
with HCl to pH 8.5. 
Trizma Base 20 mM 
NaCl 0.3 M 
 
5X Loading Buffer. 1 M DTT was added to 5X loading buffer just before use 
and 3 μl of 5X loading buffer was added to 12 μl of each sample. This sample 
preparation was used for SDS PAGE during SLP characterisation, Periodic acid–
Schiff Glycoprotein Staining and lectin blotting. 
Trizma Base 125 mM 
Glycerol 10% 
SDS 2% 
Bromophenol Blue 0.05% (w/v) 
DTT 0.25 M 
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Separating gel (12.5% (w/v)). Solution was dissolved in dH2O to required 
volume. Ammonium persulphate and TEMED were added last before pouring 
over the gels. Gel was covered with isopropanol to exclude air and aid the 
polymerisation. This sample preparation was used for SDS PAGE during SLP 
characterisation, Periodic acid–Schiff Glycoprotein Staining and lectin blotting. 
Acrylamide/Bisacrylamide (30% stock) 12.5% 
Tris-HCl pH 8.8 1.5 M 
SDS 1% 
Ammonium persulphate 0.5% (w/v) 
TEMED 0.1% (v/v) 
 
Stacking gel (5% (w/v)). Formulation was dissolved in dH2O to required 
volume. Ammonium persulphate and TEMED were added last before pouring 
over the gels. This sample preparation was used for SDS PAGE during SLP 
characterisation, Periodic acid–Schiff Glycoprotein Staining and lectin blotting. 
Acrylamide/Bisacrylamide (30% stock) 5% 
Tris-HCl pH 8.8 0.5 M 
SDS 1% 
Ammonium persulphate 0.5% (w/v) 
TEMED 0.1% (v/v) 
 
Electrode running buffer. Buffer was dissolved in dH2O to required volume. 
Trizma Base 25 mM 
Glycine 200 mM 
SDS 17 mM 
 
Coomassie Stain. Solution was made up in dH2O to required volume. 
Brilliant Blue 0.2% 
Methanol 45% 
Acetic Acid 10% 
 
Destain Solution. Solution was made up in dH2O to required volume. 
Methanol 25% 
Acetic Acid 10% 
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Wash buffer for fluorescent lectin staining. Solution was made up in dH2O to 
required volume. 
TBS 1X 
MgCl2 1 mM 
CaCl2 1 mM 
 
Fluorescent lectin buffer. Solution was made up in dH2O to required volume. 
TBS 1X 
MgCl2 1 mM 
CaCl2 1 mM 
BSA 1% 
 
Tris-buffered Saline (TBS) 10X. Buffer was made up in dH2O and pH was 
adjusted to pH 7.6. Buffer was used for lectin blotting and fluorescent lectin 
staining analysis. 
NaCl 150 mM 
Trizma Base 50 mM 
 
MEDIA 
Fastidious Anaerobe Broth (FAB) for C. difficile culture. Broth powder was 
soaked in water for 10 min and then brought to boil. Solution was autoclaved for 
15 min and 121°C. 
Broth powder 29.7 g per 1 L 
 
Brain Heart Infusion Broth (BHI) for C. difficile culture. Broth powder was 
soaked in water for 10 min and warmed gently to dissolve. Solution was 
autoclaved for 15 min and 121°C. 
Broth powder 37 g per 1 L 
 
Ex vivo colon culture. Media was prepared freshly on the day. 
RPMI 50 ml 
Penicillin (10 000 U/ml) and Streptomycin 
(10 000 µg/ml) 
0.5 ml 
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APPENDIX B – SLP CHARACTERISATION 
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Table A1 The concentration of the SLP stocks.  
C. difficile Ribotype SLP Concentration (µg/ml) 
001 3335 
002 1195 
010 1037 
014 2456 
027 2100 
046 800 
078 7234 
 
Figure A1 SLPs from various ribotypes were examined for presence of endotoxin 
contamination and protein concentration was measured using BCA assay. LAL 
endotoxin assay was carried out to ensure that any immune response was indeed due 
to the SLPs and not due to potential contamination from other bacterial sources (A). 
A Bicinchoninic acid (BCA) assay was performed on all samples to determine the protein 
concentration for each batch of SLPs. This was of great importance as a standard volume of 
each SLP was required for cell stimulation. The standard curve was calculated with a four-
parameter (quadratic) curve (B) and equation of the line was used to calculate total 
concentration (C). This table presents representative results for each ribotype used in this 
project. 
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APPENDIX C – RT QPCR QUALITY ASSURANCE  
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Figure A2 Ppia and B2m were identified as endogenous controls for colonic gene 
expression. Normalised amounts of mRNA from ex vivo culture, susceptibility model and 
infection model were converted into cDNA using a High Capacity cDNA Mastermix. The 
cDNA was mixed with primers for GUSB, PPIA, B2M, RPS18 and TBP and FAST SYBR 
Mastermix. Samples were assayed in triplicates and analysed on LightCycler®96. Results 
are mean geometric of Cq values. 
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Table A2 Sequences of Prime Time® qPCR Primers used in this study. All primers were sourced from IDT. 
Gene Protein Ref Seq ID Forward Primer (5’ → 3’) Reverse Primer (3’ → 5’) Exon Location 
Muc1 MUC1 NM_013605 GACTGCTACTGCCATTACCTG CCTACCATCCTATGAGTGAATACC 6 – 7 
Muc2 MUC2 NM_023566 TCAAAGTGCTCTCCAAACTCTC CAGCTCCTCTCAGAATTCCAC 40 – 43 
Muc3 MUC3 XM_355711 CTTGTCACCTGTCCAGAACC AACCACTACAGAAGTTGCCA 13 – 14 
Muc4 MUC4 NM_080457 GACAAGTTAGTCCTGACATCCC CAGCCTCTCCAAGAAATGTAGT 18 – 19 
Muc5ac MUC5AC NM_010844 CTGGTTGAGTGGTTGTGTGT CCCATGTGTATTCCTCTCCCA 31 – 32 
Muc6 MUC6 NM_181729 GCAGTTGGAGACACAAAGGTA CATGACATCCACTCTCACACC 31 – 33 
Muc13 MUC13 NM_010739 CTCCTTGTCCTTAAGACCGTAG CCTAATCCCTACGCAAACCAG 12 – 13 
Muc15 MUC15 NM_172979 GTTCTGGTGCATTGTCTAATCG GTGCTTCACTGCTTAGCCTT 3 – 4 
Muc20 MUC20 NM_146071 GCCTGTCCCTTTGAGTGAAG CCCTCCTTGTCTTCTGCTG 1 – 2 
Ccl2 MCP1 NM_011333 AACTACAGCTTCTTTGGGACA CATCCACGTGTTGGCTCA 1 – 3 
Ccl3 MIP1α NM_011337 CGATGAATTGGCGTGGAATC CCTTGCTGTTCTTCTCTGTACC 1 – 2 
Ccl5 RANTES NM_013653 GCTCCAATCTTGCAGTCGT CCTCTATCCTAGCTCATCTCCA 2 – 3 
Cxcl2 MIP1β NM_009140 CAGAAGTCATAGCCACTCTCAAG CTTTCCAGGTCAGTTAGCCTT 2 - 4 
Il1b IL-1β NM_008361 GACCTGTTCTTTGAAGTTGAC CTCTTGTTGATGTGCTGCTG 3 – 4 
Il2 IL-2 NM_008366 GCAGGATGGAGAATTACAGGAA GCAGAGGTCCAAGTTCATCTTC 1 – 3 
Il6 IL-6 NM_031168 AGCCAGAGTCCTTCAGAGA TCCTTAGCCACTCCTTCTGT 4 – 5 
Il10 IL-10 NM_010548 GGCATCACTTCTACCAGGTAA TCAGCCAGGTGAAGACTTTC 1 – 3 
Il12a IL-12p35 NM_001159424 CACTGGAACTACACAAGAACGA AAGTCCTCATAGATGCTACCAAG 3 – 5 
Il23a IL-23 NM_031252 GATCCTTTGCAAGCAGAACTG ACCAGCGGGACATATGAATC 1 – 3 
Il17a IL-17A NM_010552 AGACTACCTCAACCGTTCCA GAGCTTCCCAGATCACAGAG 2 – 3 
Tnfa TNFα NM_013693 AGACCCTCACACTCAGATCA TCTTTGAGATCCATGCCGTTG 2 – 4 
Tgfb TGFα NM_019919 CCGAATGTCTGACGTATTGAAGA GCGGACTACTATGCTAAAGAGG 20 – 21 
Tlr2 TLR2 NM_011905 CAACTTACCGAAACCTCAGACA CCAGAAGCATCACATGACAGA 2 – 3 
Tlr4 TLR4 NM_021297 AGCTCAGATCTATGTTCTTGGTTG GAAGCTTGAATCCCTGCATAG 1 – 2 
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Table A2 Sequences of Prime Time® qPCR Primers used in this study. All primers were sourced from IDT. 
Gene Protein Ref Seq ID Forward Primer (5’ → 3’) Reverse Primer (3’ → 5’) Exon Location 
Tlr5 TLR5 NM_016928 GGAACATATGCCAGACACATCT TGAAGATCACACTCATGAGCAAG 3 – 4 
Tlr9 TLR9 NM_031178 GAATCCTCCATCTCCCAACA TCACAGGGTAGGAAGGCA 1 – 2 
Stat3 STAT3 NM_213660 AGTCTCGAAGGTGATCAGGT GTTCAAGCACCTGACCCTTAG 13 - 15 
Il22b 
(Ilfifb) 
IL-22 NM_054079 AATGAATCTTTGTGGTTATCAAGTCT AAGTGAGAAGCTAACGTCCAC 5 - 5 
Reg3g REGIIIγ NM_011260 GATTCGTCTCCCAGTTGATGT CTCCATGACCCGACACTG 4 - 5 
Fut2 FUT2 NM_018876 CCAGAGGAAAGGAGAAAGGT GTCCTGAACGAAGAGCCAAG 1a – 3b 
Nans NANS NM_053179 GTTAGTGTCCCCAGATCCAAC GAATTCAGCCACGACCAGTA 2 - 3 
Cdh1 CDH1 NM_009864 AGTCTCGTTTCTGTCTTCTGAG GAGCTGTCTACCAAAGTGACG 3 – 4 
Ocln OCLN NM_008756 GTTGATCTGAAGTGATAGGTGGA CACTATGAAACAGACTACACGACA 6 – 7 
Gusb GUSB NM_010368 GAGAACTGGTATAAGACGCATCA GAACAGCCTTCTGGTACTCC 1 – 2 
Ppia PPIA NM_008907 CAAACACAAACGGTTCCCAG TTCACCTTCCCAAAGACCAC 4 – 5 
B2m B2M NM_009735 GGGTGGAACTGTGTTACGTAG TGGTCTTTCTGGTGCTTGTC 1 – 2 
Rps18 RPS18 NM_011296 ACACCACATGAGCATATCTCC CCTGAGAAGTTCCAGCACAT 2 – 3 
Tbp TBP NM_013684 CCAGAACTGAAAATCAACGCAG TGTATCTACCGTGAATCTTGGC 4 – 5 
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APPENDIX D – FLUORESCENT LECTIN STAINING CONTROLS   
A BUFFER  
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Figure A3 Buffer-only probing and pre-incubation with corresponding monosaccharide confirmed lectin specificity. Slides were probed with buffer and fluorescence 
was not detected (A). FITC-labelled lectins were pre-incubated for 30 min with 0.5 M of corresponding monosaccharide sugar. Lectins-monosaccharide solutions were then 
used to probe the surface of colonic epithelium. The fluorescent signal was reduced in case of all lectins used in this study, as observed on tissue histochemistry images (B-K),  
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Fluorescent Signal from Lectins
in Control Group (Suceptibility Model)
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Figure A4. Monosaccharide Specificity total fluorescence signal (B) was compared to signal 
in susceptibility study (A).  
